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General introduction and outline of the thesis
Introduction
Diabetes, defined by the presence of chronically elevated blood glucose 
concentrations, is a global pandemic, with a sharply increasing prevalence 
from 108 million in 1980 to an estimated 422 million adults having diabetes 
in 2014 [1]. Different types of diabetes exist: whereas type 2 diabetes (T2D) is 
accounting for 85-95% of all diabetes cases, around 10% can be attributed to 
type 1 diabetes (T1D) or other types of diabetes. Diabetes is associated with 
several long-term vascular complications, including retinopathy, neuropathy, 
nephropathy and cardiovascular disease. The increased prevalence of diabetes is 
mainly attributed to over-nutrition and sedentary behavior, which both promote 
obesity, the main risk factor for T2D. Although not related to lifestyle, also the 
incidence and prevalence of T1D is rising [2]. 
Pathophysiology 
Type 1 diabetes
The pathophysiology of type 1 and type 2 diabetes is different. Type 1 diabetes 
is an autoimmune disease, which is most often diagnosed in childhood or young 
adulthood. Autoreactive T cells almost completely destroy the insulin-producing 
β-cells in the pancreas, resulting in absolute insulin deficiency in individuals with 
type 1 diabetes. In healthy individuals, insulin is secreted in response to elevated 
blood glucose levels, inhibits hepatic glucose production and mediates glucose 
uptake from the blood into tissues (liver, skeletal muscle and adipose tissue). 
Even under fasting conditions, low levels of insulin are required, hence, patients 
with type 1 diabetes are completely dependent on treatment with exogenous 
insulin. 
Type 2 diabetes
In contrast to the absolute insulin deficiency in type 1 diabetes, patients with 
type 2 diabetes suffer from a relative lack of insulin. In patients with type 2 
diabetes, a decreased biological effect of insulin, termed insulin resistance, is 
the main pathophysiological disturbance. Insulin resistance is strongly related 
to obesity, but also dependent on body fat distribution and other factors. During 
the development of obesity, the adipose tissue is expanding, leading to increased 
release of (non-esterified) fatty acids, as well as inflammatory mediators such as 
adipokines and cytokines [3]. All of these factors may impair local and systemic 
insulin signaling, resulting in insulin resistance. Initially, pancreatic β-cells 
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compensate for impaired insulin signaling by increasing insulin production, 
temporarily maintaining normoglycemia. Ultimately however, progressively 
increased insulin resistance leads to β-cell exhaustion and relative insulin 
secretion deficiency, resulting in chronic hyperglycemia and type 2 diabetes. 
Several mechanisms are suggested to contribute to β-cell dysfunction, amongst 
which gluco- and lipotoxicity, oxidative stress and endoplasmatic reticulum 
stress are likely the most important [4]. When discovered during an early 
stage, hyperglycemia can be reduced using life style interventions. If a change 
in lifestyle is not sufficient, patients are treated with glucose-lowering agents 
including metformin, yet may ultimately require insulin therapy to reduce 
hyperglycemia. 
Diabetes-associated complications
Hyperglycemia-associated vascular complications
Chronic hyperglycemia is a risk factor for several diabetes-associated 
complications. It contributes to microvascular complications affecting small 
vessels including retinopathy, neuropathy and nephropathy [5]. Additionally, 
hyperglycemia is a risk factor for macrovascular complications affecting large 
vessels leading to coronary artery disease, peripheral arterial disease and 
stroke. After age, hyperglycemia is the second most important risk factor 
for cardiovascular disease in patients with diabetes [6]. The importance of 
hyperglycemia in driving diabetes-associated complications was demonstrated 
in the Diabetes Control and Complications Trial (DCCT). As part of this trial, T1D 
patients received intensive glucose-lowering therapy leading to significantly 
lower HbA1c levels and reduced microvascular complications after a follow-
up period of 6.5 years compared with patients receiving conventional therapy 
with higher HbA1c levels [5]. Consequently, the therapeutic aim in patients 
with diabetes is to maintain stable and near-normal HbA1c levels. At the end 
of the DCCT, the conventional treatment group switched to more intensive 
treatment, while the intensive group relaxed the therapy slightly, resulting in 
similar HbA1c levels in both groups one year after the trial. Both patients groups 
were subsequently followed up for a mean of 17 years in the Epidemiology of 
Diabetes Interventions and Complications (EDIC) study. Although both patient 
groups followed intensive glucose-lowering therapies and HbA1c levels were 
comparable between groups, patients initially receiving conventional therapy 
with elevated levels of HbA1c were still at higher risk for the development 
of microvascular and macrovascular complications [7], an observation that 
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was defined as ‘hyperglycemic memory’. Thus, a period of hyperglycemia has 
unfavorable effects many years after better glucose control has been obtained, 
which further stresses the importance to maintain stable and near-normal 
HbA1c levels already from the onset of the disease. 
Hypoglycemia-associated vascular complications
Insulin therapy aiming for near-normal HbA1c levels increases the risk for 
hypoglycemia. Hypoglycemia is the most common complication of insulin 
therapy. Patients with diabetes using insulin, experience on average one 
hypoglycemic event per week and one severe event – meaning that patients 
need external help - per year [8, 9]. Severe hypoglycemia is characterized 
by various acute neuroglycopenic symptoms ranging from difficulties to 
concentrate to more severe symptoms like seizures or coma and accounts for 
up to 10% of deaths in young adults with type 1 diabetes [10]. In patients with 
type 1 diabetes above 30 years of age, cardiovascular disease is responsible 
for the largest proportion of deaths. The direct association between severe 
hypoglycemia and cardiovascular disease in patients with T1D is still debated. 
Some studies have reported an association between severe hypoglycemia and 
all-cause mortality as well as cardiovascular disease in patients with type 1 
diabetes [11, 12], whereas other studies did not confirm this association [13]. 
Although T2D patients experience hypoglycemia less frequently compared with 
T1D patients [14], the link between severe hypoglycemia and cardiovascular 
disease has been established in numerous studies in T2D patients [15-17]. While 
fatal arrhythmias may occur during an acute hypoglycemic event [18], it is more 
likely that a longitudinal relationship exists between severe hypoglycemia and 
cardiovascular events. Interestingly, some studies reported increased circulating 
pro-inflammatory cytokines and pro-thrombotic factors after hypoglycemia, 
indicating inflammation as a possible link between hypoglycemia and 
cardiovascular disease [19, 20].  
Increased risk for infections
In addition to micro- and macrovascular complications, various epidemiological 
studies have revealed an increased rate for infections, as well as increased severity 
of infections in patients with diabetes [21]. On the one hand, patients suffer from 
increased severity of common infections, for example evidenced by an increased 
risk for hospitalization as well as admittance to intensive care units after influenza A 
infection [22]. On the other hand, patients with diabetes have a strongly increased 
susceptibility to specific pathogens, such as Mycobacterium tuberculosis [23], 
Candida albicans and fungi of the order Mucorales [24]. Glycemic control seems 
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to be a dominant factor in altering the susceptibility to infections. Patients 
with poorly controlled diabetes or those experiencing diabetic ketoacidosis, for 
instance, are at a particularly high risk to develop mucormycosis, an invasive 
fungal infection [25]. Factors contributing to the increased risk for infections in 
patients with diabetes may either directly affect the invading pathogen or disturb 
host-pathogen interactions. Glycosuria, for example, may directly increase 
bacterial growth, contributing to an increased incidence of urinary tract infections 
in patients with diabetes and elevated blood glucose levels [26]. Additionally, 
lower urinary cytokines and urinary leukocyte cell counts were found in patients 
with diabetes, indicative of altered immune cell function [27].
Involvement of the immune system in diabetes and its complications
Immune cells play a central role in the pathogenesis of diabetes; in T1D in 
the form of an auto-immune process, in T2D with obesity-associated chronic 
inflammation. Furthermore, immune cells play an important role in the 
pathophysiology of diabetes-associated complications (Figure 1). Patients with 
diabetes have impaired acute immune responses, resulting in an increased 
susceptibility for infections, but are also characterized by a chronic pro-
inflammatory state, contributing to vascular complications of diabetes. 
Impaired acute immune responses
Impaired immune responses in the context of diabetes affect a broad range of 
cell types. Neutrophils, for instance, play an important role in phagocytosis and 
killing of bacteria. In diabetes, neutrophil migration as well as phagocytosis and 
killing capacity are diminished (summarized in [28]), ultimately contributing to 
an increased risk for infection. Other functional alterations include the release of 
cytokines illustrated by impaired production of the monocyte-derived cytokine 
IL-1β in response to Mycobacterium tuberculosis in patients with diabetes [29]. 
Chronic inflammation
Although patients with diabetes have impaired acute immune responses to 
pathogens, there is also evidence for excessive and chronic ineffective immune 
cell activation. First, immune cell numbers are altered in diabetes. Leukocyte 
numbers are higher in patients with T2D, but not T1D, compared with healthy 
controls [30] and elevated white blood cell counts in T2D patients have been 
associated with diabetic complications [31]. Mechanistically, it has been 
shown that hyperglycemia promotes proliferation of myeloid progenitor cells 
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in the bone marrow of mice, leading to neutrophilia and monocytosis, which 
together promote the development of atherosclerosis [32]. Second, immune 
cell composition is altered in diabetes. T2D and T1D patients had more activated 
T helper and cytotoxic T cells compared with healthy controls [30]. In mice, 
hyperglycemia increased mainly pro-inflammatory monocytes [32]. Whether the 
ratio of classical monocytes towards the more pro-inflammatory non-classical 
monocytes is altered in patients with T2D or T1D is currently unknown. Third, 
in addition to changes in immune cell numbers and composition, inflammatory 
function of specific immune cells in patients with diabetes is disturbed. 
Increased inflammasome activation and production of the pro-inflammatory 
cytokine IL-1β has been observed in monocyte-derived macrophages from 
T2D patients [33]. In line with this, increased gene expression of IL-1β was also 
found in PBMCs from T1D patients [34]. In addition to elevated levels of pro-
inflammatory cytokines, also increased expression of pathogen-receptors were 
detected in patients at the onset of disease [35]. 
Inflammation is not only observed on a cellular, but also on a systemic level. 
Low grade inflammation in the development and onset of diabetes is reflected 
by elevated levels of a broad spectrum of circulating inflammatory factors, 
such as hsCRP, TNF-α and interleukins, including IL-1β, IL-6, and IL1RA [36-38]. 
Several studies have shown that increased levels of circulating inflammatory 
factors, particularly hsCRP, predict the development of cardiovascular disease, 
accounting for about two-thirds of deaths in people with diabetes [39, 40]. In 
support of the causality of this relationship is the recent demonstration that 
treatment with the IL-1β inhibitor canakinumab not only reduced IL-6 and hsCRP 
levels, but importantly decreased the cardiovascular event rates in patients with 
a high cardiovascular risk, such as patients with diabetes [41].
15
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Figure 1. The role of myeloid cells in diabetes and diabetes-associated complications. 
Altered function of monocytes and macrophages plays an important role in the pathogenesis of 
diabetes and diabetes-associated complications. A Patients with diabetes have an increased risk 
for cardiovascular disease and atherosclerosis. Patients with diabetes have increased numbers 
of circulating monocytes. Additionally, monocytes produce more pro-inflammatory cytokines. 
Increased activation of monocytes contributes to plaque formation and increases the risk for 
atherosclerosis. B Patients with diabetes have an increased risk for infections, for example 
with Mycobacterium tuberculosis (Mtb.). Macrophages have impaired phagocytic capacity and 
impaired cytokine production, leading to impaired bacterial clearance, here exemplified by 
granuloma formation after Mtb. infection. C Patients with T2D are characterized by increased 
infiltration of macrophages in pancreatic islets. Macrophages secrete cytokines, such as IL-1β, 
which impair beta cell function and contribute to impaired insulin-secretion. D Obese adipose 
tissue is characterized by increased infiltration with immune cells. Importantly, macrophages 
accumulate in so called crown-like structures (CLS) around dead adipocytes, indicating 
impaired phagocytic capacity of macrophages. Macrophages in obese adipose tissue are pro-
inflammatory and secrete increased amounts of pro-inflammatory cytokines, for example IL-6. 
Adipose tissue inflammation and elevated production of pro-inflammatory cytokines promote 
the development of insulin resistance and T2D. Images of organs were taken from the Noun 
Project.
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Adipose tissue inflammation
Although the adipose tissue has long been regarded as an energy-storage, it 
became apparent that adipose tissue also senses nutrient status, regulates 
energy mobilization and secretes various proteins, including pro-inflammatory 
cytokines. The adipose tissue is nowadays viewed as an important source of 
circulating inflammatory mediators. In the context of obesity, one of the risk 
factors for the development of T2D, the secretory profile of the adipose tissue 
is shifted towards a more pro-inflammatory state. TNFα was the first cytokine 
shown to be produced in elevated concentrations by expanding adipose tissue, 
promoting the development of insulin resistance [42]. On a molecular level, 
TNFα was shown to directly inhibit insulin receptor signaling in adipocytes [43], 
hepatocytes [44], and myocytes [45], providing the first line of evidence 
between inflammation and the development of both local and systemic insulin 
resistance. Follow-up studies have revealed that other cytokines, such as IL-1β, 
are produced by adipose tissue and also have the potential to inhibit insulin 
signaling and subsequently promote insulin resistance [46]. 
Both adaptive and innate immune cells have been implicated in the development 
of obesity-induced inflammation. Whereas immunosuppressive cells, such as 
regulatory T cells [47], eosinophils [48] and anti-inflammatory macrophages [49] 
populate lean adipose tissue, obese adipose tissue is characterized by 
pro-inflammatory immune cells, such as NK cells [50], neutrophils [51], mast 
cells [52], effector T cells [53] and pro-inflammatory macrophages [49, 54]. 
Pro-inflammatory immune cells, such as macrophages, contribute to adipose 
tissue inflammation, for example by secreting pro-inflammatory cytokines [55, 56]. 
 
For a long time, it was thought that obese adipose tissue is characterized by an 
accumulation of pro-inflammatory M1 macrophages, which contribute to insulin 
resistance, while quiescent M2 macrophages reside in lean adipose tissue and 
maintain homeostasis [49, 54]. In recent years it became apparent that macrophage 
polarization is more complex and goes beyond the M1 vs. M2 polarization model [57]. 
In obese adipose tissue, specific phenotypes exist not expressing elevated 
levels of markers characterizing classically activated M1 macrophages, but 
rather markers of so-called metabolic activation, such as proteins involved in 
lipid storage (PLIN2) and export (ABCA1) [58]. This may reflect adaptation of 
adipose tissue macrophages to the lipid-rich metabolic environment in obese 
adipose tissue. Accordingly, exposure of macrophages to increased amounts of 
glucose, insulin and fatty acids - metabolites increasingly abundant in obesity 
and diabetes - induced a similar activation pattern [58]. Metabolic activation 
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of immune cells may be receptor-mediated, for example via the insulin 
receptor, but may also be induced by changes in intracellular metabolism. 
Metabolic substrates, such as glucose, can be taken up by immune cells and 
directly interfere with intracellular energy metabolism. Changes in intracellular 
metabolism may subsequently influence inflammatory function of immune cells. 
 
 
Immunometabolism
Basic concepts of immunometabolism
The close interaction of cellular metabolism pathways and immune cell function 
is a central topic in the emerging research field of immunometabolism. The basic 
principle in metabolism, that physical activity increases energy demand, can 
be transferred to a cellular level. Whereas resting immune cells require limited 
amounts of energy, activated cells require increased amounts of ATP to fuel 
efficient effector functions. Additionally, cells require specific metabolites, for 
instance specific intermediates, to allow for cell growth and proliferation. Otto 
Warburg already described in the 1930s that differentiated cells generate energy 
mainly by oxidative phosphorylation (OXPHOS), whereas proliferative cancer 
cells mainly rely on aerobic glycolysis, even under normoxic conditions [59] 
– a phenomenon termed the Warburg effect. Although at the level of molar ratio 
between glucose and ATP the amount of ATP generated by aerobic glycolysis is 
low compared to the amount generated by oxidative metabolism, the glycolytic 
rate can be rapidly activated allowing for a fast increase in ATP production 
needed for proliferation. Additionally, cancer cells accumulate tricarboxylic 
acid (TCA) cycle intermediates, which can serve as substrates for biosynthetic 
processes. Oxaloacetate and α-ketoglutarate, for example, can provide carbon-
backbones for amino acid synthesis.
Intracellular metabolism as a determinant of immune cell function
The Warburg effect is not restricted to cancer cells, but is also characteristic 
for activated immune cells (Figure 2). Upon stimulation with the bacterial cell-
wall component lipopolysaccheride (LPS), macrophages switch from OXPHOS 
to anaerobic glycolysis [60]. At the same time, cells stimulated with LPS have 
a disrupted TCA cycle, leading to accumulation of the TCA cycle intermediates 
citrate and succinate [60]. This metabolic phenotype is characterizing pro-
inflammatory M1 macrophages, but not anti-inflammatory M2 macrophages [61]. 
M2 macrophages are characterized by an intact TCA cycle and ATP-generation 
via increased oxidative phosphorylation and fatty acid oxidation. 
18
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Figure 2. Metabolic pathways influencing immune cell function. 
Myeloid cells use energy in the form of ATP to fuel various functions, for instance phagocytosis 
and cytokine production. One of the main energy substrates for immune cells is glucose. 
Extracellular glucose is transported into the cytoplasm via GLUT1 and subsequently converted 
into pyruvate. Pyruvate is transported into mitochondria and fueling the TCA cycle. The TCA 
cycle generates the reducing agents NADH and FADH2, which are needed for ATP production 
through oxidative phosphorylation (OXPHOS) in the electron transport chain. Additionally, 
various TCA cycle intermediates – citrate, α-ketogutarate (α-KG), succinate and oxaloacetate 
(OA) – function as substrates for biosynthetic processes, such as amino acid and lipid 
biosynthesis. In addition to carbohydrate metabolism, fatty acid oxidation (FAO) and fatty acid 
synthesis (FAS) play important roles in immune cell metabolism. Upon cellular activation with 
the bacterial cell wall component lipopolysaccharide (LPS), cellular metabolism of myeloid cells 
is reprogrammed. Cellular glucose uptake is increased and enhancing glycolytic rates. Pyruvate 
is subsequently converted via anaerobic glycolysis to lactate, a process supporting fast energy 
production. Stimulation with LPS also decreases OXPHOS and leads to the accumulation of 
TCA cycle intermediates. The accumulation of succinate, for example is increasing HIF1α-levels 
and subsequently promoting IL-1β production.    
19
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Differences in cellular energy metabolism have been linked to specific cellular 
functions. Accumulation of the TCA cycle intermediate succinate, for instance, 
stabilizes the transcription factor HIF1α, contributing to increased production 
of IL-1β [60]. Interestingly, HIF1α, via the induction of PDK1, can also activate 
glycolysis to accommodate functional changes including the migration of 
macrophages [62]. Accordingly, extracellular glucose was shown to regulate 
structural changes in the cytoskeleton, which are important for morphodynamic 
changes of macrophages in response to pathogenic stimuli, for instance in the 
context of phagocytosis [63]. Nevertheless, phagocytosis is also dependent on 
other metabolic pathways. Alterations in cellular membrane structures during 
phagocytic processes require availability of lipids and accordingly, phagocytosis 
was prevented after inhibition of fatty acid synthesis [64]. Consequently, diverse 
metabolic pathways can contribute to specific immune cell function.
Extracellular factors as modulators of immune cell metabolism and 
function
Intracellular metabolism can be determined by external stimuli, by intrinsic 
factors, such as genetics and epigenetics, but will also be modulated by the 
external metabolic environment. Thus, on the one hand, specific signaling 
molecules may impact metabolic signaling routes, while on the other hand, 
nutrient availability may directly change metabolic flux after transport of 
metabolic substrates into the cell. There are indications that a change in metabolic 
flux related to differences in substrate availability translates to functional 
changes. For example, overexpression of the glucose transporter GLUT1 led to 
increased glucose uptake and a pro-inflammatory macrophage phenotype [65], 
whereas overexpression of the fatty acid transport protein 1 (FATP1) 
induced an anti-inflammatory phenotype [66]. When availability of metabolic 
substrates is changing, cells need to adapt their metabolism in order to sustain 
cellular function. Monocytes deprived of glucose, for instance, shift their 
metabolism to oxidative phosphorylation and can thereby maintain cytokine 
production [67]. Availability of metabolic substrates may depend on cellular 
location, since metabolites are differently distributed in the circulation versus 
tissues. As such, low glucose and high lactate concentrations in ischemic tissues 
may promote immune tolerance by influencing T cell metabolism [68]. Substrate 
availability is also influenced by nutrition. Increased postprandial availability of 
glucose was demonstrated to fuel glycolysis and pro-inflammatory responses in 
macrophages [69], highlighting the interplay between metabolism and immune 
cells on a cellular and systemic level.
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Circulating immune cells of patients with diabetes reside in a very different 
microenvironment compared with healthy individuals. While the main metabolic 
disturbance in patients with diabetes is hyperglycemia, they also experience 
episodes of hypoglycemia due to insulin treatment, during which there is limited 
availability of the major energy substrate for immune cells. It has already been 
demonstrated in vitro that glucose deprived monocytes have defective ROS-, 
but functional cytokine production [67]. Whether this is relevant in patients with 
diabetes in a physiologic situation is currently unknown. In addition to glucose, 
also plasma concentrations of other metabolites, such as fatty acids and amino 
acids, are altered in patients with diabetes and may thus impact on immune cell 
metabolism and function. Furthermore, other factors interfering with cellular 
metabolism, such as insulin, may be relevant in patients with diabetes. Due 
to the exogenous systemic administration, people with T1D have chronically 
elevated circulating insulin levels, as is true for patients with T2D on insulin 
treatment. Similarly, people with T2D not treated with insulin are also often 
characterized by compensatory hyperinsulinemia due to insulin resistance. 
Recent studies indicate that insulin might also regulate glucose metabolism 
in murine macrophages [69] and T cells [70]. Whether this is also the case in 
humans remains unknown. 
Outline of the thesis
Diabetes, a state of chronic, intermittent, hyperglycemia, is associated with 
the presence of a low grade systemic inflammation. Vice versa, immune cells 
and inflammatory factors seem to be involved in the development of diabetes 
and of diabetes-associated vascular complications. Although several studies 
have demonstrated altered activation of myeloid cells in patients with diabetes, 
molecular mechanisms or potential drivers to explain disturbed immune cell 
function remain insufficiently understood. Particularly the potential role and the 
alterations in intracellular metabolism of immune cells have not been investigated. 
In patients with diabetes, immune cells reside in a specific environment that 
differs from healthy individuals. This holds true both for circulating immune 
cells and for cells residing in tissues. It has been well established that metabolic 
factors can modulate immune cell function by reprogramming intracellular 
metabolism. Accordingly, the specific microenvironment in patients with diabetes 
may alter intracellular metabolism, contributing to disturbed immune cell 
function and diabetic complications (Figure 3). This thesis aims to investigate in 
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more detail the influence of various diabetes-associated factors on intracellular 
metabolism and function of human monocytes and macrophages. Understanding 
immunometabolism in the context of diabetes and diabetes-associated 
complications may open new therapeutic perspectives. 
In this thesis, we first reviewed current literature focusing on immune cell 
metabolism in patients with diabetes as well as studies investigating the 
influence of relevant diabetes-associated factors on immune cell metabolism 
and function (Chapter 2). 
To better understand how intracellular metabolism of myeloid cells can be 
changed by diabetes-associated factors in patients with diabetes, we first 
established normal immunometabolic responses of human myeloid cells to 
different stimuli. Whereas TLR4-induced changes in intracellular metabolism are 
relatively well studied, it is unclear whether other TLRs lead to a similar metabolic 
phenotype or whether metabolic reprogramming is stimulus-dependent in 
human monocytes. We therefore investigated how diverse pathogenic stimuli 
influence metabolism of human monocytes. Additionally, we explored how 
cellular metabolism is linked to function, in particular cytokine production and 
phagocytosis. The results of these studies are described Chapter 3.
Changes in immune cell metabolism are not only induced by specific pathogenic 
stimuli, but also by the metabolic environment. Inflammatory activation 
of immune cells is often accompanied by activated glycolysis, reflected by 
increased production of lactate. It has been shown that lactate has systemic anti-
inflammatory effects in mice. It is less clear, however, how lactate exerts anti-
inflammatory effects on human immune cells and whether this is relevant in vivo. 
While diabetes in itself is not associated with increased lactate levels, physiological 
and pathological conditions occur where circulating lactate levels are increased. 
Chapter 4 describes how extracellular lactate can modulate metabolic fluxes and 
cytokine production of human immune cells both in vitro and in vivo. The latter 
was achieved by lactate infusions in patients with type 1 diabetes. 
Activated immune cells are highly dependent on glycolytic metabolism. 
Consequently, disturbances in plasma glucose levels in patients with diabetes 
may impact on immune cell function. Several studies have shown that not only 
hyperglycemia, but also episodes of severe hypoglycemia are associated with 
an increased risk for cardiovascular disease in patients with diabetes, which may 
be related to inflammation. Indeed, increased levels of circulating cytokines 
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have been observed after hypoglycemia, but it remains unknown how increased 
cytokine production after hypoglycemia is mediated and whether disturbances 
in immune cell metabolism are involved. In Chapter 5 we therefore explored 
acute effects of insulin-induced hypoglycemia on immune cell composition and 
ex vivo cytokine production of PBMCs and monocytes both in healthy individuals 
and in patients with type 1 diabetes. Based on the results obtained in Chapter 5, 
we analyzed hypoglycemia-induced recruitment of immune cell subsets with 
flow cytometry in more detail in Chapter 6.
Insulin is involved in systemic regulation of glucose homeostasis and mediates 
postprandial glucose uptake into tissues. While recent studies have indicated that 
insulin may regulate glucose metabolism in murine macrophages and T cells, it is 
currently unknown whether insulin also affects (glucose) metabolism in human 
immune cells. Such an effect may be very relevant for patients with diabetes, 
because they mostly have chronically elevated insulin levels. In Chapter 7 we 
investigated both short- and long-term effects of in vitro insulin stimulations on 
metabolism and function of human monocytes and macrophages.
In addition to glycolysis, also other metabolic pathways influence cellular 
function of myeloid cells. This may be of particular importance in lipid-rich 
environments, such as the adipose tissue. Obese adipose tissue is characterized 
by an accumulation of inflammatory immune cells, such as macrophages. 
Although inflammatory and metabolic adaptations of murine adipose tissue 
macrophages have been increasingly characterized during the last years, it 
remains elusive how the local tissue environment influences cellular metabolism 
and function of human myeloid cells. In the work presented in Chapter 8, we 
therefore compared human myeloid cells from three different compartments 
(blood, subcutaneous adipose tissue and visceral adipose tissue) in order to 
reveal how the lipid-rich environment in the adipose tissue affects immune cell 
metabolism and function.
Finally, we summarize the results of the presented studies in Chapter 9 and 
discuss future research perspectives as well as implications for patients in 
Chapter 10. 
23
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Figure 3. Aim of the thesis. 
Several metabolic factors, such as glucose, insulin and fatty acids, contribute to the pathogenesis 
of diabetes and diabetes-associated complications. Additionally, the function of monocytes and 
macrophages is disturbed in patients with diabetes and also associated with the pathogenesis 
of diabetes and diabetes-associated complications. We hypothesize that metabolic factors 
directly interfere with intracellular metabolism of monocytes and macrophages and thereby 
alter cellular function, promoting diabetes-associated complications. Images of factors 
influencing metabolism were taken from the Noun Project.  
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ABSTRACT
The environment induces metabolic reprogramming of immune cells via 
specific signaling pathways. Recent studies have uncovered that changes in cell 
metabolism affect key immune cell functions including cytokine production and 
migration. In diabetes, these functions are either insufficiently or excessively 
activated, translating into diabetes-associated complications, including 
an increased susceptibility for infections and accelerated cardiovascular 
disease. Diabetes alters the abundance of environmental signals, including 
glucose, insulin and lipids. Subsequently, changes in environmental signals 
drive metabolic reprogramming, impair immune cell function, and ultimately 
contribute to diabetes-associated complications. Here, we review recent studies 
on changes in innate immune cell metabolism, especially in myeloid cells, 
driven by environmental signals relevant to diabetes, and discuss therapeutic 
perspectives of targeting metabolism of immune cells in diabetes.
Highlights
Diabetes is characterized by both impaired acute immune responses and a chronic 
low-grade inflammation, contributing to diabetes-associated complications including 
infections and cardiovascular disease.
Changes in immune cell metabolism may be the initial trigger for aberrant immune 
responses in diabetes.
Various metabolic pathways including glycolysis, mitochondrial metabolism and lipid 
metabolism are altered in immune cells from diabetes patients.
Environmental signals including glucose, fatty acids, cholesterol, insulin, diabetes drugs 
and circulating pro-inflammatory factors are elevated in diabetes patients and may 
directly impact on immune cell metabolism and ultimately function.
Understanding the impact of environmental signals on immune cell metabolism 
and function in diabetes may lead to the discovery of novel biomarkers for diabetic 
complications as well as new therapeutic targets.
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Impaired innate immune cell function in diabetes patients
Innate immune cells not only provide a first line of defense against invading 
pathogens, but also contribute significantly to the pathogenesis of various 
common diseases such as cardiovascular disease, cancer and diabetes. Both 
type 1 diabetes (T1D) and type 2 diabetes (T2D) are accompanied by chronic 
activation of innate immune cells, as shown by increased cytokine production [22] 
and inflammasome (see Glossary) activation [10]. Chronically activated innate 
immune cells contribute to the development of peripheral insulin resistance 
and β-cell dysfunction, but also aggravate diabetic complications, such as 
cardiovascular disease. Macrophage accumulation at various locations including 
adipose tissue, pancreatic islets and the vascular wall is central in these processes 
(Box 1). Macrophages exert various functions including cytokine production, 
phagocytosis of pathogens and efferocytosis, which are impaired in chronically 
activated cells in diabetes. 
Glossary
Bioenergetic health index (BHI): calculated based on mitochondrial capacity and 
flexibility, it has been proposed as a marker of mitochondrial dysfunction [1]
Coronary artery disease (CAD): is the most common type of cardiovascular disease and 
caused by atherosclerosis. Common risk factors include high blood pressure, obesity and 
diabetes.
Efferocytosis: is the process of removal of apoptotic cells by phagocytic cells, including 
macrophages. Defective efferocytosis has been implicated in several diseases like 
systemic lupus erythematosus, atherosclerosis and diabetes.
Extracellular acidification rate (ECAR): reflects glycolytic activity. End products of the 
glycolysis, protons and lactate, are secreted into the medium, leading to acidification.
Inflammasomes: are multiprotein complexes that are formed upon inflammatory 
signaling and process cytokines like IL-1β or IL-18 into their active form.
Interleukin-1β (IL-1β): is a central cytokine in innate host defense. It is produced as 
an inactive precursor and can be cleaved into its active form by processing through 
inflammasomes. 
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Conversely, diabetes is also associated with decreased innate immune cell 
activation, especially during acute inflammatory responses. This is reflected by 
aberrant cytokine production, for example impaired production of IL-1β, a key 
cytokine in host defense, by peripheral blood mononuclear cell (PBMCs) from 
patients with T1D [23] or T2D [24]. Impaired cytokine production may contribute 
to an increased susceptibility to infections [12], for instance tuberculosis [26], in 
patients with diabetes. In addition, a defective neutrophil function in diabetes 
patients also contributes to their increased susceptibility to infections [2].
Accordingly, immunomodulatory treatments aimed at restoring innate 
immune cell response may be valuable for patients with diabetes [28, 29]. 
Immunomodulatory treatments aim at either boosting insufficient or dampening 
excessive immune activation and may thus still have limited effects in diabetes, 
where both phenomena occur. Consequently, therapies tackling the underlying 
mechanisms are warranted. One important mechanism underlying impaired 
immune cell function in diabetes are alterations in cellular metabolism. 
Glossary (Continuing)
Macrophages: are phagocytic innate immune cells, residing in tissues. They originate 
from circulating monocytes or from fetal progenitor cells residing in tissues. The various 
phenotypes and functions of macrophages are tissue-specific and determined by 
activation through endogenous or exogenous factors.
Maximal respiration: reflects mitochondrial capacity. Uncouplers (e.g. FCCP) disrupt the 
proton gradient and mitochondrial membrane potential and thereby uncouple oxygen 
consumption from ATP production, leading to maximal oxygen consumption.
Peripheral blood mononuclear cells (PBMCs): consist of lymphocytes (T cells, B cells, 
NK cells) and monocytes. They can easily be isolated from whole blood by separating 
them from polymorphonuclear cells using differential centrifugation. 
Reactive oxygen species (ROS): are produced in the cytosol as well as in mitochondria 
and are an important component of host defense. Enhanced ROS production, as a 
response to various cellular stressors, however, can cause damage and lead to apoptosis.
Reserve capacity/Spare respiratory capacity (SRC): Difference between maximal and 
basal respiration; reflects mitochondrial flexibility and the cell’s ability to respond to an 
increased energy demand.
Box 1. Innate immune cells contribute to the pathogenesis of diabetes
Innate immune cells in the circulation as well as in tissues are central in the pathogenesis 
of diabetes and -associated complications. 
Both T1D and T2D patients have a higher risk for various types of infections [12]. 
Macrophages play a central role in the host defense against pathogens by producing 
cytokines, phagocytosing and killing bacteria, and by producing reactive oxygen species 
(ROS). Impaired macrophage functions in diabetes patients contribute to a higher risk 
for infections. For instance, alveolar macrophages of diabetic mice showed impaired 
phagocytosis of Mycobacterium tuberculosis, probably due to altered expression of 
receptors important for pathogen recognition [15].   
T1D and T2D patients have an increased risk to develop cardiovascular disease and 
atherosclerosis. Macrophages, derived from circulating monocytes, are the most 
abundant cells in atherosclerotic plaques. By taking up lipids, macrophages develop 
into foam cells and contribute to local inflammation and plaque development. Next 
to macrophages, NK cells likely contribute to atherosclerosis by increasing lesion size 
through release of perforin and granzyme B [16]. 
Adipose tissue inflammation is one of the major driving forces of obesity-induced insulin 
resistance. In the healthy state, immune cell infiltration is important to maintain adipose 
tissue homeostasis. Macrophages have lipid buffering capacity and are important for 
clearance of apoptotic adipocytes by efferocytosis. Obesity is characterized by increased 
accumulation of macrophages in the adipose tissue and clustering of adipose tissue 
macrophages in crown-like structures around dead adipocytes, indicating that the balance 
in the adipose tissue is disturbed. Next to their abundance, also phenotype and function 
of adipose tissue macrophages is changing, leading to impaired efferocytosis capacity 
and aberrant cytokine production, resulting in the development of insulin resistance [19]. 
Recent evidence suggests, that obesity also promotes proliferation of NK cells in adipose 
tissue, which in turn induces differentiation of pro-inflammatory macrophages [20]. 
In the pancreas, macrophages are probably involved in regulating cell proliferation and islet 
morphogenesis [25]. In the development of T2D, increased infiltration of macrophages is 
observed in pancreatic islets. Accumulation of macrophages is accompanied by elevated 
levels of pro-inflammatory cytokines that impair β-cell function, ultimately resulting in 
β-cell failure in T2D [27].
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Cellular metabolism of immune cells
The close link between cellular metabolism and function has been intensively 
investigated during the last decade leading to a new research field termed 
‘immunometabolism’. It has become apparent that innate immune cells exploit 
cellular energy metabolism to induce cytokine production [30], to control 
migration [31], and to shift polarization from anti- to pro-inflammatory 
macrophages [32]. 
Whereas the quiescent state of anti-inflammatory macrophages is associated 
with fatty acid metabolism and oxidative phosphorylation (OXPHOS), pro-
inflammatory macrophages require anaerobic glycolysis [32, 33]. One of 
the best studied cellular models in the field of immunometabolism are 
macrophages exposed to the bacterial cell wall component lipopolysaccharide 
(LPS). After stimulation with LPS macrophages undergo a switch from OXPHOS 
to glycolysis, also called the Warburg effect, which is crucial for functional 
responses including cytokine production [30]. However, recent studies have 
demonstrated that metabolic reprogramming is heterogeneous and depends 
on the type of stimulation [34] as well as substrate availability and usage [35]. 
Alterations in cellular metabolism are determined by intrinsic factors, including 
genetics [36] and epigenetics [37], yet can also be influenced by environmental 
factors, including availability of nutrients [35] and the presence of specific 
signaling molecules [38]. Environmental factors may vary dependent on the 
cellular location (circulation vs. tissue), daily fluctuations (circadian rhythm) or 
the individual’s health status. For instance, glucose levels are higher in arterial 
compared to venous blood and fluctuate over the day with postprandial peaks. 
In addition to these rather acute changes, which may influence immune cells 
transiently, chronic alterations of glucose levels also occur. In diabetes, patients 
suffer from chronic hyperglycemia, which may induce more severe, long-lasting 
alterations in immune cell metabolism.   
Evidence for environmental signals influencing innate immune 
cell metabolism in patients with diabetes
There is robust evidence for alterations in mitochondrial metabolism and 
function of immune cells isolated from diabetes patients compared to healthy 
controls (Box 2). Differences may partly be due to intrinsic immune cell properties 
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like genetic variations, but may also be triggered by external factors. Various 
environmental signals influencing metabolism including glucose, insulin and fatty 
acids, are increased in patients with diabetes and may either directly impact on 
metabolism by serving as an energy substrate or indirectly by inducing signaling 
pathways or epigenetic modifications affecting metabolism. Alterations in cellular 
metabolism subsequently affect immune cell function and thereby contribute to 
the development of diabetes-associated complications (Figure 1). 
Here we will review recent literature on metabolic profiles of innate immune 
cells from patients with diabetes and discuss recent studies investigating effects 
of (metabolic) factors influencing immune cell metabolism. We will focus on 
circulating immune cells and (adipose tissue) macrophages, which both play a 
crucial role in chronic inflammation and diabetes-associated complications. 
Box 2. Defective mitochondrial metabolism in immune cells of diabetes 
patients 
Various studies have compared metabolism of immune cells isolated from patients with 
diabetes and healthy individuals. Due to the key role in ATP production, mitochondria 
and the electron transport chain (ETC) have been frequently studied. Mitochondria have 
their own genome, encoding for 37 genes, among those several subunits of the ETC. 
Mitochondrial DNA (mtDNA) was damaged (strand breaks or cross-linked) in PBMCs 
of diabetes patients compared to healthy individuals [5]. Damaged mtDNA is known to 
be associated with mitochondrial dysfunction and indeed, mitochondria in PBMCs from 
T2D patients have a more polarized membrane potential, indicative of disturbed energy 
production [7]. Furthermore, mitochondrial mass was lower and PBMCs contained 
smaller and more spherical mitochondria. Functional relevance of these phenotypical 
changes was demonstrated in a study comparing T2D patients with healthy controls. 
T2D patients had a higher mitochondrial membrane potential and lower mitochondrial 
mass which was associated with endothelial dysfunction [11]. Defective mitochondrial 
metabolism was confirmed by extracellular flux analysis, which revealed higher basal 
oxygen consumption of PBMCs isolated from T2D patients compared to controls [13]. 
Moreover, maximal respiration, fueled by the uncoupling agent FCCP was increased. 
Currently, most studies investigate metabolism of immune cells from patients with 
diabetes in PBMCs. Since PBMCs are composed of different immune cell subtypes, which 
have distinct bioenergetic profiles [4], it would be valuable to investigate the contribution 
of specific innate immune cells to the observed metabolic differences in patients with 
diabetes.
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Figure 1. Environmental signals affect innate immune cell metabolism and function in 
diabetes. 
Various factors including insulin, fatty acids, glucose and cholesterol influence cellular 
metabolism of innate immune cells. Activation of metabolic pathways is involved in the 
regulation of several macrophage functions including phagocytosis, cytokine production, 
migration and ROS production. These functions are important for host defense against 
pathogens, as well as tissue homeostasis. In diabetes, levels of insulin, fatty acids, glucose and 
cholesterol are elevated, leading to disturbed metabolic pathways and subsequently impaired 
immune cell function, characterized by either insufficient or excessive immune cell activation. 
Impaired immune cells contribute to several diabetes-associated complications including a 
higher risk for infections, atherosclerosis and insulin resistance. BCAA = branched chain amino 
acids, ROS = reactive oxygen species
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Importantly, alterations in metabolism are not limited to these cell types, but are 
likely involved in impaired function of other innate immune cells as well (Box 3). 
Finally, we will provide an outlook of the potential therapeutic interventions 
into innate immune cell metabolism in diabetes and its usage as a potential 
biomarker for immune cell dysfunction.
Glucose
Uncontrolled glucose metabolism is central in the pathogenesis of diabetes, 
leading to hyperglycemia, but also incidental hypoglycemia can occur as a side 
effect of insulin therapy. Both hyper- and hypoglycemia may impact on immune 
cell metabolism and function directly by changing substrate availability, since 
glucose is an important energy source for immune cells [30]. Nevertheless, 
glucose availability may also lead to long-term adaptations of innate immune 
cells, mediated by epigenetic changes [39].  
Box 3. Metabolic changes in other innate immune cells in diabetes
In addition to macrophages, also neutrophils and NK cells contribute to the pathogenesis 
of diabetes-associated complications.
Decreased phagocytic and bactericidal activities of neutrophils contribute to an 
increased susceptibility for infections in patients with diabetes [2]. In contrast to other 
innate immune cells, neutrophils barely generate ATP in the mitochondria and thus rely 
primarily on glycolytic metabolism [3, 4]. Consequently, altered glucose levels in diabetes 
impact on neutrophil metabolism and function. In diabetic rats, the activity of several 
enzymes involved in glucose and glutamine metabolism was altered, leading to impaired 
phagocytosis and H2O2-production [8]. In patients with diabetes, neutrophil phagocytosis 
was not affected, however, killing capacity was impaired, and dependent on extracellular 
glucose concentrations [17]. Interestingly, insulin infusion directly increased phagocytosis 
and killing capacity of neutrophils in healthy individuals [18]. Consequently, future studies 
investigating metabolic changes in neutrophils induced by insulin are warranted.
Similarly, altered glycolytic metabolism in NK cells may contribute to diabetes-associated 
complications. NK cells isolated from obese children have increased extracellular 
acidification rates (ECAR), accompanied by increased mTOR activity and mitochondrial 
production of ROS, leading to impaired effector functions, as perforin and granzyme B 
release [21]. It needs to be determined whether disturbed metabolism of NK cells also 
occurs in adult patients with diabetes and which environmental signals, e.g. glucose or 
insulin, are inducing alterations in NK cell metabolism. 
40
Environmental signals influencing myeloid cell metabolism and function in diabetes
Hyperglycemia
Hyperglycemia increases the number of circulating monocytes in diabetic mice 
by stimulating myelopoiesis in the bone marrow, mediated via S100A8/A9 [40]. 
This is reflected in T1D patients, where plasma levels of S100A8/A9 correlate 
with leukocyte numbers and coronary artery disease (CAD). 
Next to promoting monocytosis, hyperglycemia also drives metabolic changes 
within monocytes. Cellular glucose uptake is mediated by transporters of the GLUT 
family. Whereas GLUT1 and GLUT3 are robustly expressed in macrophages [41, 42], 
gene expression levels of GLUT2 and the insulin-regulated GLUT4 are barely 
detectable. In contrast to GLUT3, GLUT1 expression is robustly upregulated in 
conditions of high energy demand, for instance upon LPS-stimulation and in 
pro-inflammatory M1 compared to anti-inflammatory M2 macrophages [41]. 
This suggests an important role for GLUT1-mediated glucose uptake during 
inflammatory responses of innate immune cells. Indeed, overexpression of GLUT1 
in macrophages not only increased glucose uptake and glycolytic metabolism, but 
also promoted a hyperinflammatory state, evidenced by increased production 
of cytokines and reactive oxygen species (ROS) [41]. Another study reported 
that GLUT1 overexpression in macrophages increased glycolytic metabolism, 
but had no effect on cytokine production [43]. In vivo, GLUT1 overexpression in 
macrophages did not affect the development of atherosclerosis in Ldlr-/- mice, 
questioning the importance of glycolytic metabolism in macrophages for the 
development of atherosclerosis in diabetes [43]. 
In vivo relevance of glycolytic metabolism in human immune cells was demonstrated 
by a study investigating monocytes and macrophages from patients with coronary 
artery disease (CAD). Monocytes and macrophages of CAD patients displayed 
increased glucose uptake and glycolytic rates with increased activation of pyruvate 
kinase PKM2, leading to enhanced production of cytokines and ROS [42]. Likewise, 
expression of several genes involved in glycolytic metabolism, for instance GLUT1 
and the transcription factor HIF1α, a key regulator of glycolytic metabolism in 
innate immune cells [44], was upregulated. One might speculate that increased 
utilization of glucose by monocytes not only occurs during CAD, but is also apparent 
in hyperglycemic diabetes patients. Interestingly, acute hyperglycemia induced by 
octreotide-dextrose infusion in healthy individuals promotes changes in several 
metabolic pathways (pyruvate metabolism, glycolysis, OXPHOS), evidenced by 
RNA-Seq of whole blood [45]. Similarly, a comparison of PBMCs from T2D patients 
to patients with metabolic syndrome and lean healthy controls revealed aberrant 
metabolic profiles related to HIF1α activity [46]. 
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Hypoglycemia
Hypoglycemia is a common adverse effect of insulin therapy and a history of serious 
hypoglycemia has been associated both with increased mortality from cardiovascular 
disease [47] and with increased circulating inflammatory markers [48, 49]. Since 
glucose is a major energy source for immune cells, low glucose concentrations 
may impair immune cell metabolism and thus function. Indeed, human monocytes 
deprived of glucose compared to cells cultured under normoglycemic glucose levels 
used OXPHOS instead of glycolysis in response to LPS-stimulation [50], suggestive 
of a metabolic and potentially functional switch based on nutrient availability. The 
increase in OXPHOS was dependent on AMP-activated protein kinase (AMPK) 
activation and mediated by increased utilization of fatty acids. Surprisingly, although 
ROS production was reduced, no functional changes related to cytokine production, 
migration or phagocytosis were observed in monocytes deprived of glucose. Upon 
shortage of a specific nutrient, cells may first maintain their functionality by using 
intracellular energy storage, for instance glycogen, and subsequently adapt their 
metabolic pathways to exploit different substrates available in the culture medium, 
like glutamine or fatty acids. Nonetheless, the in vivo relevance of several hours of 
complete absence of specific nutrients should be carefully considered. 
In vivo, hypoglycemia will normally only last for a limited period of time, but the 
immunological consequences may sustain over time. We have shown that short-
term hypoglycemia leads to an adrenaline-mediated increase of circulating immune 
cells both in healthy controls and in patients with T1D [51]. In ex vivo studies, PBMCs 
as well as monocytes isolated during hypoglycemia produced more cytokines 
compared to cells isolated during euglycemia. Although cells isolated after 
hypoglycemia did not differ in glucose consumption or lactate production in 24h ex 
vivo stimulations, short-term effects of hypoglycemia on cellular metabolism might 
be masked by culturing the cells. Moreover, repeated hypoglycemia may have a 
more long-lasting impact on immune cells, potentially mediated by epigenetic 
changes, which may alter responses to a secondary stimulus. 
Amino acids
In addition to glucose, macrophages utilize increased amounts of glutamine 
upon LPS-stimulation [52]. Amino acids can provide tricarboxylic acid (TCA)-
cycle intermediates via anaplerosis [53]. Additionally, they regulate specific 
enzymes and functions, for instance arginine, which is a substrate for arginase, 
an important enzyme for macrophages involved in tissue repair [54].    
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Plasma levels of several amino acids have been shown to be abnormal in patients 
with diabetes. For instance, branched-chain amino acid (BCAA) levels were 
elevated in T2D patients and individuals with impaired fasting glucose compared 
to healthy individuals [55]. Plasma levels of the BCAAs isoleucine, leucine and 
valine as well as the aromatic amino acids tyrosine and phenylalanine are even 
used to predict the risk for the development of diabetes [56]. Interestingly, 
valine and leucine were not only elevated in plasma from patients with impaired 
fasting glucose or T2D compared to controls, but also within PBMCs [57], 
indicating a role in the regulation of immune cell function.
In vitro treatment of PBMCs with BCAAs leads to activation of mTOR and 
ROS production, however, only at concentrations above physiological and 
pathophysiological levels [58]. Within cells, BCAAs are transaminated by branched-
chain aminotransferase (BCAT). Transamination by BCAT is the first step in converting 
BCAAs into metabolites that can enter the TCA cycle. TCA cycle metabolites are 
important for appropriate cellular responses during LPS stimulation. Consequently, 
inhibition of BCAT1, the cytosolic form of BCAT, in human monocyte-derived 
macrophages reduced LPS-induced glycolysis and oxygen-consumption [59]. 
Accordingly, elevated BCAA levels in plasma and PBMCs in diabetes may be 
processed to TCA cycle metabolites intracellularly. TCA cycle metabolites fuel 
inflammation, for instance during LPS-stimulation [30], and thus elevated BCAAs 
may contribute to chronically activated innate immune cells in diabetes. Accordingly, 
BCAT1 inhibition may inhibit chronic inflammation in diabetes. 
Interestingly, inhibition of BCAT1 by the leucine analogue ERG240 decreased levels 
of itaconate and IRG1, an enzyme involved in itaconate synthesis, suggesting a link 
between BCAAs and itaconate [59]. Itaconate is an anti-inflammatory metabolite 
which modulates interferon responses via activation of the transcription factor 
NRF2 [60]. Whether itaconate levels are altered in immune cells from patients with 
diabetes and whether this is associated with BCAA levels is currently unknown. 
Lipids
T2D is often accompanied by dyslipidemia, illustrated by increased circulating 
concentrations of triacylglycerols and free fatty acids. In addition, other lipid 
species including cholesterols and sphingolipids are affected. Since lipids are 
energy substrates for innate immune cells [61] and also have important signaling 
functions [62], alterations in  concentrations of circulating lipids may modulate 
immune cell metabolism and function. 
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Fatty acids
Effects of elevated fatty acid levels on immune cells of patients with diabetes 
are rather unexplored, however, PBMCs isolated from T1D patients compared to 
healthy individuals had increased lipid accumulation and more peroxidized lipids 
after treatment with oleate, an unsaturated fatty acid [63]. It is unknown whether 
this effect is also existing for other (un-) saturated fatty acids and whether it is 
relevant for T1D and T2D patients in vivo. Impaired lipid accumulation in PBMCs 
may impair cellular function as cells migrate into specific tissues. For example, 
macrophages in the adipose tissue exert lipid buffering functions and thus 
increased lipid accumulation may lead to disturbed lipolysis [64]. Additionally, 
lipid accumulation in lipid droplets may also influence secretion and storage 
of inflammatory mediators like prostaglandins and modulate activity of 
interferon-induced proteins during infections [65]. It would thus be valuable to 
characterize lipid droplet number and content (lipid and protein composition) 
of macrophages from diabetes patients and to correlate them to immune cell 
function.
Fatty acid metabolism within immune cells of diabetes patients appears to be 
abnormal, as increased expression of long-chain acyl-coA synthetase 1 (ACSL1) 
was found in monocytes isolated from T1D patients compared to healthy 
individuals as well as in macrophages from Streptozotozin-induced diabetic 
mice [66]. ACSL1 converts free long-chain fatty acids into fatty acyl-CoA esters. 
Increased ACSL1 activity in mouse macrophages is accompanied by elevated 
acyl-CoA levels, a precursor of lipid synthesis including prostaglandins. In 
contrast, macrophages lacking ACSL1 had decreased levels of acyl-CoA leading 
to decreased prostaglandin production and reduced production of cytokines 
and chemokines, ultimately leading to protection from diabetes-induced 
development of atherosclerosis. Currently, it is unknown whether increased 
expression of ACSL1 in monocytes from T1D patients is similarly affecting 
immune cell function. 
Other genes involved in lipid metabolism that might influence immune cell 
function in patients with diabetes are HSL, UCP2 and PPARγ. Expression levels 
of all three genes were lower in PBMCs isolated from obese patients at risk to 
develop metabolic disease (with increased free fatty acid concentrations in the 
circulation) compared to metabolically healthy obese patients and healthy lean 
individuals [67], suggesting that a deranged lipid metabolism in immune cells is 
relevant for the development of T2D. 
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Cholesterol and oxysterols
Other lipid species that might impact on immune cell metabolism and 
function are cholesterol and cholesterol-derivatives, like oxysterols. Obese 
women or women with metabolic syndrome have increased circulating 
levels of various oxysterols, namely 7-oxocholesterol, 4α-hydroxycholesterol 
and 25-hydroxycholesterol [68]. 25-hydroxycholesterol has differential 
immunomodulatory effects; it amplifies inflammation in the context of viral 
infections [69], yet also inhibits inflammasome activation and production of IL-1β 
[70]. Whether 25-hydroxycholesterol can modulate inflammation in the context 
of diabetes is unknown. One might speculate that increased concentrations 
of extracellular 25-hydroycholesterol may contribute to impaired cytokine 
production in the context of infections, however, this might also depend on 
intracellular cholesterol metabolism. 
Interestingly, cholesterol metabolism within immune cells of diabetes patients 
is altered. A gene network in PBMCs containing cholesterol metabolism genes 
was associated with BMI as well as T2D, suggestive of a link between intracellular 
cholesterol metabolism and inflammation in T2D [71]. The deregulated gene 
network comprises genes involved in sterol uptake (LDLR, MYLIP), sterol 
synthesis (SCD, FADS1, HMGCS1, FDFT1, SQLE, CYP51A1, SC4MOL) and efflux 
(ABCA, ABCG1), that would collectively promote elevated cellular cholesterol 
content. Accumulation of cholesterol in macrophages leads to increased foam 
cell formation and in addition may affect inflammatory signaling via increased 
incorporation of cholesterol-enriched lipid rafts in the plasma membrane [72]. 
Additionally, increased cholesterol content in cells from diabetes patients may 
disturb interferon-signaling [73].  
Sphingolipids and ceramides
T2D patients have increased plasma levels of sphingolipids, for instance 
dihydroceramide and sphingomyelin, compared to T1D patients and healthy 
individuals [74]. Interestingly, sphingolipid metabolism was also altered in PBMCs 
of T2D patients compared to T1D patients and healthy individuals. Increased 
gene expression of enzymes involved in sphingolipid metabolism, for instance 
dihydroceramide desaturase 1 and sphingomyelin synthase 1, were found in 
PBMCs from T2D patients compared to T1D patients and healthy controls. 
Deficiency of sphingomyelin synthase 1 decreased LPS-induced cytokine signaling 
in macrophages as well as atherosclerosis in Ldlr-/- mice [75], suggesting that 
increased sphingomyelin synthase 1 in PBMCs of T2D patients might contribute 
to increased inflammatory gene expression and atherosclerosis. 
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Insulin
Hyperinsulinemia is observed in the development of obesity-induced insulin 
resistance, but is also occurring in patients on insulin therapy. In addition to 
regulating glucose and lipid metabolism in liver and adipose tissue, the insulin 
signaling cascade is also active in immune cells. Stimulation of human immune 
cells with insulin induces activation of the key metabolic regulators AKT [76] and 
mTOR [77]. Consequently, insulin might be involved in regulating intracellular 
fate of glucose in innate immune cells. Indeed, early studies have shown an 
increase of hexokinase and decrease of glutaminase activity in macrophages 
treated with insulin [78]. In parallel, more recent evidence suggests that 
insulin may directly enhance glycolysis in macrophages, thereby inducing IL-1β 
production [38]. One may speculate that insulin thereby contributes to 
increased IL-1β production of immune cells from patients with diabetes [10], 
nevertheless it remains to be determined whether immune cells can develop 
insulin resistance, as observed in other insulin-sensitive tissues.
In addition to glycolysis, insulin also regulates lipid metabolism, which may 
be very relevant for immune cells. Indeed, insulin was shown to inhibit activity 
of hormone sensitive lipase (HSL), an important enzyme in cholesterol ester 
metabolism, in macrophages [79]. Inhibition of HSL might lead to accumulation 
of esterified cholesterol, resulting in foam cell formation. Since HSL activation 
by insulin was observed in a macrophage cell line, it needs to be verified, whether 
HSL is also activated in cells from diabetes patients in vivo.
Most studies investigating effects of insulin on immune responses were performed 
using murine cells. Consequently, studies investigating effects of insulin on 
human immune cell metabolism and function, especially in vivo, are warranted. 
Several lines of evidence have suggested important in vivo immunomodulatory 
effects of insulin. For instance, insulin was suggested to suppress TLR4-signaling 
in human leukocytes, leading to impaired signaling pathways in T2D patients [77]. 
Additionally, T2D patients had increased infiltration of macrophages into 
adipose tissue after starting insulin therapy [80], which might be attributed 
to a direct effect of insulin on monocyte migration into the adipose tissue. 
Interestingly, mice lacking the insulin receptor on myeloid cells have decreased 
adipose tissue inflammation [81] and insulin infusions in mice led to more 
adipose tissue inflammation [82]. How insulin affects macrophage numbers 
in the adipose tissue and whether direct metabolic effects of insulin on innate 
immune cells are involved still needs to be determined. 
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Other environmental signals
It is evident that the environmental signals described above are not the only 
factors influencing innate immune cell metabolism and function in diabetes. 
Various exogenous factors, such as diabetes drugs (Box 4) may impact immune 
cell metabolism. Moreover, various endogenous factors, which do not serve as 
metabolic substrates, can influence metabolic signaling pathways, for instance 
circulating inflammatory factors, that may in part originate from inflamed 
adipose tissue. Obesity induced insulin-resistance is accompanied by increased 
plasma levels of various adipokines. Leptin was already shown to influence lipid 
droplet formation in macrophages via activation of mTOR [83]. Likewise, other 
adipokines or cytokines might be relevant environmental signals influencing 
immune cell metabolism, both locally and systemically. Additionally, increased 
levels of complement factors are associated with insulin resistance and diabetes. 
Circulating levels of complement factor C3, for instance, were associated with 
increased insulin resistance [84]. Complement factors have been shown to alter 
metabolism of immune cells in various ways [85], but whether this is relevant in 
diabetes is currently unexplored.  
In vivo, effects of single metabolites on immune cells may be limited, as 
synergistic effects of multiple signals will ultimately determine immune cell 
function. A combination of glucose, insulin and fatty acids for instance was shown 
to induce metabolically activated macrophages, with a phenotype similar to 
that of adipose tissue macrophages [86]. Consequently, to unravel mechanisms 
contributing to immune dysfunction in diabetes patients, studies should identify 
interactions and possible synergistic effects of different environmental signals. 
Furthermore, in vitro effects of single environmental signals should be carefully 
compared to phenotypes of cells from patients.
Concluding remarks and future perspectives
There is robust evidence for innate immune dysfunction in diabetes patients and 
evidence for deregulation of metabolism in innate immune cells from diabetes 
patients. However, studies linking immune cell metabolism to cellular function 
in diabetes patients are scarce. It is well established that environmental factors 
can influence cellular metabolism and thereby control functions of immune cells 
in vitro, but evidence from primary human cells in vitro and the translation of 
results to patients with diabetes is currently lacking. 
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Integrative studies combining measurements of metabolites in the circulation 
and in corresponding samples of innate immune cells on the one hand with 
functional phenotyping of immune cells (e.g. cytokine production, phagocytosis, 
migration) and clinical parameters on the other hand would be valuable to 
identify environmental signals influencing metabolism and function of immune 
cells. The challenge will be to distinguish factors and metabolites that drive 
immune cell dysfunction in diabetes from those that are a consequence of 
aberrant immune responses. Another future challenge relates to the frequent 
use of PBMCs. Since different immune cell subtypes have specific metabolic 
profiles [4] and exert different functions, future studies investigating effects of 
environmental signals on specific immune cell subtypes are warranted. 
Immunometabolism in diabetes as a biomarker
Elucidating changes in immune cell metabolism in diabetes not only helps 
in understanding mechanisms involved in the pathogenesis of diabetic 
complications, but also in developing biomarkers to identify patients at risk for 
Box 4. Influence of diabetes drugs on innate immune cells 
In addition to endogenous signals, metabolism and function of innate immune cells may 
also be regulated by exogenous factors, like drugs interfering with systemic glucose 
metabolism.
The most commonly prescribed drug for the first-line treatment of T2D is the biguanide 
metformin, which inhibits gluconeogenesis in the liver and increases glucose uptake in 
peripheral tissues. For a long time, metformin was thought to act solely via activation of 
AMPK, however, it was found to also inhibit activity of complex I in the electron transport 
chain. In vitro, metformin inhibited LPS-induced IL-1β production in mouse macrophages 
by inhibiting complex I activity [6]. Accordingly, metformin inhibited complex I activity 
in human PBMCs isolated from healthy individuals [9]. In vivo, two months treatment 
with metformin in T2D patients decreased IL-1β production in monocyte-derived 
macrophages [10]. This effect was attributed to activation of AMPK and underlines the 
immunomodulatory effects of medications interfering with metabolism.
Thiazoledinidiones are PPARγ agonists and another class of drugs applied in diabetes. In 
macrophages, pioglitazone lead to increased expression of stearoyl-CoA desaturase 1 (SCD-
1), an enzyme converting saturated into unsaturated fatty acids [14]. PPARγ agonists decrease 
macrophage apoptosis and ER stress in macrophages. Whether PPARγ agonists also impact 
fatty acid metabolism and function of human immune cells in vivo needs to be determined.
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diabetic complications. MtDNA damage was higher in PBMCs from patients with 
diabetic retinopathy [87] and diabetic nephropathy [88] compared to patients 
with diabetes only or healthy individuals. Additionally, PBMCs from patients with 
diabetic nephropathy had decreased reserve capacity and maximal respiration, 
less mitochondrial flexibility and a lower bioenergetic health index (BHI) 
compared to PBMCs from patients with diabetes only and healthy individuals [88]. 
Accordingly, metabolic profiles of PBMCs, assessed by measurements of metabolic 
flux or by gene expression of key metabolic regulators, may serve as biomarkers 
for other diabetic complications or might even predict the risk to develop diabetes. 
Ideally, metabolic changes in immune cells may be identified with a simple assay, 
determining only few key metabolites in PBMCs or even whole blood. Changes in 
metabolic profiles of PBMCs may partly reflect exposure of circulating immune 
cells to specific signals that also affect other cell types, for instance endothelial 
cells or vascular smooth muscle cells. Consequently, identifying environmental 
signals modulating immune cell metabolism may have important implications for 
other cell types and corresponding therapies.
Immunometabolism as a therapeutic target in diabetes
Immune cell metabolism might not only serve as a biomarker, but also as a therapeutic 
target to prevent and treat diabetic complications. On the one hand, therapies 
may aim at restricting the availability of a metabolic substrate for cell metabolism, 
for instance cholesterol. On the other hand, they may directly target intracellular 
metabolic pathways. Possible targets may be single genes affecting immune cell 
metabolism and function, for instance ACSL1, or a whole gene network, for instance 
targeted by the transcription factor HIF1α. A major challenge in targeting immune 
cell metabolism is specificity, since metabolic pathways are usually exploited by 
several cell types and thus not specific to innate immune cells. Nanoparticles may 
be used to target drugs specifically to myeloid cells. Furthermore, innate immune 
cell metabolism may also be regulated by specifically targeting certain isoforms 
of metabolic enzymes. For instance, HIF1α is an important regulator of glycolysis 
and inflammation in myeloid cells [44], whereas HIF2α seems to have antagonistic 
functions [89]. Similarly, macrophage activation regulates a switch from the liver-type 
phosphofructokinase-2 (PFK2) (PFKFB1) to the ubiquitous PFK2 (PFKFB3), which 
leads to higher fructose-2,6-bisphosphate levels and increased glycolytic flux [53]. 
Activating or inhibiting the specific PFK2 isoforms may thus help in modulating 
macrophage activation in diabetes. 
Therapies targeting the cellular metabolism of innate immune cells may exploit 
drugs which modulate metabolism and which are already available. As mentioned 
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above, treatment with metformin for two months in T2D patients activated 
AMPK and decreased IL-1β production in monocyte-derived macrophages [10], 
implying that targeting immune cell metabolism may be beneficial in improving 
immune cell function and thus in ameliorating chronic inflammation in T2D. 
Moreover, the exploration of drugs targeting tumor metabolism [90] may be 
useful, since the high energy demand of overactive innate immune cells shows 
many parallels with regulation of metabolic pathways in tumor cells. 
Overall, investigating immunometabolism in patients with diabetes not only 
provides mechanistic insights into pathogenic mechanisms, but will lead to the 
identification of metabolites and metabolic phenotypes of immune cells that 
can serve as biomarkers as well as the identification of therapeutic targets to 
treat patients at risk for diabetes-associated complications related to aberrant 
immune responses.
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Outstanding questions
Which metabolic pathways regulate which specific immune cell function?
Which findings related to immunometabolism from the murine system can be directly 
translated into humans?
Is hyperglycemia altering glucose metabolism and inflammatory function of innate 
immune cells, thereby contributing to atherosclerosis in humans?
How are insulin-induced changes in immune cell metabolism regulating human immune 
cell function?
What are the unknown signals influencing immune cell metabolism in diabetes?
Can drugs targeting immune cell metabolism improve diabetes-associated complications? 
Is there a clinical benefit of immune cell metabolism-modulating compared with immune-
modulating therapies?
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ABSTRACT
Microbial stimuli such as lipopolysaccharide (LPS) induce robust metabolic 
rewiring in immune cells known as the Warburg effect. It is unknown whether this 
increase in glycolysis and decrease in oxidative phosphorylation (OXPHOS) is a 
general characteristic of monocytes that have encountered a pathogen. Using 
CD14+ monocytes from healthy donors, we demonstrated that most microbial 
stimuli increased glycolysis, but that only stimulation of Toll-like receptor (TLR) 
4 with LPS led to a decrease in OXPHOS. Instead, activation of other TLRs, 
such as TLR2 activation by Pam3CysSK4 (P3C), increased oxygen consumption 
and mitochondrial enzyme activity. Transcriptome and metabolome analysis 
of monocytes stimulated with P3C versus LPS confirmed the divergent 
metabolic responses between both stimuli, and revealed significant differences 
in the tricarboxylic acid cycle, OXPHOS and lipid metabolism pathways 
following stimulation of monocytes with P3C versus LPS. At a functional level, 
pharmacological inhibition of complex I of the mitochondrial electron transport 
chain diminished cytokine production and phagocytosis in P3C- but not LPS-
stimulated monocytes. Thus, unlike LPS, complex microbial stimuli and the 
TLR2 ligand P3C induce a specific pattern of metabolic rewiring that involves 
upregulation of both glycolysis and OXPHOS, which enables activation of host 
defence mechanisms such as cytokine production and phagocytosis.   
61
3
INTRODUCTION
Otto Warburg first described the concept of metabolic rewiring in tumour cells in 
the 1930s, and showed that differentiated cells rely on mitochondrial oxidative 
phosphorylation (OXPHOS) to generate ATP whereas tumour cells switch to 
aerobic glycolysis under normoxic conditions [1]. In recent years immunologists 
have discovered that this metabolic shift also underpins the activation and 
function of immune cells.
T-helper cells, such as activated TH1 and TH17 cells, are characterised by active 
glycolysis [2], whereas quiescent T-cells, such as regulatory and memory T 
cells, rely on OXPHOS and fatty acid oxidation for their ATP production [2, 3]. 
Similar parallels can be drawn between polarized macrophages, where pro-
inflammatory M1 macrophages are highly glycolytic, but anti-inflammatory 
M2 macrophages rely mainly on OXPHOS and fatty acid oxidation [4, 5].  These 
metabolic adaptations are thought to accommodate various functional outputs. 
For instance, intracellular metabolites such as succinate [6] and itaconate [7] 
serve not only as tricarboxylic acid (TCA) cycle intermediates but are also closely 
linked to cytokine production, macrophage polarization and microbial killing. 
As such, the shift from OXPHOS to glycolysis following activation, known as the 
Warburg effect, has been adopted as a core paradigm in the field of immunology [8]. 
Currently, the field is dominated by studies in the murine system, which have 
primarily investigated the influence of Toll-like receptor (TLR) ligands, such as 
lipopolysaccharide (LPS) on cellular metabolism [4, 7, 9, 10]. Few studies have 
investigated this switch in human immune cells [11], and it is unclear whether 
all microbial stimuli induce the Warburg effect. To build on this, we examined 
whether different microbial stimuli could induce the Warburg effect in human 
monocytes. Whole-pathogen lysates were used to represent both gram-positive 
and gram-negative bacteria, whereas TLR4 (LPS) and TLR2 (Pam3CysSK4 
(P3C)) ligands were used at different concentrations for mechanistic studies. 
Additionally, we investigated the consequences of metabolic rewiring on two 
functional outputs: cytokine production and phagocytosis. 
Surprisingly, we discovered that a shift from OXPHOS to glycolysis was 
observed only in monocytes stimulated with concentrations of 1-100 ng ml-1 
LPS, but not in monocytes stimulated with P3C or other bacterial lysates. In 
monocytes stimulated with P3C, increased OXPHOS was needed for retention 
of their phagocytic capacity and cytokine production. These findings therefore 
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challenge the notion that a shift from OXPHOS to glycolysis underlies activation 
of all immune cells upon microbial stimulation. Instead, we propose that each 
individual stimulus induces a complex set of metabolic programmes that govern 
the function of a given immune cell. 
MATERIALS & METHODS
Healthy volunteers
PBMCs were isolated from blood donated by healthy male volunteers after 
informed consent. Ethical approval was obtained from the CMO Arnhem-
Nijmegen (NL32357.091.10). 
Isolation of PBMCs and CD14+ Monocytes 
Isolation of PBMCs was performed by differential centrifugation over Ficoll-
Paque PLUS (GE Healthcare Biosciences). Monocytes were separated from the 
PBMCs by hyperosmotic density gradient centrifugation over Percoll (Sigma-
Aldrich) and washed once with PBS. Cells were counted in a Coulter counter 
(Coulter Electronics). Alternatively, CD14+ monocytes were purified from freshly 
isolated PBMCs using MACS microbeads for positive selection, according to the 
manufacturer’s instructions (Miltenyi Biotec).
Stimulation experiments
Monocytes (2 × 105 per well) were used for Seahorse measurements, while 1 × 
106 monocytes per well were used for cytokine, RNA and western blot analysis. 
Monocytes were cultured in Roswell Park Memorial Institute (RPMI) 1640 
medium (no glucose; Gibco) supplemented with 10 μg ml−1 gentamicin (Gibco), 
10 mM pyruvate (Gibco), 10 mM HEPES (Sigma-Aldrich), 5.5 mM glucose 
(Sigma-Aldrich) and 10% human pooled serum, and stimulated with RPMI 1640, 
0.1–10 μg ml−1 P3C (EMC Microcollections), 0.1–100 ng ml−1 LPS from E. coli 
(Sigma-Aldrich), 10 μg ml−1 poly(I:C) (Invivogen), 5 μg ml−1 Mycobacterium 
tuberculosis (strain H37Rv) lysate, 1 × 106 organisms ml−1 E. coli (ATCC 35218) 
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or 1 × 106 organisms ml−1 S. aureus (clinical isolate). Unless stated otherwise, 
monocytes were stimulated with 10 ngml−1 LPS or 10 μg ml−1 P3C for 24 h. 
Monocytes were treated with 2DG (Sigma-Aldrich) to block glycolysis, with 
rotenone (Sigma-Aldrich) in combination with antimycin A to block complex I 
of the ETC, with TRIF inhibitory peptide (Pepinh-TRIF; InvivoGen) or with 
control peptide (Pepinh-Control; InvivoGen) to inhibit TRIF signalling, with 
GW9962 (Sigma-Aldrich) to inhibit PPAR-γ, with rosiglitazone (Sigma-Aldrich) 
to activate PPAR-γ, or with dimethyl itaconate (Sigma-Aldrich). For experiments 
related to hypoxia, monocytes were stimulated with LPS or P3C for 24 h and 
then incubated in hypoxic (1% oxygen) or normoxic (20% oxygen) conditions 
for 2 h before measuring the phagocytic capacity of the monocytes. Cell culture 
supernatants were collected and stored at −20 °C. Cells were lysed in TRIzol 
reagent (Invitrogen) and stored at −80 °C until RNA isolation was performed, 
or stored at −80 °C until processed for western blot analysis as described below.
Cytokine measurements
The production of IL-1β and TNF-α was measured using commercial enzyme-
linked immunosorbent assay (ELISA) kits (R&D Systems), and IL-6 and IL-10 
concentrations were also measured by ELISA (Sanquin).
Lactate measurements
Lactate was measured from cell culture supernatants after perchloric acid 
precipitation. The resulting supernatants were neutralized with NaOH. An 
enzymatic assay, in which lactate was oxidized and the resulting H2O2 was 
coupled to the conversion of Amplex Red reagent to fluorescent resorufin 
by horseradish peroxidase, was used to determine lactate levels. Either 30 μl 
lactate standard or 200-fold diluted sample was added to a black, 96-well, flat-
bottomed plate, followed by 30 μl reaction mix, which consisted of 0.6 μl 10 U ml−1 
horseradish peroxidase (Sigma-Aldrich), 0.6 μl 100 U ml−1 lactate oxidase (Sigma-
Aldrich), 0.3 μl 10 mM Amplex Red reagent (Life Technologies) and 28.5 μl PBS. 
The assay was incubated for 20 min at room temperature, and the fluorescence 
of resorufin (excitation/emission maxima of 570/585 nm) was measured on a 96-
well plate reader (Biotek).
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Extracellular flux analysis
Real-time OCR and ECARs of monocytes were analysed using an XF-96 Extracellular 
Flux Analyzer (Seahorse Bioscience). In short, basal metabolic rates of monocytes 
seeded in quintuplicate were determined during four consecutive measurements 
in unbuffered Seahorse medium (8.3 g DMEM powder, 0.016 g phenol red and 
1.85 g NaCl in 1 l Milli-Q water, pH set at 7.4 at 37 °C; sterile filtered) containing 
5.5 mM glucose and 2 mM L-glutamine. After three basal measurements, three 
consecutive measurements were taken following the addition of 1.5 μM oligomycin, 
1 mM carbonyl cyanide-4-(trifluoromethoxy) phenylhydrazone (FCCP) and 2 μM 
antimycin together with 1 μM rotenone. Glucose (20 mM) and pyruvate (1 mM) were 
added together with FCCP to fuel maximal respiration. All compounds used during 
the Seahorse runs were acquired from Sigma-Aldrich. SRC was determined as the 
absolute increase in OCR after FCCP injection compared with basal OCR. Equal cell 
numbers in the wells were assessed by measuring total DNA content using a Quant-iT 
dsDNA Assay kit (Thermofisher Scientific). The 96-well plates for Seahorse 
measurements were pretreated with Cell-Tak Cell and Tissue Adhesive (Corning).
Mitochondrial respiratory chain enzyme measurements
Assays for the measurements of the activity of the mitochondrial respiratory chain 
enzymes and citrate synthase were based on previously described methods [12-14]. 
The assays were performed  on a KoneLab autoanalyzer as described previously [15]. 
 
 
Western blotting 
Monocytes were lysed in 100 μl lysis buffer (1 M Tris buffer, pH 7.4, 0.5 M 
EDTA, 5 M NaCl, 10% ND40, 0.5 M NaF, 2.5% sodium deoxycholate, PhosSTOP 
(Roche) and cOmplete (Roche)). The cell homogenate was frozen, thawed and 
processed for western blot analysis according to the manufacturer’s instructions. 
Western blotting was carried out using Mini-PROTEAN TGX precast gels (Bio-
Rad). Proteins were transferred using the Trans-Blot Turbo system (Bio-Rad) 
according to the manufacturer’s instructions. Primary antibodies against the 
following proteins were used: actin (Sigma-Aldrich), phospho-AKT (S473) (Cell 
Signalling), total AKT (Cell Signalling), hydroxylated HIF-1α (Cell Signalling), 
PARP (Cell Signalling) and caspase-3 (Cell Signalling). Unmodified full scans of 
the blots can be found in Supplementary Figs 7 and 8.
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Phagocytosis assay
For the phagocytosis assay, 1.5 × 105 CD14+ monocytes were seeded into a 96-well 
plate and stimulated for 24 h with RPMI 1640, LPS (10 ng ml−1) or P3C (10 μg ml−1) 
(four replicates each). Inhibitors (1 μM rotenone or 1 mM 2DG) were added to 
the cells 30 min before the phagocytosis assay. Phagocytosis was assessed using 
a Vybrant Phagocytosis Assay kit (Molecular Probes). 
Cell Viability assessment by annexin V staining
The percentage of cells that underwent early or late apoptosis was determined 
by labelling with annexin V–fluorescein isothiocyanate (Biovision) and staining 
with propidium iodide (Sigma-Aldrich), according to the manufacturer’s 
instructions. Treated CD14+ cells were gently scraped after incubation with 
Versene solution (Gibco) for 15 min on ice, washed with PBS and resuspended in 
200 μl RPMI 1640. The cells were incubated on ice in the dark with 1 μl annexin 
V–fluorescein isothiocyanate for 15 min, followed by a 5 min incubation with 1.5 
μl propidium iodide. The relative level of apoptotic cells was detected by flow 
cytometry within 1 h, using a FC500 flow cytometer (Beckman Coulter), and the 
data were analysed using Kaluza 1.3 software (Beckman Coulter).
RNA isolation and qPCRs
RNA was isolated from CD14+ cells using TRIzol reagent (Invitrogen), according 
to the manufacturer’s protocol. RNA was transcribed into complementary DNA 
by reverse transcription using an iScript cDNA Synthesis kit (Bio-Rad). Primer 
sequences used for the qPCR are listed in Supplementary Table 1. Power SYBR 
Green PCR Master Mix (Applied Biosystems) was used for qPCR in an AB Step One 
Plus Real-time PCR System (Applied Biosystems) or a CFX384 Real-Time PCR 
Detection System (Bio-Rad). qPCR data were normalized to the housekeeping 
gene human β2-microglobulin.
Metabolite measurements
CD14+ monocytes (3 × 106) were seeded in each well of a six-well plate and 
stimulated for 24 h with RPMI 1640, LPS (10 ng ml−1) or P3C (10 μg ml−1) (two 
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replicates each). Dry cell pellets were flash frozen and stored at −80 °C. Of 
note, the same samples were used for both transcriptomics and metabolomics. 
Samples were shipped to Metabolon for processing and measurement. A total 
of 512 compounds of known structural identity were detected. Samples were 
prepared using the automated MicroLab STAR system from Hamilton Company. 
Raw data were extracted, peak identified and quality-control processed using 
Metabolon’s hardware and software. Peaks were quantified by measurement of 
the area under the curve. Metabolite data normalized to protein concentration 
(measured by a Bradford assay; Metabolon) was used for all analyses.
MetaboAnalyst 3.0 was used to explore and characterize the data set. Data 
were autoscaled, and an unsupervised analysis using PCA was performed to 
determine clustering and separation [16]. A heatmap representing the top 25 
metabolites ranked by the analysis of variance was generated. 
Microarray analysis
RNA was purified from human CD14+ monocytes using TRIzol reagent (Invitrogen), 
followed by an additional round of purification with RNeasy Minikit columns 
(Qiagen). RNA quality was assessed using RNA 6000 nanochips on the Agilent 2100 
Bioanalyzer (Agilent). Purified RNA (100 ng) was labelled with the Affymetrix WT 
PLUS reagent kit (Affymetrix) and hybridized to an Affymetrix Human Gene 1.1 ST 
array plate (Affymetrix). Hybridization, washing and scanning were carried out on 
an GeneTitan platform (Affymetrix) according to the manufacturer’s instructions. 
Arrays were normalized using the robust multi array average method [17, 18]. 
Probe sets were defined according tothe method of Dai et al. [19]. In this method, 
probes are assigned to Entrez IDs as a unique gene identifier. The P values were 
calculated using an intensity-based moderated t-statistic [20]. The microarray 
data have been submitted to the Gene Expression Omnibus (accession no. 
GSE78699). Expression changes in whole blood ex vivo  (GSE55375) [21] and 
in vivo  (GSE6269) [22] were extracted from publically available microarray data 
sets using the analysis pipeline described above.
Electron microscopy
For EM analysis of mitochondria, cells were fixed in 2% glutaraldehyde in 0.1 
M phosphate buffer (pH 7.4) and were postfixed for 1 h in 1% osmium tetroxide 
and 1% potassium ferrocyanide in 0.1 M cacodylate buffer. After being washed 
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in buffer, cells were dehydrated in an ascending series of aqueous ethanol and 
were subsequently transferred via a mixture of propylene oxide and Epon to 
pure Epon 812 as embedding medium. Ultrathin gray sections (60–80 nm) were 
cut, contrasted with aqueous 2% uranyl acetate, rinsed, and counterstained with 
lead citrate, air dried, and examined in a JEOL JEM1010 electron microscope 
(JEOL, Welwyn Garden City, UK) operating at 80 kV.
Statistics
For normally distributed parametric data the student’s t-test was used. For non-
parametric data the Wilcoxon signed-rank test was used. 
Data availability 
The data that support the findings of this study are available from the 
corresponding author upon request. Microarray data is publically available in 
the Gene Expression Omnibus under accession no. GSE78699.
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RESULTS
LPS uniquely downregulates OXPHOS compared with other 
bacterial stimuli 
CD14+ human monocytes were stimulated with a panel of commonly used 
concentrations of TLR ligands (LPS or P3C) or whole-pathogen lysates 
(Escherichia coli, Staphylococcus aureus or Mycobacterium tuberculosis) for 24 
h to investigate changes in metabolism and cytokine production. An increased 
extracellular acidification rate (ECAR) (Fig. 1a) and lactate production (Fig. 1b) 
in response to all stimuli suggested a universal increase in glycolysis following 
microbial stimulation. This was accompanied by changes in gene expression of 
enzymes in the glycolysis pathway. Specifically, expression of the first enzyme 
of glycolysis, hexokinase 2 (HK2), and the rate limiting enzyme fructose 
6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 (PFKFB3) was 
increased by all stimuli (Fig. 1c). Cytokine production (tumour-necrosis factor-α 
(TNF-α), interleukin (IL)-6, IL-1β and IL-10), a function that has been linked to 
changes in cellular metabolism [6], was also increased by all stimuli (Fig. 1d).
Next, we assessed the oxidative capacity of monocytes by measuring oxygen 
consumption rate (OCR) and spare respiratory capacity (SRC). SRC is an indicator 
of the total mitochondrial capacity of a cell, which represents the amount of 
spare energy available during periods of stress [23]. As reported previously [24], 
LPS lowered the basal OCR and SRC of human monocytes. In contrast, P3C and 
bacteria lysates increased basal OCR and SRC (Fig. 2a,b). 
69
3
Figure 1 | Glycolysis is upregulated in human monocytes after stimulation with various 
pathogenic stimuli for 24 h. 
a–d, ECAR (a), lactate production (b), expression of glycolytic enzymes (c) and cytokine 
production (d) of human monocytes treated with TLR ligands or whole-pathogen lysates 
were measured. All data (means ± s.e.m.) are from two experiments with a total of six to eight 
donors. *P < 0.05, **P < 0.01, ***P < 0.001 (paired two-tailed Student’s t-test). 
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Supporting these results, LPS decreased the activity of several enzymes in 
the mitochondrial electron transport chain (ETC), whereas P3C increased their 
activity (Fig. 2c). Similarly, microarray analysis revealed lower expression levels 
of genes that comprise the five ETC complexes in monocytes stimulated with 
LPS compared with P3C (Fig. 2d). 
Protein levels of classical regulators of energy metabolism, AKT and HIF-1α, 
were equally activated after LPS or P3C stimulation (Fig. 2e), suggesting that 
these regulators are unlikely to control OXPHOS. Mitochondrial function has 
recently been suggested to be linked to mitochondrial morphology [25]. Using 
electron microscopy, the mitochondria appeared to be larger in LPS- compared 
with P3C-stimulated monocytes (Fig. 2f). 
The transcriptome of LPS- versus P3C-treated monocytes 
reveals specific patterns of metabolic rewiring 
To validate the expression profiles of LPS- and P3C-stimulated monocytes, we 
used a publically available data set of ex vivo LPS- or P3C-stimulated whole blood. 
Principle component analysis (PCA) using genes of selected metabolic pathways 
derived from the Kyoto Encyclopedia of Genes and Genomes (KEGG) revealed a 
clear separation of untreated versus LPS- versus P3C-treated cells in both data 
sets (Fig. 3a,b). We then compared the expression levels of individual genes in each 
metabolic pathway and, as expected, observed robust changes in gene expression 
induced by LPS- or P3C-stimulated monocytes (Supplementary Fig. 1a). Overall, 
LPS led to a decrease in expression of metabolic genes compared with P3C, most 
noticeably those in the TCA cycle, OXPHOS and peroxisome proliferator-activated 
receptor (PPAR) signaling pathways (Fig. 3c and Supplementary Fig. 1a). These 
observations were validated in the ex vivo whole-blood data set (Fig. 3d). 
Of note, a similar PCA performed with publically available expression data of 
peripheral blood mononuclear cells (PBMCs) from individuals with acute E. coli 
versus S. aureus infections showed clustering that was not as distinct as LPS- versus 
P3C-stimulated monocytes (Supplementary Fig. 1b). Similarly, the metabolic 
gene expression profiles of LPS- versus P3C-stimulated monocytes showed little 
overlap with the expression profiles of PBMCs from individuals with acute E. coli 
versus S. aureus infection (Supplementary Fig. 1c). Unlike a pure population of 
monocytes, PBMCs are a heterogeneous mix of circulating immune cells with 
distinct bioenergetic profiles and distribution of respiratory chain proteins [26]. 
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LPS-treated monocytes displayed a pronounced decrease in the expression 
of genes involved in lipid handling and usage (Fig. 3d and Supplementary Fig. 
1a). Many genes in this pathway, including PPAR-γ and its targets (LPL, FABP4 
and PDK4), had lower expression in LPS- versus P3C-stimulated monocytes, 
suggesting that PPAR-γ may regulate the difference in OXPHOS between the two 
stimuli (Fig. 3e).To test this hypothesis,we inhibited PPAR-γ using the antagonist 
GW9662 and found that basal OCR was mostly unaffected (Supplementary Fig. 2a). 
GW9662 decreased IL-1β and increased IL-10 levels (Supplementary Fig. 2b). 
Treatment with rosiglitazone, a PPAR-γ agonist, had little effect on OCR and 
cytokine production in LPS- and P3C-stimulated monocytes (Supplementary Fig. 
2a,b). Together, these results do not implicate PPAR-γ as the primary regulator 
of the oxidative capacity of P3C-stimulated monocytes. Instead, PPAR-γ may 
be upregulated as a consequence of the higher levels of polyunsaturated fatty 
acids found in monocytes stimulated with P3C compared with LPS (Fig. 3f ). 
These fatty acids would function as natural ligands of PPAR-γ.
The TIR-domain-containing adapter-inducing interferon-β (TRIF) pathway is 
specifically activated downstream of TLR4 but not TLR2. Therefore, we tested 
whether poly(I:C), a TLR3 ligand that signals exclusively via TRIF, would induce 
a similar pattern of metabolic rewiring to LPS. As with P3C, stimulation with 
poly (I:C) increased ECAR and OCR (Supplementary Fig. 2c), suggesting that 
TRIF is not involved in the metabolic rewiring of LPS-treated cells. Additionally, 
inhibition of TRIF using an inhibitory peptide did not affect cytokine secretion 
or metabolic gene expression of LPS-treated cells (Supplementary Fig. 2d,e).
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LPS has dose-dependent effects on OXPHOS in human monocytes 
The concentrations of 10 ng ml−1 LPS and 10 μg ml−1 P3C used in our experiments 
are those used most commonly in the literature. To test whether the differences 
in regulation of OXPHOS were dose dependent, we stimulated monocytes with 
a range of LPS (from 0.1 to 100 ng ml−1) or P3C (from 0.1 to 10 μg ml−1) doses and 
measured metabolic and functional outcomes. Various doses of LPS (1–100 ng 
ml−1) induced greater levels of IL-1β (Fig. 4a) and other cytokines (Supplementary 
Fig. 3a) compared with P3C, whereas the lowest dose of LPS (0.1 ng ml−1) was 
similar to P3C. Basal ECAR was similar for all conditions (Fig. 4b); however, OCR 
and SRC varied across the different doses of LPS but not P3C (Fig. 4c). The higher 
doses of LPS (1–100 ng ml−1) decreased the oxidative capacity of monocytes, 
whereas the lowest dose (0.1 ng ml−1) increased OXPHOS similarly to P3C. 
To test whether these changeswere reflected at a transcriptional level, we 
measured the expression of genes involved in glycolysis (PFKFB3 and GAPDH) 
and fatty acid metabolism (PPAR-γ, LPL, LIPA and CPT-1α) (Fig. 4d,e). In line 
with our findings, expression of these genes in monocytes stimulated with the 
low dose of LPS (0.1 ng ml−1) was comparible with monocytes stimulated with 
P3C (10 μg ml−1), but not with 10 ng ml−1 LPS.
Lastly, time-dependent differences in OXPHOS were observed between the 
standard doses of 10 ng ml−1 LPS and 10 μg ml−1 P3C. At 4 h post-treatment 
with LPS, the basal OCR and SRC of stimulated monocytes were increased. 
With the exception of E. coli, the stimuli had no effect on OCR and SRC at 4 h 
poststimulation (Fig. 4f). Glycolysis, as measured by ECAR and lactate 
production, was similar among all stimuli (Supplementary Fig. 3b,c). Differences 
in expression of genes involved in glycolysis and fatty acid metabolism were less 
pronounced after 4 h compared with 24 h between the two conditions (Fig. 4g,h). 
These transcriptional differences in kinetics were validated in the whole-blood 
data set stimulated with LPS versus P3C (Supplementary Fig. 3d,e). 
Although metabolic rewiring can be dependent on the maturation and activation 
state of cells, measurement of human leukocyte antigen (HLA)-DR revealed no 
differential effect on activation by 0.1 or 10 ng ml−1 LPS or by 10 μg ml−1 P3C 
(Supplementary Fig. 4a,b). P3C-stimulated monocytes expressed slightly more 
CD11c and CD83 compared with LPS. Nevertheless, stimulation with 0.1 ng ml−1 
LPS and 10 ng ml−1 LPS led to a similar maturation pattern, despite differences in 
OXPHOS, suggesting that the extent of monocyte maturation probably cannot 
explain differences in metabolic rewiring following LPS and P3C stimulation.      
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Functional consequences: OXPHOS is needed for phagocytosis, 
while cytokine production relies on both OXPHOS and glycolysis 
in P3C-stimulated monocytes
We next investigated how cytokine production and phagocytosis are influenced 
by the different metabolic programmes induced by LPS or P3C. As described 
elsewhere [27], inhibition of glycolysis with 2-deoxy-D-glucose (2DG) decreased 
IL-1β (Fig. 5a) and other cytokines (Supplementary Fig. 5a) in both conditions. 
Inhibition of OXPHOS using the complex I inhibitor rotenone lowered cytokine 
production only in P3C-stimulated cells (Fig. 5b). This points to a P3C-specific 
reliance on OXPHOS for cytokine production. In contrast to the results of Kelly 
et al. [28], IL-10 levels were decreased in rotenone-treated cells after LPS-
stimulation (Supplementary Fig. 5b). Rotenone did not affect cell death, as 
assessed by annexinV/propidium iodide staining and measurement of cleaved 
caspase-3 and poly(ADP–ribose) polymerase (PARP) (Supplementary Fig. 5c, d).
Next we determined the phagocytic capacity of stimulated monocytes and found 
that LPS lowered phagocytic rates compared with P3C (Fig. 5c). To determine 
whether OXPHOS facilitated the higher phagocytic capacity of P3C- versus LPS-
treated cells, we inhibited complex I of the ETC with rotenone. Treatment with 
rotenone significantly decreased the phagocytic capacity of P3C-stimulated 
monocytes, whereas untreated or LPS-treated monocytes were unaffected. 
However, lowering of oxygen consumption using hypoxic culture conditions (1 
versus 5% O2) had no effect (Supplementary Fig. 5e). 2DG also did not affect 
the phagocytic capacity of stimulated monocytes, suggesting that OXPHOS, 
but not glycolysis, is an important determinant of the phagocytic capacity of 
human monocytes (Fig. 5c).
Metabolite analysis reveals pronounced differences in TCA cycle 
metabolites between LPS- and P3C-stimulated monocytes 
To increase our understanding of differences in metabolic rewiring between 
LPS- and P3C-treated monocytes, we measured intracellular levels of over 
500 metabolites. PCA confirmed a robust separation in metabolic responses 
following LPS and P3C stimulation (Fig. 5d). A heat map of the top 25 
differentially regulated metabolites showed increased levels of succinate, 
citrate and itaconate specifically in LPS-treated cells, whereas gulonate levels 
were highly increased upon P3C stimulation (Fig. 5e). These findings appear 
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to match the two previously described breaks in the TCA cycle at citrate and 
succinate following LPS stimulation [29], but indicate that these breaks might 
be absent in P3C-stimulated monocytes (Fig. 5f). An increase in expression of 
IRG1, which converts citrate to itaconate, in LPS- but not in P3C-stimulated cells 
further supported these findings (Fig. 5g). Moreover, LPS stimulation decreased 
the expression of two TCA cycle enzymes, IDH1 and SDH, present after each 
break in the TCA cycle (Fig. 5g).
As shown above (Fig. 5e), itaconate has been reported to accumulate 
intracellularly in LPS-treated mouse macrophages [30]. To test whether 
itaconate plays a functional role in cytokine production, membrane-permeable 
dimethyl itaconate was added before LPS or P3C stimulation. Levels of IL-1β, 
IL-6 and IL-10 were all decreased, whereas levels of TNF-α were mainly 
unaffected following LPS or P3C stimulation (Supplementary Fig. 6a). Moreover, 
dimethyl itaconate did not change glycolytic metabolism, as assessed by lactate 
production, in either LPS- or P3C-stimulated monocytes (Supplementary Fig. 6b). 
These results highlight the importance of intracellular metabolites in the 
regulation of immune cell function and demonstrate their immunomodulatory 
potential independent of the pathogenic stimulus. 
81
3
Fi
gu
re
 5
 | 
D
iff
er
en
ti
al
 m
et
ab
o
lic
 re
w
ir
in
g 
o
f h
um
an
 m
o
n
o
cy
te
s 
st
im
ul
at
ed
 w
it
h
 L
P
S
 o
r P
3C
 le
ad
s 
to
 fu
n
ct
io
n
al
 d
iff
er
en
ce
s 
in
 c
yt
o
ki
n
e 
pr
o
d
uc
ti
o
n 
an
d 
ph
ag
oc
yt
os
is
. 
82
Microbial stimulation of different Toll-like receptor signaling pathways induces diverse metabolic 
programs in human monocytes
Fi
gu
re
 5
 | 
D
iff
er
en
ti
al
 m
et
ab
o
lic
 r
ew
ir
in
g 
o
f 
h
um
an
 m
o
n
o
cy
te
s 
st
im
ul
at
ed
 w
it
h
 L
P
S
 o
r 
P
3C
 le
ad
s 
to
 f
un
ct
io
n
al
 d
iff
er
en
ce
s 
in
 c
yt
o
ki
n
e 
pr
o
d
uc
ti
o
n 
an
d 
ph
ag
oc
yt
os
is
. 
a,
b,
 IL
-1
β 
pr
od
uc
ti
on
 o
f m
on
oc
yt
es
 p
re
tr
ea
te
d 
w
it
h 
2D
G
 (a
) o
r r
ot
en
on
e 
(b
) f
or
 1
 h
 b
ef
or
e 
ad
di
ti
on
 o
f L
PS
 o
r P
3C
 fo
r 2
4 
h.
 c
, P
ha
go
cy
to
si
s 
of
 m
on
oc
yt
es
 
st
im
ul
at
ed
 w
it
h 
LP
S 
or
 P
3C
 f
or
 2
4 
h 
an
d 
tr
ea
te
d 
w
it
h 
2D
G
 o
r 
ro
te
no
ne
 f
or
 3
0 
m
in
 b
ef
or
e 
th
e 
st
ar
t 
of
 t
he
 a
ss
ay
. 
d,
 P
C
A
 p
lo
t 
ba
se
d 
on
 in
tr
ac
el
lu
la
r 
m
et
ab
ol
it
es
. e
, H
ea
tm
ap
 o
f t
he
 to
p 
25
 m
et
ab
ol
it
es
 m
os
t d
iff
er
en
ti
al
ly
 re
gu
la
te
d 
in
 m
on
oc
yt
es
 s
ti
m
ul
at
ed
 w
it
h 
LP
S
 o
r P
3C
 fo
r 2
4 
h,
 w
it
h 
re
d 
re
pr
es
en
ti
ng
 
hi
gh
er
 a
nd
 b
lu
e 
re
pr
es
en
ti
ng
 lo
w
er
 a
bu
nd
an
ce
. f
, S
ch
em
e 
sh
ow
in
g 
th
e 
re
la
ti
ve
 a
bu
nd
an
ce
 o
f T
C
A
 c
yc
le
 in
te
rm
ed
ia
te
s 
in
 m
on
oc
yt
es
 s
ti
m
ul
at
ed
 w
it
h 
LP
S 
or
 P
3C
 fo
r 2
4 
h.
 U
ni
ts
 o
n 
th
e 
y 
ax
is
 a
re
 g
iv
en
 a
s 
re
la
ti
ve
 m
et
ab
ol
it
e 
le
ve
ls
 n
or
m
al
iz
ed
 to
 c
el
lu
la
r p
ro
te
in
 c
on
te
nt
. g
, R
el
at
iv
e 
ex
pr
es
si
on
 o
f g
en
es
 in
vo
lv
ed
 
in
 r
eg
ul
at
in
g 
le
ve
ls
 o
f T
C
A
 c
yc
le
 in
te
rm
ed
ia
te
s.
 D
at
a 
(m
ea
ns
 ±
 s
.e
.m
.)
 a
re
 fr
om
 t
w
o 
ex
pe
ri
m
en
ts
 w
it
h 
a 
to
ta
l o
f fi
ve
 d
on
or
s 
(a
–c
) o
r f
ro
m
 o
ne
 e
xp
er
im
en
t 
w
it
h 
fiv
e 
do
no
rs
 (d
–g
). 
*P
 <
 0
.0
5,
 *
*P
 <
 0
.0
1 
(p
ai
re
d 
tw
o-
ta
ile
d 
St
ud
en
t’s
 t-
te
st
).
83
3
DISCUSSION
Evidence acquired mostly from in vitro stimulations of myeloid cells with LPS has 
pinpointed an increase in glycolysis and decrease in OXPHOS as characteristic 
of activated pro-inflammatory innate immune cells [31]. Our study recapitulates 
these findings in human monocytes exposed to LPS, but also demonstrated that 
a decrease in OXPHOS following activation of myeloid cells is not a universal 
response to pathogenic stimuli. Furthermore, we have linked different metabolic 
routes adopted by human monocytes following microbial stimulation to host 
defence functions, such as cytokine release and phagocytosis.   
Increased glucose utilisation following activation with TLR ligands or bacterial 
stimuli has been demonstrated previously [9] and has led to the identification 
of various upstream regulators of glycolysis, including AKT and HIF1α [6]. 
Our studies confirm these findings in human monocytes [6], as inhibition 
of glycolysis with 2DG reduced IL-1β production after stimulation with LPS 
or P3C. Although some conflicting results in murine dendritic cells [9] versus 
macrophages [6] have been reported, in human monocytes 2DG also decreased 
TNF-α, IL-6 and IL-10 production. Together with higher glycolytic rates, LPS-
stimulated monocytes displayed decreased OXPHOS and metabolic flexibility. In 
contrast, stimulation with P3C or lysates from E. coli, S. aureus or M. tuberculosis 
resulted in increased or unaltered OXPHOS and metabolic flexibility. Thus, the 
classical Warburg effect induced by LPS is not a universal prerequisite for pro-
inflammatory cytokine responses.
Pathogen-specific metabolic rewiring may fuel different functional outputs. 
In this study, we showed that the phagocytic capacity of human monocytes is 
related to their oxidative capacity. LPS stimulation lowered OXPHOS as well 
as the phagocytic capacity of monocytes in comparison with P3C stimulation. 
Similarly, inhibition of complex I of the ETC with rotenone decreased the 
phagocytic capacity of P3C-stimulated monocytes. Phagocytosis is an energy-
demanding process [32], and OXPHOS, unlike glycolysis, is characterized by 
a high ATP yield. Thus, OXPHOS seems to be more capable of supporting the 
bioenergetic demands of phagocytosis. Interestingly, the phagocytic capacity 
of monocytes was unaffected by short-term hypoxia, which, while activating 
HIF-1α, may not result in complete inhibition of mitochondrial respiration.
Previous studies have shown that macrophages are dependent on several 
metabolic pathways for phagocytosis [33, 34], making it likely that other 
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pathways, such as fatty acid oxidation, also contribute to phagocytosis. 
Similarly, as seen for phagocytosis, inhibition of OXPHOS decreased cytokine 
production from P3C- but not LPSstimulated monocytes, further emphasizing 
the fact that different stimuli may use convergent or redundant metabolic 
pathways to execute their inflammatory functions.
We attempted to delineate the differences in OXPHOS between LPS- and P3C-
stimulated monocytes in several ways. First, we examined the contribution of TRIF 
signalling, as both stimuli induce MyD88 signalling, whereas only LPS has been 
shown to activate TRIF. Poly(I:C), a TLR3 ligand exclusively recruiting TRIF [35], 
increased the oxidative capacity of monocytes, thus making it unlikely that 
signalling via TRIF contributes to the LPS-induced decrease in OXPHOS. Second, 
we looked at PPAR-γ, which has been shown to promote OXPHOS and stimulate 
mitochondrial biogenesis in mouse macrophages [36] and has been linked to the 
regulation of phagocytosis in human macrophages [37]. Although expression 
of PPAR-γ was greater in P3C- than in LPS-stimulated cells, stimulation or 
inhibition of PPAR-γ did not affect OXPHOS or the cytokine production of LPS- 
or P3C-stimulated monocytes. It is more likely that the activation of PPAR-γ by 
P3C is a consequence of stimulation rather than responsible for P3C-induced 
metabolic rewiring. Third, mitochondrial morphology was visualized. A recent 
study linked changes in mitochondrial morphology to the metabolic differences 
observed between glycolytic T-effector cells and OXPHOS-dependent T-memory 
cells. Mitochondrial fusion in T-memory cells favoured OXPHOS and fatty acid 
oxidation, whereas fission in T-effector cells led to loosening of the cristae, 
which resulted in less efficient transport of electrons through the ETC and in 
turn promoted glycolysis as an alternative fuel source [38]. Electron microscopy 
revealed larger mitochondria after LPS stimulation, suggesting that changes 
in mitochondrial morphology might contribute to differences in OXPHOS and 
metabolic rewiring after LPS versus P3C stimulation. Last, metabolome analysis 
was executed and revealed an increased presence of metabolites that have 
been shown to accumulate in a broken TCA cycle in LPS-stimulated murine 
macrophages [6, 7] in LPS- but not in P3Cstimulated human monocytes. These 
metabolites, such as citrate, succinate and itaconate, have been identified as 
important regulators of intracellular metabolism and inflammatory activation. 
For example, excess citrate is transported into the cytosol, where it is converted 
into acetyl-CoA for fatty acid synthesis, and into oxaloacetate, which promotes 
nitric oxide production, which can inhibit components of the mitochondrial ETC 
via nitrosylation [39]. These metabolites may thus serve to maintain the reduced 
respiratory capacity of LPS-stimulated monocytes. 
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Itaconate treatment of LPS-stimulated mouse macrophages has been shown to 
dampen the inflammatory response by modulating mitochondrial respiration [40]. 
Likewise, pretreatment of monocytes with itaconate lowered cytokine release 
not only in LPS- but also
in P3C-stimulated cells, demonstrating that itaconate can modulate the 
inflammatory response of human monocytes, irrespective of the stimulus. The 
modulatory effects of itaconate may be relevant in septic patients, in whom 
IRG1, the enzyme responsible for itaconate production, was found to be highly 
upregulated in their PBMCs [41]. Itaconate also plays a key role in LPS-induced 
tolerance in mouse macrophages [41]. 
Additionally, we identified gulonate to be specifically induced in P3C-stimulated 
monocytes. Gulonate is part of the glucuronic acid pathway, an alternative 
pathway for the oxidation of glucose that produces activated UDP-glucuronate. 
Gulonate is ultimately converted to D-xylulose 5-phosphate, which enters 
the pentose phosphate pathway. Therefore, gulonate and gulonate-derived 
metabolites may represent an alternative pathway to oxidize glucose in P3C-
treated cells. Specific metabolites that accumulate in P3C-treated cells, including 
gulonate, may preserve OXPHOS through as yet unidentified mechanisms.
Although LPS and P3C are often used as a model for Gramnegative bacteria 
(such as E. coli) and Gram-positive bacteria (such as S. aureus) respectively, ex 
vivo stimulations of human monocytes with LPS, E. coli, P3C or S. aureus led to 
varied metabolic profiles. In the case of LPS, a low dose (0.1 ng ml−1) induced 
similar metabolic changes to P3C, whereas higher doses led to the characteristic 
decrease in OXPHOS. This suggests that differences in signaling strength, rather 
than qualitative signalling differences between LPS and P3C, may explain the 
divergent metabolic phenotype. Of much interest, however, are the parallels of 
low-dose LPS (0.1 ng ml−1) with acute in vivo infections of E. coli, and of high-dose 
LPS (1–100 ng ml−1) with sepsis, which has recently been characterized by defects 
in OXPHOS and energy metabolism in leukocytes [42]. Concentrations of LPS 
above 0.1 ng ml−1 seem to cross a certain signalling threshold at which not only 
is glycolysis increased but OXPHOS is also reduced to maintain ATP production. 
These dose-related effects therefore emphasize the complexity of intracellular 
metabolic adaptations and the importance of selecting representative in vitro 
models for disease.
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This study highlights the complexity of metabolic rewiring in activated human 
immune cells and demonstrates the importance of understanding pathogen-
specific metabolic reprogramming. We propose that each pathogen induces 
a highly specific metabolic programme in human innate immune cells, 
thereby determining the functional output of the cells. While some functional 
outputs, such as cytokine release, may be relatively similar, the underlying 
metabolic routes may vary significantly. Targeting metabolic routes to alleviate 
inflammatory conditions or improve antimicrobial host defence thus holds 
therapeutic promise, but tailor-made approaches are warranted.
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Supplementary Figure 1 
Microarray analysis of the following datasets: human monocytes stimulated with LPS (10 ng/
mL) or P3C (10 μg/mL) for 24 h (ex vivo: monocytes), or PBMCs isolated from patients with an E. 
coli or S. aureus infection (in vivo: PBMCs; data retrieved from GSE6269). (a) Heat map of genes 
from selected KEGG-derived metabolic pathways in the ex vivo monocyte dataset. Expression 
data are presented as signal log ratio (SLR) of LPS vs. P3C, LPS vs. RPMI or P3C vs. RPMI. For 
each pathway significantly different regulated genes (q<0.01) are shown. Genes with a SLR>1.5 
or SLR<-1.5 are highlighted in bold. (b) PCA plot of the in vivo PBMC dataset based on genes 
part of selected KEGG-derived metabolic pathways. (c) Heat map of genes of selected KEGG-
derived metabolic pathways. Expression data are presented as signal log ratio (SLR) of LPS vs. 
P3C or E. coli vs. S. aureus. For each pathway the top fifteen most differentially higher (red) and 
lower (blue) expressed genes in LPS- vs. P3C- stimulated monocytes are shown. 
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Supplementary Figure 2 
(a) Basal oxygen consumption rate (OCR) of human monocytes pretreated with the PPARγ-
inhibitor GW9662 for 1 h before addition of LPS or P3C for 24 h. (b) Cytokine production of 
human monocytes pretreated with GW9662 or the PPARγ-activator rosiglitazone for 1 h before 
addition of LPS or P3C for 24 h. (c) Basal extracellular acidification rate (ECAR), OCR and spare 
respiratory capacity (SRC) of human monocytes treated with various TLR ligands for 24 h. (d, e) 
Cytokine production (d) and gene expression (e) of  human monocytes pretreated with either 
a TRIF-specific inhibitory peptide or a control peptide for 1 h before addition of LPS or P3C for 
24 h. Data (mean ± s.e.m.) are from one experiment with five donors (a), one experiment with 
three to five donors (b), two experiments with a total of eight donors (c) or one experiment with 
three donors (d, e). * p<0.05, ** p<0.01 (paired two-tailed t-test). 
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Supplementary Figure 3 
(a) Cytokine production of human monocytes treated with several doses of LPS and P3C for 24 
h. (b) Basal extracellular acidification rate (ECAR) and lactate production of human monocytes 
stimulated with TLR ligands or whole pathogen lysates for 4 h. (c) Basal oxygen consumption 
rate (OCR) and real-time changes in OCR of human monocytes stimulated with TLR ligands or 
whole pathogen lysates for 4 h, assessed during the sequential treatment with oligomycin, FCCP 
and antimycin A/rotenone. (d, e) Microarray analysis of the following datasets: human monocytes 
stimulated with LPS (10 ng/mL) or P3C (10 μg/mL) for 24 h (ex vivo: monocytes), and whole blood 
stimulated with LPS (1 ng/mL) or P3C (200 ng/mL) for 1-24 h (ex vivo: whole blood; data retrieved 
from GSE55375). (d) PCA plot of the whole blood dataset based on genes part of selected KEGG-
derived metabolic pathways. (e) Heat map of genes part of selected KEGG-derived metabolic 
pathways. Expression data are presented as signal log ratio (SLR) of LPS vs. P3C. For each 
pathway the top fifteen most differentially increased (red) or decreased (blue) genes in LPS- vs. 
P3C-stimulated monocytes are shown. Data (mean ± s.e.m.) are from one experiment with five 
donors (a) or from two experiments with a total of five to six donors (b-c). * p<0.05, ** p<0.01 
(paired two-tailed t-test). 
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Supplementary Figure 4 
Maturation markers present on human monocytes stimulated with LPS or P3C for 24 h. (a) 
Representative flow cytometry plots from one donor. (b) Mean fluorescent intensity (MFI) 
representing the presence of maturation markers in monocytes of three donors. Data (mean ± 
s.e.m.) are from one experiment with three donors. 
Supplementary Table 1 
Primer sequences used to examine gene expression levels by RT-qPCR.
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Supplementary Figure 5 
(a, b) Cytokine production of monocytes pretreated with either 2-Deoxyglucose (2DG) (a) 
or rotenone (b) for 1 h before addition of LPS or P3C for 24 h. (c, d) Cell death in monocytes 
pretreated with rotenone for 1 h prior to addition of LPS or P3C for 24 h, assessed by annexinV-
PI-staining (c) and Western blot for PARP and cleaved caspase-3 (d). (e) Phagocytic capacity of 
monocytes stimulated with LPS or P3C for 24 h and held under normoxic or hypoxic conditions 
for 2 h prior to the start of the assay. Data (mean ± s.e.m.) are from two experiments with a 
total of five donors (a-b), or one experiment with three donors (c-e). * p<0.05, ** p<0.01 (paired 
two-tailed t-test). 
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Supplementary Figure 6 
Cytokine (a) and lactate (b) production of human monocytes pretreated with dimethyl itaconate 
(DI) for 1 h before addition of LPS or P3C for 24 h. Data (mean ± s.e.m.) are from one experiment 
with three donors. * p<0.05, ** p<0.01 (paired two-tailed t-test). 
Supplementary Figure 7 
Original scans and figures of Western blot images used in Figure 2e. The red box indicates the 
relevant samples. 
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Supplementary Figure 8 
Original scans and figures of Western blot images used in Supplementary Figure 5d. The red box 
indicates the relevant samples.

4In vitro and in vivo effects of lactate on 
metabolism and cytokine production of 
human primary PBMCs and monocytes
 
Jacqueline M. Ratter, Hanne M.M. Rooijackers, Guido J. Hooiveld, Anneke 
G.M. Hijmans, Bastiaan E. de Galan, Cees J. Tack and Rinke Stienstra
Frontiers in Immunology (2018)
4
100
In vitro and in vivo effects of lactate on metabolism and cytokine production of human primary PBMCs 
and monocytes
ABSTRACT
Lactate, the end product of anaerobic glycolysis, is produced in high 
amounts by innate immune cells during inflammatory activation. Although 
immunomodulating effects of lactate have been reported, evidence from 
human studies is scarce. Here we show that expression of genes involved in 
lactate metabolism and transport is modulated in human immune cells during 
infection and upon inflammatory activation with TLR ligands in vitro, indicating 
an important role for lactate metabolism in inflammation. Extracellular lactate 
induces metabolic reprogramming in innate immune cells, as evidenced by 
reduced glycolytic and increased oxidative rates of monocytes immediately 
after exposure to lactate. A short-term infusion of lactate in humans in vivo 
increased ex vivo glucose consumption of PBMCs, but effects on metabolic 
rates and cytokine production were limited. Interestingly, long-term 
treatment with lactate ex vivo, reflecting pathophysiological conditions in local 
microenvironments such as tumor or adipose tissue, significantly modulated 
cytokine production with predominantly anti-inflammatory effects. We found 
time- and stimuli-dependent effects of extracellular lactate on cytokine 
production, further emphasizing the complex interplay between metabolism 
and immune cell function. Together, our findings reveal lactate as a modulator 
of immune cell metabolism which translates to reduced inflammation and 
may ultimately function as a negative feedback signal to prevent excessive 
inflammatory responses.  
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INTRODUCTION
Intracellular metabolism influences functional properties of immune cells, with 
high glycolytic rates observed during pro-inflammatory responses [1]. Lactate, 
the end product of the glycolytic route, is produced and secreted in high amounts 
by innate immune cells upon inflammatory activation [2]. Interestingly, high 
lactate concentrations in tumor microenvironments are known to alter the 
phenotype of monocytes and macrophages by decreasing cytokine production 
and migration [3, 4]. Apart from its role in the tumor microenvironment, 
immunomodulatory effects of lactate may also be relevant in the adipose 
tissue, where concentrations vary dependent on the metabolic state [5] or in 
the circulation, where lactate levels are known to fluctuate. Circulating lactate 
levels range from 0.5-2 mM and can increase up to 10-25 mM after intense 
exercise [6, 7] or during  pathophysiologic conditions, such as sepsis [8], where 
plasma lactate levels may increase to levels above 4mM [9, 10].
Various cell types, including innate immune cells, can sense extracellular 
lactate concentrations via lactate receptors on their cell surface, for instance 
via the G-protein-coupled receptor GPR81. It has been suggested that GPR81 is 
required for the inhibitory effects of extracellular lactate on lipopolysaccharide 
(LPS)-induced IL-1β production of murine macrophages and human PBMCs 
in vitro [11]. In vivo, anti-inflammatory effects are underscored by studies 
demonstrating reduced inflammation during hepatitis  [11] and prevention of 
inflammation in a TNBS-induced colitis model [12] after lactate administration. 
Inhibition of NF-κB and inflammasome activation mediate anti-inflammatory 
effects of lactate [11], but exact underlying mechanisms remain unknown.
Although various studies have focused on GPR81-mediated effects of lactate, 
lactate can also be taken up by cells via monocarboxylate transporters (MCTs) and 
might thereby directly affect cellular metabolism and function. Expression and 
modulation of MCTs have been shown to be important for immune cell function 
in T cells and macrophages [13, 14]. Lactate treatment decreased glucose 
uptake of LPS-stimulated human monocytes [15] and high concentrations of 
extracellular lactate decreased extracellular acidification rates (ECAR) of mouse 
macrophages independent of GPR81 [16]. Together, these results suggest direct 
effects of lactate on cellular metabolism that might contribute to modulation of 
immune cell function.
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A central enzyme in lactate metabolism is lactate dehydrogenase (LDH). The 
two different isoforms LDHA and LDHB assemble in five different combinations 
into tetramers with different kinetic properties. LDHA has a higher affinity for 
pyruvate compared with lactate, thus converting pyruvate into lactate and 
NAD+, whereas LDHB preferentially converts lactate into pyruvate fueling 
oxidative metabolism. Whereas LDHA has been implicated in IFNγ-production 
by T cells [17] and anti-tumor activity of macrophages [18], the function of LDHB 
in immune cells remains elusive.
We hypothesized that extracellular lactate directly influences intracellular 
metabolism of human immune cells and thereby also their inflammatory output. 
We tested this hypothesis by examining the regulation of genes involved in lactate 
metabolism during immune cell activation. Furthermore, we studied the effects 
of extracellular lactate on metabolism and function of primary human immune 
cells isolated from blood of healthy individuals as well as effects of a short-term 
lactate infusion in people with type 1 diabetes (T1D), a disease associated with 
inflammatory traits, on ex vivo inflammatory responses of immune cells. Our 
results demonstrate that intracellular lactate metabolism is modulated during 
inflammatory activation of human immune cells. Furthermore, extracellular 
lactate affects immune cell metabolism and cytokine production time- and 
concentration-dependently and may thus serve as a negative feedback signal 
limiting inflammation.
MATERIALS AND METHODS
Healthy volunteers
Buffy coats from healthy donors were obtained after written informed consent 
(Sanquin Blood Bank, Nijmegen, the Netherlands). Additionally, PBMCs were 
isolated from fresh blood donated by healthy volunteers. Ethical approval was 
obtained by the institutional review board of the Radboud university medical 
center and all participants gave written informed consent before participation. 
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Patients with type 1 diabetes
We enrolled twelve patients with type 1 diabetes who participated in a larger 
study that consisted of either one or two glucose clamp experiments [19]. Patients 
were eligible if they had an HbA1c level <9.0 % (75 mmol/mol) and were free 
from macrovascular and microvascular complications, except for background 
retinopathy. Exclusion criteria included a history of cardiopulmonary disease, 
age > 50 years, and the use of drugs other than insulin interfering with glucose 
metabolism. None of the participants used immunomodulatory drugs. The 
institutional review board of the Radboud university medical center approved 
the study and all study participants gave written informed consent before 
participation. 
In vivo lactate infusions
Enrolled patients with type 1 diabetes underwent a stepped hyperinsulinemic-
euglycemic-hypoglycemic glucose clamp, as described previously [19]. 
Briefly, insulin was infused continuously (60 mU/m2/min) with intravenous 
administration of glucose 20% at a variable dose, guided by arterial glucose 
values (Biosen C-line; EKF Diagnostics) measured at 5-min intervals to maintain 
plasma glucose at 5.0 mmol/l (euglycemia) and 2.8 mmol/l (hypoglycemia), 
respectively. Approximately 15 minutes after achieving euglycemia, a primed 
(40 µmol/kg/min for 15 min) continuous (25 µmol/kg/min) infusion of sodium 
lactate (600 mmol/L; prepared by the Department of Pharmacy, Radboud 
university medical center, Nijmegen, The Netherlands) was administered, 
while plasma glucose levels were maintained at 5 mmol/L. Blood samples for 
isolation of PBMCs were taken just prior to starting the lactate infusion (when 
stable euglycemia (blood glucose 5.0 mmol/L) was reached, T=0), and after 25 
minutes of lactate infusion (T=1) and stable euglycemia. For the current study 
no samples were obtained under hypoglycemic conditions. 
Analytical methods
Peripheral total and differential white blood cell count were determined on a 
Sysmex XN-450. 
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Isolation of PBMCs and CD14+ monocytes 
Isolation of PBMCs was performed by differential centrifugation over Ficoll-
Paque™ PLUS (GE Healthcare Biosciences). CD14+ monocytes were purified from 
freshly isolated PBMCs using MACS microbeads for positive selection, according 
to the manufacturer’s instructions (Miltenyi Biotec). PBMCs from buffycoats were 
enriched for monocytes by hyperosmotic density gradient centrifugation over 
Percoll (Sigma-Aldrich) (used for experiments in Figure 9A-D).
Stimulation experiments
For analysis of cytokine release, 5 x 105 PBMCs or 1 x 105 monocytes were used 
per well in a 96-well plate. Cells were cultured in RPMI 1640 (no glucose, Gibco) 
supplemented with 50 μg/mL gentamycin (Gibco), 1 mM pyruvate (Gibco), 10 
mM HEPES (Sigma-Aldrich), 5.5 mM glucose (Sigma-Aldrich). If indicated cells 
were pretreated with sodium lactate (used for in vivo experiments and described 
above) and stimulated with either medium, 10 ng/mL of the TLR4 agonist 
lipopolysaccharide (LPS) from Escherichia coli (Sigma-Aldrich) or 10 μg/mL of 
the TLR2 agonist Pam3CysSK4 (Pam3Cys) (EMC Microcollections). If indicated 
α-cyano-4-hydroxycinnamic acid (Sigma-Aldrich) or sodium oxamate (Sigma-
Aldrich) were added prior to the stimulation. 
Cytokine measurements
The production of interleukin (IL)-1β, IL-6, tumour necrosis factor (TNF)-α (R&D 
Systems), and IL-10 (Sanquin) was measured by ELISA. 
Glucose measurements
Glucose concentrations were measured in cell culture supernatants. 
Measurements were based on an enzymatic reaction in which glucose is oxidized 
and the resulting H2O2 is coupled to the conversion of Amplex Red reagent to 
fluorescent resorufin by horseradish peroxidase. The fluorescence of resorufin 
(excitation/emission maxima 570/585 nm) was measured on a 96-well plate 
reader (BioTek). 
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Extracellular flux analysis 
Real-time OCR and ECAR of monocytes were analyzed using a XF-96 Extracellular 
Flux Analyzer (Seahorse Bioscience). Basal metabolic rates of monocytes 
seeded in quintuplicate were determined during consecutive measurements in 
unbuffered Seahorse medium (8.3 g DMEM powder, 0.016 g phenol red and 1.85 
g NaCl in 1 L water, pH set at 7.4 at 37 °C; sterile filtered) containing 5.5 mM 
glucose and 2 mM L-glutamine. After three basal measurements, subsequent 
measurements were performed following the addition of medium containing 
either 0, 3.5 or 15 mM Na-L-lactate. If indicated, mitochondrial metabolism 
was assessed by the subsequent injection of oligomycin A (1μM), FCCP (1μM) 
together with pyruvate (1mM) and antimycin A (2,5μM) together with rotenone 
(1,25μM) (all from Sigma-Aldrich). Flux measurements were normalized to total 
DNA content using a Quant-iT dsDNA high sensitivity assay kit (Thermofisher 
Scientific). The 96-well plates for Seahorse measurements were pretreated with 
Cell-Tak Cell and Tissue Adhesive (Corning).
RNA isolation and RT-PCR
For mRNA expression analysis, cells were lysed in TRIzol reagent (Invitrogen) and 
RNA isolation was performed according to the manufacturer’s instructions. RNA 
was transcribed into complementary DNA by reverse transcription using the 
iScript cDNA synthesis kit (Bio-Rad). Power SYBR Green PCR Master Mix (Applied 
Biosystems) was used for semiquantitative RT-PCR in a StepOnePlus™ Real-
Time PCR System (Applied Biosystems). Expression data were normalized to the 
housekeeping gene β2M. Primers with the following sequences were used: B2M_
forward ATGAGTATGCCTGCCGTGTG, B2M_reverse CCAAATGCGGCATCTTCAAAC, 
LDHA_forward ATGGCAACTCTAAAGGATCAGC, LDHA_reverse 
CCAACCCCAACAACTGTAATCT, LDHB_forward TCCGCACGACTGTTACAGAG, 
LDHB_reverse TTGCCTCTTCTTCCGCAACT.
Metabolite measurements
Metabolite quantities displayed in Figures 1D-E were retrieved from 
metabolome analysis of CD14+ monocytes stimulated with LPS or Pam3Cys 
as described earlier [20]. Data from metabolite measurements normalized to 
protein concentration was used.
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Microarray analysis
Expression changes in PBMCs isolated from patients (mostly pediatric) with acute 
infections (confirmed microbiologic diagnosis of Escherichia coli, Staphylococcus 
aureus, Streptococcus pneumonia or influenza A) were retrieved from publically 
available microarray data (GSE6269) [21]. Expression changes in human 
monocytes stimulated with LPS and Pam3Cys were retrieved from (GSE78699) 
[20]. Arrays were normalized using the robust multiarray average method 
[22, 23]. Probe sets were defined according to the method of Dai et al. [24]j. 
In this method, probes are assigned to Entrez IDs as a unique gene identifier. 
The p values were calculated using an intensity-based moderated t-statistic [25]. 
Statistical analysis
Differences between two variables were compared with the paired Wilcoxon’s 
signed rank test. For comparison of 3 or more variables Friedman’s test with 
post-hoc Dunn’s test (for selected pairs) was used. For correlation analysis 
Spearman’s rank test was used. All data are expressed as mean ± standard 
deviation (SD), unless otherwise specified. A p-value <0.05 was considered 
statistically significant. Statistical analyses were performed with GraphPad 
Prism or IBM SPSS Statistics 22. Heatmaps were generated in R studio using 
ggplot2 or the corrplot package.
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RESULTS
Lactate metabolism is involved in inflammatory responses of 
human immune cells
Gene expression of the lactate transporter MCT4 (SLC16A3) is upregulated, 
whereas LDHB expression is downregulated in PBMCs isolated from patients 
with acute infections compared with healthy controls (Figure 1A), indicating 
an important role for lactate metabolism in circulating immune cells during 
inflammation. Expression of the lactate transporter MCT1 (SLC16A1) was 
not affected significantly. To further decipher the potential role of lactate 
metabolism for human immune cells, we analyzed gene expression in monocytes 
stimulated with TLR-ligands in vitro. Stimulation of human monocytes with 
the TLR4-agonist LPS and the TLR2-agonist Pam3CysSK4 (Pam3Cys) both 
increased gene expression of SLC16A3 and decreased expression of LDHB 
compared with unstimulated cells (Figure 1B). LDHA and MCT1 expression were 
decreased in monocytes stimulated with LPS, but not affected significantly in 
cells stimulated with Pam3Cys. In line with these findings, we found increased 
extra- and intracellular lactate levels in monocytes stimulated with LPS or 
Pam3Cys compared with unstimulated cells (Figures 1C, D). Interestingly, 
intracellular pyruvate levels were higher in LPS- compared with Pam3Cys-
stimulated monocytes (Figure 1E). Different pyruvate/lactate ratios may 
indicate differential activation of LDH in LPS- versus Pam3Cys-stimulated cells. 
The change in LDHB, but not LDHA, expression upon stimulation of PBMCs 
correlated significantly with IL-1β production (Figures 1F-H), indicating an 
interaction of lactate metabolism, especially LDHB, and immune cell function.
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Figure 2. In vitro, lactate acutely shifts metabolism of human monocytes to oxidative 
phosphorylation. 
(A-D) Change of ECAR (A, B) and OCR (C, D) in human CD14+ monocytes after exposure to 
lactate, presented as raw data or % baseline (before lactate injection). (E) OCR/ECAR after 
lactate injection. (F) Spare respiratory capacity (SRC) after lactate injection. Each dot represents 
one healthy individual. n=7-9, * p<0.05, ** p<0.01, Wilcoxon signed rank test (A, C), Friedman 
test with post-hoc Dunn’s test (B, D, E-F).
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Lactate acutely affects metabolism of human monocytes in vitro
The importance of LDH and MCTs in regulating inflammatory responses 
is indicative for a role of lactate in modulating immune cell metabolism. 
Recently, it was demonstrated that very high concentrations of lactate (68mM) 
immediately inhibit glycolysis of murine macrophages [16], but whether this 
effect is relevant for human immune cells at physiologic concentrations remains 
to be determined. Therefore, we investigated direct effects of Na+-lactate at 
concentrations occurring in the circulation after exercise or in pathophysiologic 
conditions (3.5mM and 15mM) on cellular metabolism of CD14+ monocytes 
isolated from blood of healthy volunteers. Lactate concentrations in this range 
decreased cytokine production by murine macrophages in vitro and plasma 
lactate levels of 3mM suppressed inflammation in mice in vivo [11]. Exposure to 
lactate immediately reduced extracellular acidification rate (ECAR) (Figures 2A, 
B) and increased oxygen consumption rate (OCR) (Figures 2C, D) of monocytes 
dose-dependently. Overall, this resulted in an acutely increased OCR/ECAR ratio 
after exposure of cells to lactate (Figure 2E), a metabolic state characteristic 
for anti-inflammatory responses. Lactate did not induce acute changes in spare 
respiratory capacity (SRC), implying no acute changes in mitochondrial capacity 
to respond to a sudden increase in energy demand (Figure 2F). Acute effects 
of extracellular lactate on monocyte metabolism were abolished, if cells were 
pretreated with the LDH-inhibitor oxamate (Figures 3A-D). The MCT-inhibitor 
α-cyano-4-hydroxycinnamic acid (α-CHCA) however only had limited effects on 
metabolic changes induced by lactate (Figures 3E-H).  
Inflammatory conditions alter lactate metabolism and may thus affect metabolic 
reprogramming induced by extracellular lactate. When lactate was added under 
inflammatory conditions (4h after stimulation with LPS), ECAR was decreased 
(Figures 4A, B) and OCR (Figures 4C, D) was increased, resulting in an increased 
OCR/ECAR ratio (Figure 4E). SRC was not affected by acute exposure to lactate 
(Figure 4F). 
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Figure 4. Lactate acutely shifts metabolism of inflammatory human monocytes to oxidative 
phosphorylation. 
CD14+ monocytes were stimulated with LPS for 4 h before metabolism was assessed. (A-D) 
Change of ECAR (A-B) and OCR (C-D) in human CD14+ monocytes stimulated for 4h with LPS 
before exposure to lactate, presented as raw data or % baseline (before lactate injection). (E) 
OCR/ECAR after lactate injection. (F) Spare respiratory capacity (SRC) after lactate injection. 
Each dot represents one healthy individual. n=4, Wilcoxon signed rank test.
A short-term lactate infusion mildly affects glycolytic metabolism 
of human PBMCs ex vivo
Since lactate immediately affected human immune cell metabolism in vitro, we 
investigated whether a short-term lactate infusion in vivo also affects immune cell 
metabolism and possibly function. Due to the potential anti-inflammatory effects of 
lactate, the infusion was performed in patients with type 1 diabetes (T1D) (see Table 
1 for patient characteristics), a condition frequently accompanied by the presence 
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of a low grade inflammatory state [26]. Consequently, we expected pronounced 
anti-inflammatory effects of lactate in patients with T1D. Lactate was infused 
during stable euglycemia (5.1±0.2 mmol/L) and increased plasma lactate levels from 
1.3±0.6 mM at baseline to 3.7±0.5 mM after 20 min of infusion (p=0.002, Figure 5A). 
In line with results in healthy individuals (Figure 2), we found that lactate 
treatment in vitro acutely increased the OCR/ECAR ratio of monocytes from 
patients with T1D (Figures 5B-F). We did not find significant differences in 
metabolism between cells isolated before (T0) and directly after lactate infusion 
(T1). However, lactate infusion increased glucose consumption of unstimulated 
cells (Figure 5G). Interestingly, glucose consumption of cells stimulated with 
LPS or Pam3Cys were not affected (Figures 5H, I). 
Table 1 Baseline characteristics in people with diabetes. 
 
Total
(n=12)
Male
(n=6)
Female
(n=6)
age (years) 26.3 ± 7.8 29.3 ± 9.6 23.3 ± 4.3
BMI (kg/m2) 23.9 ± 2.2 24.5 ± 1.8 23.3 ± 2.6
duration of diabetes (years) 11.3 ± 4.4 8.2 ± 3.4 14.5 ± 2.8
HbA1c      
   % 7.1 ± 0.6   6.9 ± 0.5 7.3 ± 0.8 
   mmol/mol 53.8 ± 7.1 51.5 ± 5.4 56.2 ± 8.2
Data are means ± SD.
A short-term lactate infusion only mildly affects ex vivo cytokine 
production of PBMCs
Although effects on glycolytic metabolism were minor, we tested whether 
lactate infusion modulated inflammatory responses of immune cells. In line 
with mild effects on metabolism, the short-term lactate infusion did not affect 
LPS-induced cytokine production ex vivo significantly (Figure 6A). Since lactate 
may affect immune cell metabolism, and metabolic pathways are differentially 
regulated by different TLR stimulations [20], PBMCs were also stimulated with 
Pam3Cys. Surprisingly, in vivo administration of lactate even mildly increased 
Pam3Cys-induced IL-1β production (Figure 6B).
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We observed substantial variation in the effect of lactate infusion on ex vivo 
cytokine production between different donors. To determine if the effect of 
lactate infusion on different cytokines was similar within one individual, we 
analyzed correlations between changes in different cytokines. Changes in LPS-
induced IL-1β production after lactate infusion correlated with changes in LPS-
induced IL-6 and TNF-α as well as Pam3Cys-induced IL-1β production (Figure 6C), 
indicating that lactate infusion had consistent effects on different cytokines 
within one person. 
Differential effects of the lactate infusion in different individuals may be due to 
different plasma lactate concentrations during the infusion, but might also be 
influenced by differences in glucose control and diabetes duration or differences 
in the inflammatory status at baseline. There was no difference in the effect of 
the lactate infusion between male and female participants (data not shown). We 
did not find any correlation of baseline lactate concentrations or the change in 
plasma lactate concentrations with the changes of the inflammatory response 
upon infusion (Figure 6D). Effects of the lactate infusion also did not depend 
on clinical parameters including glucose levels, HbA1c or duration of diabetes. 
However, the reduction in LPS-induced IL-1β production after lactate infusion 
correlated with the number of monocytes within the PBMCs before lactate 
infusion (Figures 6D, E) and with unstimulated gene expression levels of LDHB 
(Figures 6D, F), indicating a role for lactate metabolism in conveying the anti-
inflammatory effects of lactate.
Anti-inflammatory effects of lactate may be concentration-dependent as 
already suggested by acute effects of lactate on cellular metabolism (Figure 2), 
and may as well be dependent on the duration of exposure to lactate. Long-term 
exposure to lactate is particularly relevant in microenvironments with high local 
lactate concentrations, for example in the tumor microenvironment or in the 
adipose tissue. Addition of lactate to the culture medium for 24 h did not induce 
any cytokine production above the detection limit in unstimulated cells (data 
not shown), but reduced LPS-induced IL-1β, TNFα and IL-10 production dose-
dependently (Figures 6G-J). In contrast to LPS-induced cytokine production, 
lactate reduced Pam3Cys-induced TNFα production, but did not affect IL-1β 
production and even increased IL-10 production (Figures 6K-N). Similar effects 
were seen in PBMCs isolated after in vivo lactate infusion. 
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Lactate decreases pro-inflammatory cytokine production of 
human PBMCs in vitro
To further explore effects of long-term exposure to lactate, we investigated 
whether extracellular lactate has similar effects on ex vivo stimulations of PBMCs 
isolated from healthy individuals compared with T1D patients. Addition of lactate 
reduced LPS-induced IL-1β, IL-6, TNFα and IL-10 production (Figures 7A-D). 
When stimulated with Pam3Cys, immunomodulatory effects of lactate were 
less pronounced. Although lactate decreased Pam3Cys-induced IL-1β and TNFα 
production (Figures 7E, G), it did not affect IL-6 (Figure 7F) and even increased 
IL-10 production (Figure 7H), suggesting stimulus-dependent effects of lactate 
metabolism. Overall, in vitro effects of lactate on cytokine production were 
comparable between patients with T1D and healthy individuals and differed 
mainly in the effect of lactate on Pam3Cys-induced IL-1β production. PBMCs 
consist of several cell types, but the measured cytokines are likely monocyte-
derived. This is also suggested by a strong correlation between cytokine 
production by PBMCs and the percentage of monocytes within PBMCs (in 
patients: r=0.72 and p=0.02 for LPS-stimulated IL-6; r=0.79 and p=0.009 for 
Pam3Cys-induced IL-1β; r=0.65 and p=0.05 for Pam3Cys-induced IL-6). Similar 
to effects in PBMCs, we also observed decreased IL-1β production in monocytes 
upon exposure to lactate (Figures 8A, B). Extracellular lactate did not affect IL-6 
(Figures 8C, D) production of monocytes and even increased production of TNFα 
(Figures 8E, F). 
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Figure 8. In vitro, lactate reduces IL-1β production of monocytes. 
Cytokine production of CD14+ monocytes from healthy individuals. Monocytes were pretreated 
with lactate for 1 h before LPS (A, C, E) or Pam3Cys (B, D, F) was added for 24 h. (A-F) n=6-8. * 
p<0.05, ** p<0.01, Friedman test with post-hoc Dunn’s test.
Immunomodulating effects of lactate are time-dependent
Compared with the strong effects of lactate on metabolism and cytokine production 
in vitro, changes in ex vivo metabolism and cytokine production after lactate infusion 
were minor. Since lactate exposure induces rapid changes in metabolism, removing 
the potential substrate may lead to rapid reversal of the induced changes, reflecting 
metabolic flexibility of human immune cells depending on nutrient availability. 
We therefore tested, whether lactate also affected cytokine production, when 
it was removed before starting the stimulation. Long-term exposure to lactate 
reduced IL-1β production of monocytes (Figures 9A, B), but when monocytes were 
exposed to lactate for 1h, and lactate was washed away before stimulation with 
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LPS or Pam3Cys, anti-inflammatory effects of lactate were abolished (Figure 9C, D). 
This suggests restored immune cell function after removal of lactate. Limited 
effects of short-term lactate treatment on monocyte function are also reflected in 
metabolism. LPS-stimulated monocytes rely mainly on glycolytic metabolism and 
have low oxidative capacity reflected in low SRC. Whereas long-term exposure to 
lactate during LPS treatment increased SRC, a short-term exposure to lactate only 
had mild effects on SRC of LPS-stimulated cells (Figure 9E). The observation that 
lactate could still affect metabolism (Figure 4) and reduced cytokine production 
when added 4h after LPS (Figure 9F), suggests that the presence of lactate during 
the stimulation may be crucial for its anti-inflammatory effects.
Figure 9. Anti-inflammatory effects of lactate are time-dependent. 
Cytokine production of monocytes from healthy individuals. (A, B) Monocytes were pretreated 
with lactate for 1 h before LPS (A) or Pam3Cys (B) was added for 24 h. (C, D) Monocytes were 
pretreated with lactate for 1 h, lactate was removed and cells were washed once before LPS 
(C) or Pam3Cys (D) was added for 24 h. (E) Monocytes were treated as described for (A) or 
(C) before metabolism was measured. (F) Monocytes were stimulated with LPS. 4 h after 
stimulation, lactate was added. (A, B) n=7, (C, D) n=5, (E) n=3, (F) n=4. * p<0.05, ** p<0.01, 
Friedman test with post-hoc Dunn’s test.
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Inhibition of lactate metabolism modulates cytokine production
To further decipher how lactate metabolism is influencing cytokines production, 
we treated PBMCs with the LDH-inhibitor oxamate. Oxamate increased LPS-
induced, but decreased Pam3Cys-induced cytokine production (Figures 10A, B). 
Accordingly, the MCT-inhibitor α-CHCA increased LPS-stimulated IL-1β 
production, but decreased Pam3Cys-induced cytokine production (Figures 10C, D), 
again indicating differential roles for lactate metabolism in TLR4- versus 
TLR2-stimulated cells. This phenotype was less pronounced in monocytes. 
Oxamate and α-CHCA both reduced LPS- and Pam3Cys-induced cytokine 
production (Figures 10E-H). Effects of the inhibitors in Pam3Cys-treated cells 
were more pronounced. Noticeably, effects of the inhibitors were similar in the 
presence and absence of extracellular lactate.
DISCUSSION
Extracellular lactate acutely shifts metabolism of human immune cells from 
glycolysis to oxidative phosphorylation in vitro and thereby influences cellular 
function. Whereas short-term lactate infusion in vivo has limited effects on 
ex vivo cytokine production, long-term exposure to lactate ex vivo has robust 
anti-inflammatory effects. This suggests rapid adaptations of human immune 
cells to lactate concentrations in the microenvironment, which may affect 
tissue-specific immune cell functions.  
Studies investigating effects of lactate on inflammation have predominantly 
focused on GPR81-mediated effects, but recent studies suggest that lactate 
may also regulate inflammation by interfering with cellular metabolism [15, 16]. 
Accordingly, we found that even low concentrations of lactate acutely modulate 
cellular metabolism of human immune cells. Although we detected acute 
changes in ECAR and OCR upon exposure of monocytes to lactate in vitro, this 
metabolic profile was not observed in monocytes isolated after lactate infusion 
in vivo. This may be a power issue, because only a limited number of patients 
could be selected for extracellular flux measurements. Alternatively, isolation 
procedures and incubation of cells in culture medium prior to the Seahorse run 
may have masked effects of lactate on cellular metabolism in vivo. Metabolic 
changes induced by lactate may be reversed rapidly upon exposure to a different 
environment due to metabolic flexibility of monocytes. This is supported by 
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in vitro experiments demonstrating limited effects of a short-term lactate exposure 
on cytokine production (Figure 9C, D) and suggests that lactate may rather have 
immunomodulating effects in local microenvironments for instance in tumors or 
in the adipose tissue, where chronic elevation of lactate levels is more likely to 
occur than in the circulation. Duration of exposure to lactate may also decide on 
the outcome of  the immunomodulating effects. Whereas several studies report 
anti-inflammatory effects of lactate after 24 h [11, 15], Samuvel et al. showed that 
cells pretreated with 20 mM lactate for 24 h followed by LPS in combination with 
lactate for another 24 h, had increased rather than decreased pro-inflammatory 
cytokine production [27]. Consequently, timing effects, which might depend on 
intracellular signaling, possibly via GPR81, or on the ever-changing metabolic 
status of immune cells, should be carefully taken into account for future studies 
on in vitro or in vivo effects of lactate on immune cells. 
Next to anti-inflammatory effects of lactate on murine macrophages, it has 
been shown that elevated levels of lactate can decrease IL-1β production of 
human PBMCs in vitro [11]. Our results demonstrate that lactate also decreased 
the production of other pro-inflammatory cytokines (IL-6, TNFα). However, it 
appears that the immunomodulatory effect of lactate is stimulus-dependent. 
Whereas lactate clearly has anti-inflammatory effects in LPS-stimulated cells, 
effects are less pronounced in Pam3Cys-stimulated cells and IL-10 production 
even increased. This may in part be explained by the different metabolic 
profiles induced by LPS and Pam3Cys in human monocytes [20]. Whereas LPS-
stimulated monocytes rely more on glycolytic metabolism, Pam3Cys induces 
more oxidative phosphorylation, evidenced by increased levels of oxygen 
consumption as well as increased mitochondrial activity in Pam3Cys- versus 
LPS-stimulated cells. Hence, the robust shift away from glycolysis towards 
oxidative phosphorylation induced by lactate may have a larger impact on the 
functional output of LPS-treated cells. Circulating lactate contributes to energy 
metabolism via the tricarboxylic acid (TCA) cycle [28]. It is well established 
that LPS-stimulation of macrophages is disrupting the TCA cycle at citrate 
and succinate [29, 30]. In contrast, the TCA cycle remains intact in Pam3Cys- 
versus LPS-stimulated monocytes [20]. Hence, this difference in TLR-specific 
metabolic rewiring may contribute to the differential effects of lactate on LPS- 
versus Pam3Cys-stimulated cells.
Recently, it was reported that effector and regulatory T cells are differently 
equipped to function in low glucose, high lactate environments. Effector T cells 
have highly active glycolytic metabolism and their function is impaired by high 
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lactate levels in the environment. Due to their active glycolysis, effector T cells 
require NAD+ regeneration, but high lactate levels promote the formation 
of pyruvate, thereby leading to LDH-mediated NAD+ depletion. In contrast, 
regulatory T cells can maintain their function in high lactate environments, 
due to upregulation of  NAD+ regeneration via oxidative phosphorylation [31]. 
Accordingly, differences in LDH-activity, as suggested by different lactate/
pyruvate ratios in LPS- vs. Pam3Cys-stimulated monocytes (Figure 1D-E), and 
differences in use of oxidative phosphorylation may differentially regulate 
cellular functions in LPS- versus Pam3Cys-stimulated cells exposed to high 
concentrations of lactate. 
Our study points to an important role for LDH activity and LDH isoforms in the 
regulation of immune cell function. We observed that effects of extracellular 
lactate on metabolism were abolished when cells were treated with the general 
LDH-inhibitor oxamate (Figure 3A-D). Effects of oxamate on cytokine production 
however seemed to be independent of the presence of extracellular lactate. To 
pinpoint the role of LDHA vs. LDHB in immune cell function and further understand 
the contribution of extracellular vs. intracellular formed lactate on immune cell 
metabolism and cytokine release, studies with isoform-specific inhibition of 
LDH would be warranted. Research regarding lactate in immune cells has been 
focused on the LDH-mediated conversion of pyruvate into lactate, which leads 
to replenishment of NAD+ and secretion of lactate. However, LDH also catalyzes 
the conversion of lactate into pyruvate. Oxidation of lactate to pyruvate 
by LDHB is localized within mitochondria and supports lipid synthesis [32]. 
It has been suggested that mitochondrial or intercellular lactate-shuttles 
are important for maintenance of metabolism, for example in the brain [33]. 
Mitochondrial lactate oxidation in immune cells is rather unexplored, but 
our results suggest that lactate is used for oxidation in immune cells. LDHB 
activation in immune cells may favor the use of oxidative phosphorylation, 
which may have beneficial effects in some and detrimental in other situations. 
For our in vivo study, we only analyzed effects of lactate infusions in patients 
with type 1 diabetes. Increased inflammasome activation and IL-1β production 
of PBMCs have been described in insulin-resistant patients with type 2 diabetes 
[34] and in newly diagnosed type 1 diabetes [26]. Consequently, we expected 
lactate to have a pronounced anti-inflammatory effect in patients with T1D. In 
contrast, effects of the lactate infusion on metabolism and cytokine production 
were limited. This may be due to the fact that participants in our study were 
relatively young and well controlled, contributing to a low inflammatory status. 
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Although a subgroup of patients had higher cytokine production at baseline 
compared with healthy controls, in general cytokine levels were in a similar 
range and we did not detect significant differences in blood leukocyte numbers 
between patients and controls. Ex vivo anti-inflammatory effects of lactate were 
similar in T1D patients compared with healthy individuals. It would be of interest 
for future studies to investigate effects of higher lactate concentrations or longer 
exposure times in vivo. Before we can investigate immunomodulating effects of 
lactate in more severe chronic inflammatory diseases (e.g. inflammatory bowel 
disease) or patients with acute inflammation (infections), we first need to better 
understand time-dependencies and mechanisms by which lactate influences 
human immune cells.    
In summary, our data suggest that lactate has anti-inflammatory effects on 
cytokine production of human PBMCs in vitro by modulating immune cell 
metabolism (Figure 11). Differential responses of LPS- and Pam3Cys-stimulated 
cells in high extracellular lactate conditions suggest that the effects of lactate 
are dependent on the metabolic signature of immune cells evoked by the 
stimulus. We propose that immunomodulatory effects of lactate may serve as 
a feedback signal to limit excessive inflammatory responses of highly glycolytic 
pro-inflammatory immune cells. 
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ABSTRACT 
Severe hypoglycemic events have been associated with increased cardiovascular 
mortality in patients with diabetes, which may be explained by hypoglycemia-
induced inflammation. We used ex vivo stimulations of peripheral blood 
mononuclear cells (PBMCs) and monocytes obtained during hyperinsulinemic 
euglycemic (5.0 mmol/L)-hypoglycemic (2.6 mmol/L) clamps in 11 healthy 
participants, 10 patients with type 1 diabetes with normal awareness of 
hypoglycemia (NAH) and 10 patients with impaired awareness (IAH) to test 
whether the composition and inflammatory function of immune cells adapt a 
more pro-inflammatory state after hypoglycemia. Hypoglycemia increased 
leukocyte numbers in healthy controls and patients with NAH, but not in those 
with IAH. Leukocytosis strongly correlated with the adrenaline response to 
hypoglycemia. Ex vivo, PBMCs and monocytes displayed a more robust cytokine 
response to microbial stimulation after hypoglycemia compared to euglycemia, 
although less pronounced in patients with IAH. Interestingly, hypoglycemia 
increased the expression of markers of demargination and inflammation in 
PBMCs. We conclude that hypoglycemia promotes mobilization of specific 
leukocyte subsets from the marginal pool and induces pro-inflammatory 
functional changes in immune cells. Inflammatory responses were less 
pronounced in IAH, indicating that counterregulatory hormone responses 
are key modulators of hypoglycemia-induced pro-inflammatory effects. 
Hypoglycemia-induced pro-inflammatory changes may promote a sustained 
inflammatory state.
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INTRODUCTION
Hypoglycemia is the most common complication of insulin therapy in people 
with type 1 diabetes [1]. Patients with type 1 diabetes experience on average 
two hypoglycemic events per week and one severe event every year [2]. The 
extent to which hypoglycemia contributes to cardiovascular disease risks in 
diabetes is debated: an association between severe hypoglycemia and increased 
mortality from cardiovascular events has been established in patients with 
type 2 diabetes [3-6], but is less consistent in type 1 diabetes [6-10], even though 
hypoglycemia occurs much more frequently in patients with type 1 than in those 
with type 2 diabetes [11]. 
An increase in circulating pro-atherothrombotic factors in response to acute 
insulin-induced hypoglycemia can link hypoglycemia to cardiovascular 
complications [12-14]. In addition, hypoglycemia has been reported to increase 
leukocyte counts and circulating pro-inflammatory cytokines in both healthy 
individuals [15-18] and in patients with type 1 diabetes [14, 19], supporting 
the concept that hypoglycemia-induced systemic inflammation contributes to 
cardiovascular complications [12, 13, 15]. 
Adrenaline, the main counterregulatory hormone response to hypoglycemia in 
patients with type 1 diabetes, may play a role in the hypoglycemia-induced pro-
inflammatory response. When adrenaline is administered to healthy individuals 
(normoglycemic conditions), it specifically mobilizes leukocytes equipped with 
cytotoxic effector potential from the marginal pool (vascular epithelium) [20]. 
However, there is lack of knowledge about the role of adrenaline in hypoglycemia-
induced changes related to inflammation.
Patients with impaired awareness of hypoglycemia (IAH) are at particularly high 
risk of hypoglycemia [21] because they lack hypoglycemia warning symptoms 
and have attenuated adrenaline responses [1, 22]. If adrenaline contributes to 
hypoglycemia-induced pro-inflammatory responses, such effects may be altered 
in type 1 diabetes patients with IAH. Under euglycemic conditions, patients 
with IAH were found to have higher leukocyte counts, as well as a higher rate 
of endothelial dysfunction and preclinical atherosclerosis than sex- and age-
matched patients with type 1 diabetes without IAH [23]. In accordance, Joy et al. 
reported that antecedent hypoglycemia, which underlies the emergence of 
IAH, resulted in greater endothelial dysfunction, but inflammatory responses to 
hypoglycemia were not enhanced after prior hypoglycemia [16]. 
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Thus, hypoglycemia has been shown to increase circulating pro-inflammatory 
cytokines, but the underlying mechanisms, the role of repeated hypoglycemia 
and the relationship with counterregulatory hormone responses, particularly 
adrenaline, are incompletely understood. Since an enhanced pro-inflammatory 
state is not exclusively reflected in the levels of circulating cytokines, we studied 
the effects of acute hypoglycemia on the composition and inflammatory output 
of immune cells. We investigated these aspects by using ex vivo stimulations 
of peripheral blood mononuclear cells (PBMCs) obtained at different time 
points during hyperinsulinemic euglycemic-hypoglycemic clamps in healthy 
participants and patients with type 1 diabetes. To assess the role of sympatho-
adrenal responses to hypoglycemia in inducing potential pro-inflammatory 
effects, we also included patients with type 1 diabetes and IAH, characterized 
by impaired counterregulatory hormone responses to hypoglycemia. 
RESEARCH DESIGN AND METHODS
Participants
We recruited eleven non-diabetic participants, ten patients with type 1 diabetes and 
normal awareness of hypoglycemia (NAH), and ten patients with IAH. Patients with 
type 1 diabetes were otherwise healthy and did not use drugs that interfered with 
glucose metabolism other than insulin. Hypoglycemia awareness state, initially 
assessed by a Dutch version of the Cox questionnaire, in which a score of 0-1 out of 
5 indicates normal awareness and a score ≥3 indicates impaired awareness [24, 25], 
was determined on the basis of the adrenaline and symptomatic responses to 
the hypoglycemic clamp. Eighteen out of twenty type 1 diabetes patients were 
correctly characterized as either having IAH or NAH using the Cox questionnaire. 
The institutional review board of the Radboud university medical center approved 
the study and all participants gave written informed consent before participation. 
Experimental design
All participants presented between 8.00 and 8.30 AM at the Clinical Research 
facility after an overnight fast, having abstained from caffeine, alcohol and 
smoking for 24h. Participants with diabetes received specific instructions to 
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avoid (nocturnal) hypoglycemia the day before the clamp. Experiments were 
rescheduled in cases of hypoglycemia in the 24 hours before the clamp. Upon 
arrival two intravenous cannulae were inserted, one into the antecubital vein 
of both forearms. One forearm was placed in a heated box (55°C) so that 
arterialized venous blood could be obtained for frequent blood sampling. The 
cannula in the contralateral arm was used for infusion of glucose 20% (Baxter 
B.V., Deerfield, IL) and insulin (insulin aspart; Novo Nordisk, Bagsvaerd, 
Denmark). Baseline plasma glucose levels were determined (Biosen C-Line, 
EKF Diagnostics, Cardiff, UK) and a two-step hyperinsulinemic (60 mU/m2/
min) euglycemic (5.0±0.2 mmol/L)-hypoglycemic (2.6±0.1 mmol/L) glucose 
clamp was initiated. Plasma glucose levels were determined every five minutes 
and after a short euglycemic phase (~20 minutes), plasma glucose levels were 
gradually decreased to 2.6 mmol/l and were maintained there for 60 minutes. 
Blood samples for measurement of adrenaline were taken at euglycemia, and 
every 20 minutes during hypoglycemia. Insulin and glucagon were determined 
at euglycemia and at 60 minutes of hypoglycemia.
Analytical methods
Plasma insulin was assessed by an in-house radioimmunoassay (RIA) [26]. After 
extraction [27], plasma glucagon was measured by RIA, with a commercially available 
kit (Eurodiagnostica, Malmö, Sweden). Plasma growth hormone and cortisol were 
determined using a routine analysis method with an Electrochemiluminescent 
Immunoassay on a Modular Analytics E170 (Roche Diagnostics, GmbH, Manheim, 
Germany). Plasma adrenaline and noradrenaline were analyzed by HPLC combined 
with fluorometric detection [28]. Peripheral total and differential white blood cell 
(WBC) count were determined using a routine patient sample analysis method (flow 
cytometric analysis on a Sysmex XE-5000). 
Isolation of PBMCs and CD14+ monocytes 
Blood samples were processed for isolation of cells immediately after being drawn 
to ensure equal quality of the samples, since previous experiments showed that 
cytokine responses were altered when blood samples were processed for isolation 
at different time points after being drawn (data not shown). Isolation of PBMCs 
was performed by differential centrifugation over Ficoll-Paque™ PLUS (GE 
Healthcare Biosciences). PBMCs were washed three times with PBS and counted 
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using a Coulter counter (Coulter Electronics).  CD14+ monocytes were purified from 
freshly isolated PBMCs using MACS microbeads for positive selection, according 
to the manufacturer’s instructions (Miltenyi Biotec, Germany).
Stimulation experiments
For analysis of cytokine release, glucose consumption and lactate production, 
5 x 105 PBMCs or 1 x 105 monocytes were used per well in a 96-well plate. Cells 
were cultured in RPMI 1640 (no glucose, Gibco) supplemented with 10 μg/mL 
gentamicin (Gibco), 10 mM pyruvate (Gibco), 10 mM HEPES (Sigma-Aldrich), 
5.5 mM glucose (Sigma-Aldrich) and stimulated with either RPMI, 10 ng/mL of 
the TLR4 agonist lipopolysaccharide (LPS) from Escherichia coli (Sigma-Aldrich), 
10 μg/mL of the TLR2 agonist Pam3CysSK4 (Pam3Cys) (EMC Microcollections, 
Germany), 1 μg/mL Mycobacterium tuberculosis (H37Rv) lysate or 1 x 106 heat-
killed organisms/mL Candida albicans conidia for 24 h. Cell culture supernatants 
were collected and stored at −20°C. 
Cytokine measurements
The production of interleukin (IL)-1β, tumour necrosis factor (TNF)-α (R&D 
Systems), IL-10, IL-6 (Sanquin) and MCP-1 (eBioscience) was measured by 
ELISA. In the analysis of cytokine production by CD14+ monocytes, participants 
were excluded from analysis when cytokine production upon stimulation of 
cells after both euglycemia and hypoglycemia was below detection limits. The 
number of ‘non-responders’ was comparable between groups. 
Glucose consumption and lactate measurements
Glucose and lactate concentrations were measured in cell culture supernatants. 
Measurements are based on an enzymatic reaction in which glucose or lactate 
is oxidized and the resulting H2O2 is coupled to the conversion of Amplex
® 
Red reagent to fluorescent resorufin by horseradish peroxidise (HRP). The 
fluorescence of resorufin (excitation/emission maxima=570/585 nm) was 
measured on a 96-well plate reader (Biotek). Glucose consumption was 
calculated by subtracting the glucose concentration measured in cell culture 
supernatants from that in culture medium incubated for 24 h without cells.  
139
5
RNA isolation and qRT-PCRs
For mRNA expression analyses, PBMCs (1,5 x 106 PBMCs per condition) were 
lysed in TRIzol reagent (Invitrogen) directly after isolation and stored at −80°C 
until RNA isolation was performed according to the manufacturer’s instructions. 
RNA was transcribed into complementary DNA by reverse transcription using 
the iScript cDNA synthesis kit (Bio-Rad). Primer sequences used for quantitative 
real-time PCR (qRT-PCR) are listed in Supplementary Table 2. Power SYBR Green 
PCR Master Mix (Applied Biosystems) was used for qRT-PCR in the CFX384 Real-
Time PCR Detection System (Bio-Rad). Expression data were normalized to the 
housekeeping gene human β2M. 
Statistical analysis
Data were tested for normality using the Shapiro-Wilk test and QQ-plots. 
Within group differences were compared with paired Student’s t-tests or 
Wilcoxon’s signed rank when data were not normally distributed. Between 
group differences were analyzed by analysis of variance (ANOVA) followed by 
pair wise Bonferroni’s post-hoc tests to delineate statistical significance, and for 
non-parametric data with the Kruskal-Wallis test and post-hoc Mann-Whitney 
U tests. For correlation analysis Pearson’s correlation coefficient was used 
for normally distributed variables and Spearman’s rank test for non-normally 
distributed data. All data are expressed as mean ± standard error of the mean 
(SEM), unless otherwise specified. A p-value <0.05 was considered statistically 
significant. Statistical analyses were performed with IBM SPSS Statistics 20.
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RESULTS
Study participants were well matched for age, gender and BMI (Table 1). Duration 
of diabetes and HbA1C did not differ significantly between both patient groups.
Plasma glucose levels (Fig. 1A) and plasma insulin levels (data not shown) were 
similar in all groups during both the euglycemic and the hypoglycemic phase, 
whereas glucagon levels increased in response to hypoglycemia in healthy controls, 
but did not change in either of the patients groups (Suppl. Table 1). Adrenaline 
levels during hypoglycemia were significantly lower in patients with IAH compared 
to healthy controls and patients with NAH (0.39 ± 0.07, 1.94 ± 0.29 and 1.90 ± 0.46 
nmol/L in patients with IAH, patients with NAH and healthy controls, respectively). 
Hypoglycemia increases total leukocyte count
The total leukocyte count increased in response to hypoglycemia in healthy controls 
and in type 1 diabetes patients with NAH, but not in patients with IAH (Fig. 1B). 
This increase was mainly due to an increase in the number of lymphocytes and to a 
lesser extent to an increase in the number of monocytes (Fig. 1C-E). Consequently, 
neutrophil-to-lymphocyte ratios decreased in response to hypoglycemia (Fig. 
1G). The change in total leukocyte count correlated positively with the adrenaline 
response to hypoglycemia (R2 = 0.70, p<0.001) (Fig. 1F). The positive correlation was 
strongest in lymphocytes (R2 = 0.75, p<0.001 ), but was also seen in monocytes (R2 
= 0.33, p=0.003) and neutrophils (R2 = 0.29, p=0.007) (Suppl. Fig. 1). Looking at the 
separate groups, the positive correlation between the change in total leukocyte 
count and adrenaline response was significant in healthy controls and type 1 
diabetes patients with NAH, but not in patients with IAH.
Table 1. Participant characteristics
Healthy controls (n=11) T1DM-NAH 
 (n=10)
T1DM-IAH
(n=10)
Age, yrs 24.5 ± 5.3 24.2 ± 5.1 25.3 ± 6.0
Sex, M/F 6:5 4:6 5:5
BMI, kg/m2 22.9 ± 1.8 22.7 ± 2.2 23.4 ± 1.4
HbA1C, % (mmol/mol) - 7.5 ± 0.6 (58.5 ± 6.9) 6.9 ± 0.7 (52.1 ± 7.8)
Duration of diabetes, yrs - 10.9 ± 4.7 13.9 ± 8.1
Total daily insulin dose, IU - 48.2 ± 12.6 48.2 ± 13.2
Data are presented as number or means ± SD
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Figure 1. Hypoglycemia induces leukocytosis in healthy controls and patients with type 1 
diabetes (T1DM) and NAH but not in T1DM-IAH who have attenuated adrenaline responses 
to hypoglycemia. (A) Time courses of plasma glucose levels during the clamp. Dashed lines 
represent the end of the euglycemic phase, and the beginning and end of the hypoglycemic 
phase, respectively. Number of circulating leukocytes (B), neutrophils (C), lymphocytes (D) 
and monocytes (E) and composition of leukocytes (G) measured with a routine patient sample 
analysis at euglycemia and after 1 h of hypoglycemia. (F) Correlation between the difference in 
leukocyte numbers during hypoglycemia vs. euglycemia and the difference in adrenaline levels 
between hypoglycemia and euglycemia. Black circles, healthy controls; black squares, T1DM-
NAH patients; black triangles, T1DM-IAH patients. *P < 0.05; **P < 0.01.
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Figure 2. PBMCs isolated after hypoglycemia produce more pro-inflammatory cytokines 
than PBMCs isolated after euglycemia. IL-6 (A), IL-1β (B), TNFα (C), MCP-1 (D) and IL-10 (E) 
production of PBMCs isolated from euglycemic or hypoglycemic conditions and stimulated 
for 24 h with LPS. Open bars, euglycemic values; black bars, hypoglycemic values. (F) Fold 
change in cytokine production (IL-6, IL-1β, TNFα) by PBMCs upon hypoglycemia compared to 
euglycemia. The gray dashed line represents euglycemic values. PBMCs were stimulated with 
the TLR4 agonist LPS, the TLR2 agonist Pam3Cys, C. albicans or lysate of M. tuberculosis. Data 
are presented as mean (continuous lines) ± S.E.M. (dotted lines). *P < 0.05; **P < 0.01.
143
5
Hypoglycemia increases ex vivo pro-inflammatory cytokine 
production 
PBMCs from healthy participants and T1DM patients with NAH isolated after 1 
h of hypoglycemia and stimulated with the TLR4 agonist LPS produced more 
pro-inflammatory cytokines (IL-6, IL1β and TNFα) compared to PBMCs isolated 
after euglycemia. Hypoglycemia had no effect on LPS-stimulated cytokine 
production of PBMCs isolated from type 1 diabetes patients with IAH (Fig. 2A-C). 
Hypoglycemia increased the production of the chemokine MCP-1 in healthy 
controls (Fig. 2D), but did not affect levels of the anti-inflammatory cytokine 
IL-10 in any of the groups (Fig. 2E). 
Hypoglycemia enhanced the TNF-α response of PBMCs stimulated with 
Pam3Cys, M. tuberculosis and C. albicans in all three groups. Hypoglycemia also 
increased the IL-6 response to M. tuberculosis in healthy controls and patients 
with NAH, but had virtually no effect on the IL-6 and IL-1β responses to Pam3Cys 
or C. albicans in either of the three groups (Supplementary Fig. 2). Altogether, 
hypoglycemia enhanced cytokine responses of PBMCs, with the most prominent 
increase in TNF-α responses (Fig. 2F).
Notably, cytokine release of stimulated PBMCs from patients with IAH isolated 
during euglycemia tended to be higher compared to cells from healthy controls 
and NAH patients, although the differences were not statistically significant. 
Hypoglycemia does not affect glycolytic metabolism of PBMCs
We then investigated whether hypoglycemia affected glycolytic metabolism 
of PBMCs. As expected, stimulation with LPS significantly increased glucose 
consumption and lactate production of PBMCs in all groups (Fig. 3A-B). However, 
there was no difference in either glucose consumption or lactate production 
between cells exposed to hypoglycemic compared to euglycemic conditions, 
whether stimulated with LPS or not stimulated. 
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Figure 3. No differences in glycolytic metabolism of PBMCs isolated from hypoglycemia vs. 
euglycemia. Glucose consumption (A) and lactate secretion (B) measured in the supernatants 
of PBMCs isolated from euglycemic or hypoglycemic conditions and cultured for 24 h with or 
without stimulation with LPS. *P < 0.05; **P < 0.01.
Hypoglycemia generally increases expression of markers for 
demargination and cells with cytotoxic effector potential 
Since adrenaline levels increased markedly in response to hypoglycemia and because 
adrenaline drives demargination of leukocytes [20], we investigated whether 
hypoglycemia altered gene expression levels of demargination markers in isolated 
PBMCs. Interestingly, hypoglycemia increased the expression of the integrin CD11a 
in PBMCs of healthy participants and type 1 diabetes patients with NAH, but not 
in patients with IAH (Fig. 4A). Hypoglycemia also increased the expression of the 
chemokine receptor CX3CR1 in PBMCs of healthy controls (Fig. 4B). 
Next, we assessed the expression of marker genes of various immune cell types 
in PBMCs exposed to hypoglycemia or euglycemia (Fig. 4C-G). Hypoglycemia 
increased the expression of CD8 but not of CD4 or CD56 in PBMCs of all groups. 
Moreover, while hypoglycemia did not alter expression of CD14, it increased 
the expression of CD16, a marker for the non-classical monocyte subset, which 
produces more cytokines than the classical monocytes in response to certain 
stimulations [29].    
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Figure 4. Increased expression of markers for demargination and cells with cytotoxic effector 
potential after hypoglycemia, assessed by qRT-PCR in PBMCs exposed to euglycemia or 
hypoglycemia. Relative expression of CD11a (A), CX3CR1 (B), CD4 (C), CD8 (D), CD56 (E), CD14 
(F) and CD16 (G). Open circles, euglycemic values; black circles; hypoglycemic values. *P < 0.05; 
**P < 0.01.
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Hypoglycemia increases ex vivo cytokine production of CD14+ cells 
Since monocytes are the major producers of pro-inflammatory cytokines 
within the heterogeneous PBMC cell population, we specifically investigated 
the effect of hypoglycemia on the inflammatory function of CD14+ monocytes. 
Hypoglycemia did not affect the percentage of isolated CD14+ monocytes within 
the PBMC fraction in either of the three groups (Fig. 5A). When stimulated ex vivo, 
CD14+ cells produced more pro-inflammatory cytokines, particularly TNFα, 
if isolated after hypoglycemia compared to euglycemia (Fig. 5B). Nevertheless, 
CD14+ cells did not have increased gene expression levels of surface markers 
characterizing pro-inflammatory monocytes (CD11a, CXRCR1, CCR5, CCR2) 
(Suppl. Fig. 3).
DISCUSSION
The present study aimed to investigate the effect of acute hypoglycemia 
on the composition and inflammatory function of circulating immune cells. 
We demonstrate that exposure to hypoglycemia leads to demargination of 
specific immune cell subtypes, and also enhances the inflammatory response 
of PBMCs and CD14+ monocytes. Notably, the hypoglycemic response of 
PBMCs was partly blunted in type 1 diabetes patients with IAH, highlighting the 
role of adrenaline in immune cell recruitment and in the acute inflammatory 
response to hypoglycemia. Our data support the concept that hypoglycemia 
shifts circulating immune cells towards a more pro-inflammatory state. When 
sustained, such enhanced inflammatory state could contribute to atherogenesis 
in people with diabetes.
In line with previous findings [15], our results demonstrate that hypoglycemia 
induces leukocytosis. The strong correlation with adrenaline responses 
to hypoglycemia suggests a role for adrenaline, which is supported by 
our observations in type 1 diabetes patients with IAH who have blunted 
counterregulatory hormone responses to hypoglycemia. Our studies now extend 
previous findings by investigating the inflammatory function of isolated immune 
cells ex vivo. Our observation that TNFα production significantly increased in 
PBMCs exposed to hypoglycemia, independent of the pathogenic stimulus (LPS, 
Pam3Cys, C. albicans or M. tuberculosis), strongly implies that the hypoglycemic 
event causes a universal potentiation of inflammatory function of the cells. Since 
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equal numbers of PBMCs were used in stimulations to compare the two glycemic 
conditions, the increased levels of circulating pro-inflammatory cytokines found 
in previous studies [15, 17-19, 30] are not only due to the increase in the number of 
circulating immune cells in response to hypoglycemia, but likely reflect changes in 
the functional status of immune cells. 
Figure 5. CD14+ monocytes isolated after hypoglycemia produce more pro-inflammatory 
cytokines than CD14+ cells isolated after euglycemia. (A) Percentage of CD14+ cells isolated by 
MACS. (B) Fold change in cytokine production (IL-6, IL-1β, TNFα) by CD14+ cells isolated from 
hypoglycemic vs. euglycemic conditions. CD14+ cells were stimulated with the TLR4 agonist 
LPS, the TLR2 agonist Pam3Cys, C. albicans or lysate of M. tuberculosis. Data is presented as 
mean (continuous lines) ± S.E.M. (dotted lines). 
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In contrast to TNFα-responses, the effect of hypoglycemia on IL-6 and IL-1β 
production was less pronounced and more variable between the different 
stimuli, suggesting that changes in pathogen-specific signalling pathways are 
involved. Such changes could either affect the expression of pattern recognition 
receptors on the cell surface or expression of their downstream effectors. If 
intracellular signalling pathways are indeed affected by hypoglycemia, this 
could also prime the immune cells to respond differently to other stimuli, such 
as pro-atherogenic factors. 
PBMCs are a heterogeneous mix of cell populations and changes in composition 
could also explain the increased cytokine production observed in response to 
hypoglycemia. However, measurements of the cellular composition of several 
PBMC samples did not reveal major changes (percentage of lymphocytes, 
monocytes, granulocytes) after hypoglycemia. Notably, CD11a and CX3CR1 
gene expression levels were increased in PBMCs exposed to hypoglycemia, 
suggesting an increase in the number of demarginated cells [20]. Recruitment 
of a distinct cell population with a different phenotype and function likely 
contributes to the observed change in inflammatory responses after exposure to 
hypoglycemia. Similar to leukocytosis experimentally induced by adrenaline [20], 
hypoglycemia increased the number of cells with cytotoxic effector potential, 
such as lymphocytes expressing CD8. Additionally, hypoglycemia increased gene 
expression levels of CD16, suggesting an increase in circulating CD16+ monocytes 
and NK cells, also secondary to adrenaline-mediated leukocytosis [20]. 
Future studies applying flow cytometric analysis of circulating immune cells, 
providing additional information on the specific surface expression of selected 
proteins on certain cell populations, would be of particular interest. 
Cytokine production was similarly altered in CD14+ cells and PBMCs exposed 
to hypoglycemia. Although we cannot distinguish between the different 
monocyte subsets (classical, intermediate, non-classical) within the population 
of isolated CD14+ cells, the increased cytokine response of PBMCs is likely based 
on the enhanced cytokine production capacity of CD14+ monocytes, since the 
percentage of monocytes was similar at hypoglycemia and euglycemia. 
Another factor that may contribute to an altered inflammatory output of 
immune cells is a shift in cellular metabolism induced by changes in the 
metabolic environment. For instance,  a highly active glycolytic metabolism has 
been shown to drive pro-inflammatory cytokine production in M1 macrophages 
and is also important for activated effector T cells [31]. However, similar glucose 
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consumption and lactate production of cells isolated from hypoglycemic 
compared to euglycemic conditions makes it unlikely that changes in 
inflammatory responses are due to changes in glycolytic metabolism of immune 
cells. We cannot fully exclude an involvement of glycolytic metabolism, since 
acute changes can occur in vivo, but might be masked at the time point that we 
measured lactate levels in vitro.
Our results revealed abrogation of hypoglycemia-induced leukocytosis and 
an attenuated inflammatory response to hypoglycemia in patients with IAH, 
potentially as a consequence of extensive prior exposure to hypoglycemia. 
The attenuated inflammatory response in patients with IAH underscores 
the contribution of counterregulatory hormones, especially adrenaline, in 
hypoglycemia-induced pro-inflammatory effects. Strikingly, hypoglycemia 
increased CD8 and CD16 expression in PBMCs of patients with IAH, indicating an 
increase in circulating cells with cytotoxic effector potential in these patients, 
even while total leukocyte count did not increase upon hypoglycemia. This 
might be explained by the minimal, albeit still significant, increase in adrenaline 
levels in response to hypoglycemia. Leukocyte numbers and cytokine responses 
during euglycemia appeared higher, but were not significantly elevated in 
type 1 diabetes patients with IAH compared to healthy participants or patients 
with NAH. Although it is tempting to attribute this trend to prior exposure to 
hypoglycemia, a larger sample size would be required to address this question. 
One could speculate that an attenuated pro-inflammatory response to acute 
hypoglycemia as observed in patients with IAH might provide some protection 
against harmful effects of subsequent hypoglycemia. Frequent hypoglycemic 
events, typical for patients with type 1 diabetes, have been reported to protect 
against hypoglycemia-induced mortality [32] or neuronal damage [33] in rats. 
These adaptive effects of recurrent hypoglycemia appear in line with the reported 
absence of increased cardiovascular mortality in type 1 diabetes patients with 
IAH compared to patients with normal awareness [10]. This contrasts with 
studies focussing on vascular effects that reported higher rates of preclinical 
atherosclerosis in patients with repeated hypoglycemia [23] and greater pro-
atherothrombotic responses and endothelial dysfunction after recurrent 
hypoglycemia [16]. Future studies are needed to determine the long-term 
consequences of repeated hypoglycemia and IAH on inflammation, immune cells 
and their inflammatory function as well as their involvement in atherogenesis. 
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The strengths of our study include the use of glucose clamps in three matched 
groups of participants under similar glycemic conditions, which enabled us to 
differentiate between the impact of diabetes and IAH. A larger sample size would 
have allowed us to differentiate better between patients with IAH and NAH, 
especially regarding baseline values. Although we analyzed gene expression of 
demargination markers and of specific cell types, flow cytometric analysis would 
have provided a more detailed characterization of changes in composition and 
inflammatory status of leukocytes. Future studies should focus on mechanistic 
studies in lymphocytes and also look into the role of neutrophils to extend our 
findings regarding gene expression data. Another limitation of this study is 
that participants with and without diabetes were healthy and relatively young. 
Inflammatory responses to hypoglycemia might differ in older patients, in those 
with (a history of) cardiovascular disease or in patients with poor glycemic control. 
We conclude that hypoglycemia leads to demargination, an increase in 
circulating immune cells with cytotoxic effector potential, and an induction 
of pro-inflammatory functional changes in PBMCs and CD14+ monocytes. 
Acute inflammatory responses to hypoglycemia were partly blunted in type 1 
diabetes patients with impaired awareness of hypoglycemia, highlighting that 
counterregulatory hormone responses are key modulators of pro-inflammatory 
responses to hypoglycemia. These data indicate that hypoglycemia induces a 
shift in inflammatory function of immune cells, which could promote a sustained 
pro-inflammatory state in diabetes patients. 
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SUPPLEMENTARY MATERIAL
Supplementary Figure 1. 
Correlation between the difference in lymphocyte (A), monocyte (B) and neutrophil (C) 
numbers during hypoglycemia versus euglycemia and the difference in adrenaline levels 
between hypoglycemia and euglycemia. Black circles, healthy controls; black squares, T1DM-
NAH patients; black triangles, T1DM-IAH patients.
Supplementary Figure 2. 
IL-6, IL-1β and TNFα production of PBMCs isolated from euglycemic or hypoglycemic conditions 
and stimulated for 24 h with Pam3Cys (A-C), C. albicans (D-F) or lysate of M. tuberculosis (G-I). 
Open bars, euglycemic values; black bars, hypoglycemic values. * p<0.05, **p<0.01
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Supplementary Table 1. 
Hormonal responses at euglycemia and after 60 minutes of hypoglycemia. Data are mean ± 
SEM, *p<0.05 for euglycemia versus hypoglycemia, †p<0.05 versus healthy controls, ‡p<0.05 
versus T1DM-IAH.
Healthy controls T1DM-NAH T1DM-IAH
EU HYPO EU HYPO EU HYPO
Glucagon (pmol/L) 15.8 ± 0.8 33.0 ± 3.7* 13.4 ± 0.8 17.7 ± 2.6† 13.0 ± 0.9 16.1 ± 3.3†
Adrenaline (nmol/L) 0.11 ± 0.02 1.90 ± 0.46*‡ 0.10 ± 0.01 1.94 ± 0.29*‡ 0.12 ± 0.02 0.39 ± 0.07*
Noradrenaline (nmol/L) 1.19 ± 0.17 1.94 ± 0.20* 1.20 ± 0.08 1.46 ± 0.07* 1.33 ± 0.15 1.51 ± 0.20
Cortisol (µmol/L) 0.38 ± 0.06 0.51 ± 0.08* 0.48 ± 0.08 0.69 ± 0.10* 0.43 ± 0.10 0.41 ± 0.08
hGH (mU/L) 8.4 ± 3.8 32.2 ± 9.5* 5.7 ± 1.6 69.2 ± 14.8* 10.2 ± 5.2 52.0 ± 12.4*
Data are mean ± SEM, *p<0.05 for euglycemia versus hypoglycemia, †p<0.05 versus healthy 
controls, ‡p<0.01 versus T1DM-IAH
Supplementary Table 2. 
Primer sequences used to assess gene expression by qRT-PCR.
target gene forward primer reverse primer
B2M ATGAGTATGCCTGCCGTGTG CCAAATGCGGCATCTTCAAAC
CD11a CAGGCTATTTGGGTTACACCG CCATGTGCTGGTATCGAGGG
CX3CR1 ATATTGGGGACATCGTGGTCT TGGCAAAGATGACGGAGTAGA
CD4 AAGGGGATACAGTGGAACTGAC GGACCTTTAGTTAAGAAGGAGCC
CD8 GCAACCACAGGAACCGAAGA GTCTCCCGATTTGACCACAGG
CD56 TGTCCGATTCATAGTCCTGTCC CTCACAGCGATAAGTGCCCTC
CD14 ACGCCAGAACCTTGTGAGC GCATGGATCTCCACCTCTACTG
CD16 ATGTGTCTTCAGAGACTGTGAAC TTTATGGTCCTTCCAGTCTCTTG
CCR2 CCACATCTCGTTCTCGGTTTATC CAGGGAGCACCGTAATCATAATC
CCR5 CAAAAAGAAGGTCTTCATTACACC CCTGTGCCTCTTCTTCTCATTTCG
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Hypoglycaemia induces recruitment of non-classical monocytes and cytotoxic lymphocyte subsets in 
type 1 diabetes
To the Editor: We recently reported enhanced ex vivo cytokine production 
of immune cells during hypoglycaemia in humans [1]. Chronic inflammation 
contributes to cardiovascular disease and atherosclerosis and may link 
hypoglycaemia to increased cardiovascular risk and mortality observed in 
individuals with diabetes [2]. 
Hypoglycaemia induces leucocytosis, possibly mediated by marked increases in 
plasma adrenaline (epinephrine) and cortisol levels. Adrenaline recruits immune 
cells from the marginal pool (vascular endothelium), likely by interfering with 
CD11a- and CX3CR1-dependent adhesion of leucocytes to the vessel wall [3]. 
Indeed, gene expression levels of CD11a and CX3CR1 were increased in peripheral 
blood mononuclear cells (PBMCs) isolated during hypoglycaemia [1]. 
It remains unknown which specific immune cell subsets are recruited in response 
to hypoglycaemia. To identify these subsets, we analysed blood samples collected 
during clamped euglycaemia or hypoglycaemia from seven people with type 1 
diabetes (three men, age 27.1±9.7 years, HbA1c 55.9±8.9 mmol/mol (7.2±0.8 %) 
and diabetes duration 11.4±5.4 years) by flow cytometry. This was a substudy of 
a larger study (ClinicalTrials.gov registration no. NCT03286816), for which we 
analysed data obtained within the control arm (for study design and endpoints, 
see [4]). The study was approved by the local institutional review board of the 
Radboud University Medical Center and all study participants gave written 
informed consent before participation. All participants had normal awareness 
of hypoglycaemia (assessed by the Dutch version of the Cox questionnaire and 
normal counter-regulatory responses to the hypoglycaemic clamp). 
Participants underwent a two-step euglycaemic (5.0 mmol/l)–hypoglycaemic (2.8 
mmol/l) glucose clamp. At the end of each glycaemic phase, blood was drawn for 
flow cytometry and to determine catecholamine levels. Undiluted blood (50 μl, 
BD Vacutainer® K2E (EDTA), BD, Plymouth, UK) was incubated for 15 min at room 
temperature in the dark with the following antibodies: CD16-FITC (mouse, dilution 
1:5), CD56-PE (mouse, 1:10) (BD Biosciences, Vianen, the Netherlands); CD14-
ECD (mouse, 1:10), CD3-ECD (mouse, 1:10), CD3-PE (mouse, 1:5), CD45-PECy7 
(mouse, 1:50), CD8-ECD (mouse, 1:10), HLA-DR-PECy5 (mouse, 1:10) (Beckman 
Coulter, Woerden, the Netherlands); CD4-PECy7 (mouse, 1:20) (ITK Diagnostics 
BV, Uithoorn, the Netherlands). After the addition of 1 ml lysis buffer (BD Pharm 
Lyse, BD Biosciences), samples were mixed, incubated for another 10 min and 
finally measured on a Beckman Coulter FC500 flow cytometer. Single staining and 
fluorescence-minus-one control stains were used to determine the position of 
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analysis gates. Flow cytometry data were analysed using Kaluza software (Beckman 
Coulter). Immune cell subset numbers were calculated based on percentages 
measured with flow cytometry and cell numbers from blood differentials measured 
on a Sysmex XN-450 (Sysmex, Etten-Leur, the Netherlands). A Spearman’s rank 
sum test was used for correlation analysis. Wilcoxon signed rank test was used to 
test differences between two related samples. All data are expressed as mean±SD. 
A p value of <0.05 was considered statistically significant. Statistical analyses were 
performed with SPSS version 22 (IBM Corporation, Armonk, NY, US).
Glucose levels during the euglycaemic–hypoglycaemic clamp were maintained at 
5.2±0.2 and 2.8±0.1 mmol/l, respectively. Hypoglycaemia significantly increased 
adrenaline levels from 0.30±0.19 to 3.40±2.27 nmol/l (p=0.018). As expected, 
hypoglycaemia increased leucocyte counts (Fig. 1a), which was predominantly 
due to increased numbers and relative percentages of lymphocytes and 
monocytes, but not neutrophils (Fig. 1b-g).
Elevated lymphocyte counts were mainly due to increased numbers of CD8+ T 
cells (Fig. 1i), which was reflected in decreased percentages of CD4+ and increased 
percentages of CD8+ T cells (Fig. 1j,k). Increased percentages of CD8+ T cells during 
hypoglycaemia were correlated with the increase in adrenaline levels (r=0.786, 
p=0.036). Additionally, hypoglycaemia increased numbers and percentages of 
NKT cells and CD16+CD56dim cytotoxic NK cells (Fig. 1l-o). Numbers of circulating 
CD16lowCD56bright NK cells were generally very low, and not different between 
the glycaemic conditions (data not shown). Hypoglycaemia increased classical 
(CD14++CD16-) and non-classical (CD14+CD16++) monocyte numbers (Fig. 1p,q). 
However, percentages of non-classical monocytes increased, while percentages 
of classical monocytes decreased (Fig. 1s,t). The ratio of classical monocytes 
measured under hypoglycaemic vs euglycaemic conditions was negatively 
correlated with the increase in adrenaline levels (r=-0.857, p=0.014). 
Increased percentages of CD8+ T cells in response to hypoglycaemia are in line 
with previous studies demonstrating increased gene expression of CD8A in PBMCs 
during hypoglycaemia [1] and are likely to be caused by increased adrenaline 
levels [3]. Although CD8+ T cells are atheroprotective in some situations, several 
pro-atherogenic effects have been demonstrated [5]. Increases in NK and NKT 
cells might also contribute to cardiovascular disease. NK cells were found in 
atherosclerotic lesions, where they increase lesion size by release of perforin and 
granzyme B [6]. Similarly, increased numbers of NKT cells, which can recognise lipid 
antigens presented via CD1d, have been observed in atherosclerotic lesions [7].
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Monocyte-derived macrophages, the most abundant cells in atherosclerotic 
plaques, differentiate into foam cells and contribute to plaque instability. 
Different monocyte subsets—classical, non-classical and intermediate—have 
distinct inflammatory and functional properties. All subsets have been related 
to cardiovascular disease risk. Nevertheless, more evidence supports the 
importance of non-classical and intermediate monocytes in the development of 
cardiovascular disease [8].
Fig. 1 Numbers of leukocytes (a), neutrophils (b), lymphocytes (c) and monocytes (d) 
and percentages of neutrophils (e), lymphocytes (f) and monocytes (g) measured during 
euglycaemia (EU) and hypoglycaemia (HYPO) in individuals with type 1 diabetes. Numbers 
and percentages of CD4+ T cells and CD8+ T cells (h–k), CD56dimCD16+ NK cells and NKT cells 
(l–o) and classical CD14++CD16-, non-classical CD14+CD16++ and intermediate CD14++CD16+ 
monocytes (p–u), measured during EU and HYPO in individuals with type 1 diabetes. were 
identified as CD45+ cells, T cells as CD3+ cells and monocytes as CD45+ HLADR+ cells. *p<0.05, 
Wilcoxon signed rank test
 
Hypoglycaemia-induced monocytosis was mainly driven by an increase in 
non-classical monocytes. This may explain increased cytokine production 
of monocytes isolated during hypoglycaemia vs euglycaemia [1], since non-
classical monocytes produce more proinflammatory cytokines [9]. 
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The clinical implications of our findings depend on various factors and require 
further investigation. First, recruitment of immune cells may differ between 
individuals with type 1 vs type 2 diabetes and between moderate vs severe 
hypoglycaemia. Additionally, the persistence of the effect on changes in circulating 
immune cell populations is currently unknown. The timeframe over which the 
distribution and function of the immune cell populations return, and whether 
this depends on the recurrence of hypoglycaemia, remain to be determined. 
Frequent hypoglycaemic events may indeed induce chronic inflammation, but 
the reduced catecholaminergic responses following recurrent hypoglycaemia 
may also have a dampening effect on inflammation. Interestingly, recent 
studies have reported that although neuroendocrine responses were reduced 
by antecedent hypoglycaemia, proatherotrombotic factors were increased [10]. 
One may speculate that acute effects of hypoglycaemia on immune cells 
promote a proatherogenic state dependent on other proatherogenic factors, for 
example, prior exposure to (chronic) hyperglycaemia. 
In conclusion, hypoglycaemia increased quantities of CD8+ T cells, cytotoxic 
NK and NKT cells and non-classical monocytes in people with type 1 diabetes. 
Our study further supports the concept that hypoglycaemia promotes acute 
inflammation in individuals with type 1 diabetes, which may contribute to a 
more chronic (sustained) proinflammatory state.
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ABSTRACT
Objective Increased glycolysis is a metabolic trait of activated innate immune 
cells and supports functional changes including cytokine production. Insulin 
drives glycolysis in non-immune cells, yet its metabolic effects on human innate 
immune cells remain unexplored. Potential effects of insulin on immune cell 
metabolism may occur acutely after a postprandial increase in plasma insulin 
levels. Additionally, chronically elevated insulin levels as observed in obese 
insulin-resistant individuals and patients with diabetes may impact on immune 
cell function. We therefore investigated the effects of acute and chronic 
exposure to insulin on metabolism and function of human myeloid cells.
Methods Monocytes were isolated from healthy individuals or from patients 
with type 1 diabetes and exposed to insulin ex vivo. Metabolism was assessed by 
immunoblotting, extracellular flux analysis and measurements of metabolites in 
cell culture medium. Cellular function was determined by ELISA and transwell 
migration assay. 
Results Human primary monocytes were responsive to insulin, as evidenced by 
activation of the PI3K/Akt/mTOR pathway. Additionally, insulin acutely increased 
both oxygen consumption and glycolytic rates of human monocytes. Insulin induced 
Akt-phosphorylation to a similar extend in monocytes derived from patients with 
type 1 diabetes compared to monocytes from healthy individuals. Therefore, we 
modeled effects of chronically elevated insulin levels in patients with diabetes by 
exposing monocytes from healthy individuals for 24h to insulin. Insulin had minor 
effects on LPS-induced cytokine production by monocytes, yet increased MCP-1-
directed migration. Supporting this observation, we identified a positive correlation 
between plasma insulin levels and macrophage numbers in adipose tissue of obese 
individuals. Long-term exposure to insulin during differentiation of monocytes 
to macrophages reduced glycolytic rates of pro-inflammatory macrophages 
differentiated with GM-CSF. In addition, insulin impaired spare respiratory capacity, 
indicating reduced mitochondrial capacity under stress conditions accompanied by 
functional changes illustrated by reduced IL-1β production. 
Conclusion Altogether, insulin acutely activates metabolism and migration 
capacity of human monocytes and induces a shift towards a more pro-
inflammatory phenotype, but chronically dampens respiratory capacity and 
inflammatory response. Differential effects of insulin may propel altered innate 
immune responses observed in patients with diabetes. 
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INTRODUCTION
Insulin is a key hormone in glucose metabolism, yet has also been appointed 
with immunomodulatory effects. Whereas plasma insulin concentrations vary 
during the day, the development of diabetes drives chronically elevated levels. 
Diabetes is caused by an absolute (type 1) or relative (type 2) insulin deficiency 
in combination with insulin resistance. To compensate for insulin resistance, 
endogenous hyperinsulinemia ensues in type 2 diabetes, and insulin levels are 
chronically increased in patients receiving exogenous insulin therapy. 
Although it has been discovered decades ago that immune cells can bind insulin [1], 
the impact of insulin on immune cell function has only recently received 
increased interest. Important evidence for a role of insulin in inflammation 
originates from studies investigating immune cell-specific deletion of the insulin 
receptor. T cell-specific deficiency of the insulin receptor, for instance, reduced 
T cell proliferation and cytokine production, resulting in poor responses to 
influenza infection in mice [2]. Myeloid-specific deficiency of the insulin receptor 
protected mice from obesity-induced insulin resistance by decreasing migration 
capacity of macrophages, leading to decreased accumulation of macrophages 
in the adipose tissue [3]. Additionally, insulin receptor deficiency in myeloid cells 
impaired IL-4-induced M2 macrophage polarization [4], suggestive of a more 
pro-inflammatory effect of insulin on myeloid cells. 
This notion is in agreement with several studies reporting pro-inflammatory 
effects of insulin on cytokine production of human monocyte and macrophage 
cell lines in vitro [5-7]. Whereas insulin also increased IL-1β production in murine 
bone marrow derived macrophages (BMDMs) [8], insulin suppressed LPS-
induced TLR4 signaling of human peripheral blood mononuclear cells (PBMCs) 
isolated from healthy individuals as well as patients with type 2 diabetes [9]. 
Whether this results in decreased cytokine production remains unknown. Insulin 
increased LPS-induced IL-6 and TNFα production in BMDMs, but decreased 
cytokine production in peritoneal and alveolar macrophages [10], suggesting 
that immunomodulatory effects of insulin may also be context-specific.
Immunomodulatory effects of insulin are dependent on signaling via PI3K [10]. 
Insulin activates various signaling pathways, including targets involved in 
reprogramming of cellular metabolism, such as Akt, mTOR and FoxO1[9]. Given 
the importance of cellular metabolism in shaping immune cell function, insulin 
may also modulate cytokine production of myeloid cells by reprogramming 
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metabolism. Interestingly, insulin increased glucose consumption of human 
monocytes [1] as well as glucose uptake and glycolytic rates of murine peritoneal 
macrophages [8]. Also other metabolic pathways of myeloid cells seem to be 
affected by insulin, including lipid metabolism [12] [13]. 
Effects of insulin on myeloid cell metabolism and function may be very 
relevant in the context of obesity and diabetes, where insulin levels are often 
chronically elevated and function of myeloid cells is disturbed and contributing 
to chronic inflammation. Whereas immunomodulatory effects of insulin are 
demonstrated in murine cells and myeloid cell lines, neither the acute effects 
of insulin on primary human cells nor long-term effects have been explored. We 
therefore investigated both short- and long-term effects of insulin on ex vivo 
cellular metabolism and function of human monocytes and monocyte-derived 
macrophages, derived from circulating cells obtained from healthy subjects and 
patients with diabetes.
MATERIALS AND METHODS
Healthy volunteers and diabetes patients
PBMCs were isolated from fresh blood donated by healthy volunteers and 
patients with type 1 diabetes. Ethical approval was obtained by the institutional 
review board of the Radboud university medical center and all participants gave 
written informed consent before participation. Additionally, buffy coats from 
healthy donors were obtained after written informed consent (Sanquin Blood 
Bank, Nijmegen, the Netherlands).
Insulin clamps
Healthy individuals underwent a hyperinsulinemic-euglycemic clamp as 
described previously [11]. Blood was isolated at baseline (after an overnight fast) 
and 25-30 min after starting a hyperinsulinemic (60 mU/m2/min) euglycemic (5 
mmol/l) clamp. Samples collected at baseline and after insulin infusion were 
used for experiments presented in Fig. 2e. Additionally, baseline samples were 
used for experiments presented in Fig. 2a, b. 
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Isolation of primary human immune cells
PBMCs were isolated from blood of healthy volunteers by differential 
centrifugation over Ficoll-Paque™ PLUS (GE Healthcare Biosciences). CD14+ 
monocytes were subsequently purified from freshly isolated PBMCs using MACS 
microbeads for positive selection, according to the manufacturer’s instructions 
(Miltenyi Biotec). Monocytes were cultured in RPMI 1640 (no glucose, Gibco, 
11879020) supplemented with 50μg/ml gentamycin, 1mM pyruvate, 5.5mM 
glucose and 10mM HEPES. For 24h stimulation experiments, 10% pooled human 
serum was added.
Differentiation of macrophages
For differentiation into macrophages (Fig. 4), PBMCs were enriched for 
monocytes by gradient centrifugation over Percoll. 150-200·106 PBMCs were 
layered on top of a hyper-osmotic Percoll solution and centrifuged for 15 minutes 
at 580 g, as described previously [12]. Cells were collected from the interphase 
and washed with PBS. After adherence for 1h, monocytes were washed once 
with PBS to remove non-adherent cells. Monocytes were differentiated for 6 
days in the presence of 5 ng/ml recombinant human M-CSF or GM-CSF (R&D). 
After 3 days of culture half of the medium was removed and fresh medium was 
added. Macrophages were cultured in RPMI 1640 (containing 11mM glucose, 
Gibco, 22409031) supplemented with 50μg/ml gentamycin, 1mM pyruvate, 
2mM glutamax and 10% pooled human serum collected from healthy donors. 
Cytokine measurements
To stimulate cytokine production, cells were exposed for 24h to 10ng/ml LPS 
from E. coli (Sigma). To stimulate IL-1β production of macrophages, cells were 
stimulated 4h with 10ng/ml LPS before 1mM ATP (Sigma) was added for 30min. 
The production of interleukin (IL)-1β, IL-6, tumour necrosis factor (TNF)-α (R&D 
Systems DY201, DY206, DY210), and IL-10 (Sanquin M9310) was measured by 
ELISA. 
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Immunoblot
Samples were loaded on Mini-PROTEAN TGX precast gels (Bio-Rad) and proteins 
were transferred using the Trans-Blot Turbo system (Bio-Rad) according to the 
manufacturer’s instructions. Antibodies for p-AKT (S473), p-4E-BP1(T37/46), 
p-p70-S6K (T389) (all Cell Signaling) and actin (Sigma) were used. 
Extracellular flux measurements
Real-time OCR and ECAR of monocytes and macrophages were analyzed using an XF-
96 Extracellular Flux Analyzer (Seahorse Bioscience). Basal metabolic rates of cells 
seeded in quintuplicate (monocytes: 200.000 wells per well, macrophages: 50.000 
cells per well) were determined during consecutive measurements in unbuffered 
Seahorse medium (8.3 g DMEM powder, 0.016 g phenol red and 1.85 g NaCl in 1 l 
water, pH set at 7.4 at 37 °C; sterile filtered) containing 5.5mM (Fig. 1) or 11 mM (Fig. 1 
& 4) glucose, 2 mM L-glutamine and 1 mM pyruvate. After three basal measurements 
in monocytes, insulin was injected at a final concentration of 100nM and changes 
in metabolism were assessed over 3 measurement cycles. For macrophages, three 
basal measurements were followed by consecutive measurements following the 
addition of oligomycin (1μM), FCCP (1μM) and antimycin A/rotenone (2.5/1.25μM). 
 
 
Lactate and glucose measurements
Measurements of lactate and glucose concentrations in cell culture supernatants 
were based on an enzymatic reaction in which lactate or glucose is oxidized (with 
lactate oxidase or glucose oxidase (Sigma)) and the resulting H2O2 is coupled 
to the conversion of Amplex Red (Life Technologies) reagent to fluorescent 
resorufin by horseradish peroxidase (Thermo Fisher Scientific). The fluorescence 
of resorufin (excitation/ emission maxima 570/585 nm) was measured on a 96-
well plate reader (BioTek). 
RT-PCR
For mRNA expression analyses, cells were lysed in TRIzol reagent (Invitrogen) 
and RNA was isolated according to the manufacturer’s instructions. RNA was 
transcribed into complementary DNA by reverse transcription using the iScript 
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cDNA synthesis kit (Bio-Rad). Power SYBR Green PCR Master Mix (Applied 
Biosystems) was used for RT-PCR in an AB Step One Plus Real-time PCR System 
(Applied Biosystems). Relative gene expression was calculated using standard 
curves. Gene expression data were normalized to the housekeeping gene β2-
microglobulin. Primer sequences can be found in Supplementary table 1.
Migration assay
Monocytes used in the migration assay were either exposed to 100 nM insulin 
(Novorapid) or medium without insulin as a control for 24h. Subsequently, 200.000 
CD14+ monocytes were added to the upper compartment of a transwell system 
(pore size: 5 µm, polycarbonate membrane, Corning) and incubated for 2h to enable 
migration towards 10 ng/ml human recombinant MCP-1 (Gibco) or medium control. 
Afterwards, cells migrated to the lower compartment were counted. 
Histology
Adipose tissue biopsies, as well as corresponding plasma glucose and insulin 
values from healthy individuals and patients with T2D were collected as part of 
a previous study. Both the control cohort, including obese participants (BMI > 25 
kg/m2) [13] and the cohort of patients with type 2 diabetes [13, 14] were described 
earlier. These studies was approved by the institutional review board of the 
Radboud university medical center and all participants gave written informed 
consent before participation. Individuals with missing data were excluded from 
the analysis. Number and size of adipocytes was analyzed digitally as described 
elsewhere [15]. Macrophages were stained with a CD68 antibody (Clone EBM11, 
Dako, Denmark). The number of macrophages is expressed as the average from 
10 random fields of view per sample. 
Statistical analysis
Two variables were compared with the paired Wilcoxon’s signed rank test. For 
comparison of 3 or more variables repeated measures 2-way ANOVA with post-
hoc Tukey’s test was used. For correlation analysis Spearman’s rank test was 
used. All data are expressed as mean ± standard deviation (SD), unless otherwise 
specified. A p-value < 0.05 was considered statistically significant.
174
Differential effects of acute versus chronic insulin exposure on metabolism and function of human 
monocytes and macrophages 
RESULTS
Insulin acutely activates metabolic pathways in primary human 
monocytes
Phosphorylation of the protein kinase Akt, a central regulator of glucose 
metabolism, via PI3K is one of the earliest signaling events downstream of the 
insulin receptor and has been detected in immune cells [2, 9]. Stimulation of 
monocytes from healthy individuals with insulin increased phosphorylation 
of Akt as well as the mTOR targets 4E-BP1 and p70-S6K (Fig. 1a), suggesting 
an important role for insulin in modulating immune cell metabolism. Indeed, 
when human monocytes were stimulated with insulin ex vivo, extracellular 
acidification rate (ECAR) increased rapidly in the presence of both normal 
(5.5mM) and high (11mM)  glucose levels in the medium (Fig.1b-c). Insulin also 
increased oxygen consumption rate (OCR) (Fig.1d-e), resulting in an unaltered 
OCR/ECAR ratio (Fig. 1f), indicative of a general activation of metabolism. 
Immune cell metabolism is closely linked to cellular functions, such as cytokine 
production [16]. Interestingly, short-term exposure to insulin prior to stimulation 
of monocytes with LPS increased production of the pro-inflammatory cytokine 
IL-6, but not TNFα and IL-1β (Fig. 1g-i).
Chronic insulin-exposure decreases lactate production of human 
monocytes
Whereas increases in insulin levels only occur short-term postprandially in 
healthy individuals, insulin levels may be chronically elevated in patients with 
diabetes. This may influence the response of myeloid cells to insulin. Of note, 
no insulin resistance appears to develop in human monocytes during diabetes, 
illustrated by similar phosphorylation levels of Akt upon insulin treatment in cells 
isolated from patients with type 1 diabetes compared with healthy individuals 
after an overnight fast (Fig. 2a-b, for patient characteristics see Table 1). 
Interestingly, in untreated cells, phosphorylation levels of Akt appeared to be 
higher in patients with diabetes compared with healthy individuals. This could 
potentially be induced by chronically elevated plasma insulin concentrations in 
patients with diabetes. 
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Table 1: Participant characteristics corresponding to Figure 2A, B
  Healty Controls T1D
  n = 6 n = 10
age, yrs 25 ± 6 25 ± 6
sex, m/f 2/4 4/6
BMI, kg/m2 23.6 ± 1.9 23.1 ± 1.5
HbA1c (%) - 7.2 ± 0.9
duration of diabetes (years) - 12.7 ± 6.7
To mimic chronically elevated insulin levels present in patients with insulin resistance 
or diabetes, we exposed monocytes to insulin for 24 h alone or during stimulation 
with lipopolysaccharide (LPS). Although insulin did not affect glucose consumption 
of monocytes (Fig. 2c), it diminished the increase in lactate production after LPS 
stimulation (Fig. 2d). Consequently, insulin may interfere with the induction of 
anaerobic glycolysis by LPS. To investigate whether this observation is relevant in vivo, 
we isolated monocytes from healthy individuals before and 30 minutes after 
initiation of a hyperinsulinemic (60 mU/m2/min) euglycemic (5 mmol/l) clamp. 
Interestingly, infusion of healthy individuals with insulin also abrogated the increase 
in ex vivo LPS-induced lactate production in monocytes, but this may be partially 
due to increased unstimulated lactate production (Fig. 2e). 
Insulin-induced changes in lactate production could potentially be mediated 
by changes in metabolic signaling pathways (see Fig. 1a) and related changes 
in expression of genes involved in cellular metabolism. Long-term exposure to 
insulin, however, did not affect gene expression levels of enzymes involved in 
glycolysis (HK2, LDHA, PDK4, PEPCK) (Fig. 2f-g) or expression of genes involved 
in fatty acid metabolism (SREBF2, INSIG1, HMGCR, FASN) (Fig. 2h-i), which are 
typically influenced by insulin in non-immune cells. 
Insulin has minor effects on cytokine production, but increases 
MCP1-directed migration of monocytes
Functionally, 24 h exposure to insulin did not induce any cytokine production 
on its own, mildly increased LPS-induced TNFα production, but did not affect 
production of IL-6, IL-1β or IL-10 (Fig. 3a-d) in monocytes from healthy individuals. 
Differential effects of short-term (Fig. 1g-i) versus long-term (Fig. 3a-d) 
insulin exposure on cytokine production suggest time-dependent effects of 
insulin on myeloid cell function. In addition to effects on cytokine production, 
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several mouse studies suggested effects of insulin on migration of myeloid 
cells [3, 17]. Overnight treatment with insulin increased migration of human 
monocytes towards MCP-1 (Fig. 3e), a chemokine produced by inflammatory 
myeloid cells and by the adipose tissue. 
Figure 2. Insulin interferes with LPS-induced lactate production of human monocytes, but 
does not affect expression of metabolic genes. A Representative immunoblot of phospho-AKT, 
total AKT and actin in human monocytes stimulated with 10nM insulin for 20 min. Monocytes 
were isolated from patients with type 1 diabetes (T1D) and healthy controls (HC) after an 
overnight fast. B Quantification of immunoblots as presented in A. C-D Glucose (C) and lactate 
concentrations (D) in supernatants of monocytes cultured in medium or stimulated with LPS for 
24h. E Lactate production of monocytes isolated at baseline or after a 30 min hyperinsulinemic-
euglycemic clamp. Cells were cultured in medium or stimulated with LPS for 24 h. F-I Gene 
expression levels in monocytes cultured for 24 h in the presence or absence of 100nM insulin 
and stimulated, if indicated, with LPS. * p < 0.05, ** p < 0.01, *** p < 0.001
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In obesity-induced insulin resistance, adipose tissue is characterized by increased 
infiltration with macrophages, contributing to adipose tissue inflammation 
(for patient characteristics see Table 2). To evaluate in vivo relevance of our 
findings, we analyzed the correlation between plasma insulin and the number 
of macrophages present in adipose tissue. Whereas numbers of macrophages 
in the adipose tissue of lean individuals correlated with adipocyte size (r=0.529, 
p=0.002), numbers of macrophages in obese adipose tissue correlated with 
plasma insulin levels (Fig. 3f, r=0.379, p=0.022). This is in accordance with a 
link between insulin and monocyte infiltration into the adipose tissue leading 
to an increase in the total number of adipose tissue macrophages during the 
development of insulin resistance. Noticeably, plasma insulin levels did not 
correlate with numbers of macrophages in adipose tissue of lean individuals or 
patients with T2D.
Long-term exposure to insulin during monocyte-to-macrophage 
differentiation dampens inflammatory responses
Since monocytes are the precursor cells of macrophages, we also investigated 
the effect of hyperinsulinemic conditions on monocyte-to-macrophage 
differentiation in vitro. We examined the effects of insulin on pro- versus anti-
inflammatory macrophage differentiation using GM-CSF versus M-CSF during 
the differentiation process. Whereas the presence of insulin during differentiation 
did not affect lactate production of the mostly anti-inflammatory M-CSF-
polarized macrophages (Fig. 4a), insulin reduced lactate production of GM-CSF-
polarized cells, which are known to secrete more pro-inflammatory cytokines, 
(Fig. 4b). We therefore focused our subsequent analysis on macrophages 
differentiated with GM-CSF. Long-term treatment with insulin did not affect 
basal ECAR (Fig. 4c) or OCR (Fig.4d), but reduced spare respiratory capacity (SRC), 
indicating reduced mitochondrial capacity under stress conditions (Fig. 4e). 
When macrophages differentiated in the presence of insulin were stimulated 
with LPS, IL-6 production was not influenced (Fig. 4f), whereas TNFα (Fig. 4g) 
and IL-1β production were significantly decreased (Fig. 4h). 
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Table 2: Participant characteristics
  lean obese T2D
  n = 33 n = 36 n = 35
age, yrs 54 ± 8 56 ± 8 61 ± 10
sex, m/f 17/16 14/22 22/13
BMI, kg/m2 23.3 ± 1.5 30.6 ± 3.1 29.5 ± 4.6
glucose (mmol/l) 5.0 ± 0.5 5.2 ± 0.6 10.9 ± 3.7
HbA1c (%) - - 8.1 ± 1.4
insulin (µIU/ml) 4.7 ± 2.3 12.7 ± 8.6 17.5 ± 9.1
adipocyte size (μm) 59.1 ± 6.8 67.6 ± 9.3 72.4 ± 7.8
no. CD68+ cells/1000 adipocytes 19 ± 25 43 ± 61 99 ± 55
Figure 4. Long-term exposure to insulin during differentiation of human macrophages 
decreases spare respiratory capacity and pro-inflammatory cytokine production. A-B Lactate 
concentrations measured in supernatants of macrophages differentiated with M-CSF (A) or GM-
CSF (B) for 6 days in the presence or absence of 100nM insulin. C-E ECAR (C), OCR (D) and SRC 
(E) of macrophages differentiated with GM-CSF in the presence or absence of 100nM insulin, 
measured on day 6 of differentiation. F-G IL-6 (F) and TNFα (G) production, measured in GM-CSF 
differentiated macrophages after 24h stimulation with LPS. H IL-1β production, measured in GM-
CSF differentiated macrophages after 4h stimulation with LPS, followed by 30 min stimulation 
with ATP. * p<0.05, ** p < 0.01
181
7
DISCUSSION
Insulin is a key hormone that controls carbohydrate, protein and lipid 
metabolism, but may also regulate immune cell metabolism and function. Our 
study reveals that insulin acutely activates metabolism and migration capacity 
in human monocytes and shifts the cells towards a more pro-inflammatory 
phenotype, but chronically dampens respiratory capacity and inflammatory 
responses. Insulin may therefore contribute to a disturbed function of myeloid 
cells observed in patients with diabetes, such as an increased susceptibility for 
infections. 
Our conclusions are based on the following findings. Insulin activates PI3K/Akt/
mTOR signaling and acutely increases glycolytic flux and oxygen consumption 
of human monocytes. Functionally, insulin induced elevated LPS-induced TNFα 
production in monocytes and increased monocyte migration towards MCP-1. 
On the contrary, long-term treatment with insulin decreased spare respiratory 
capacity and pro-inflammatory cytokine production of monocyte-derived 
macrophages.
Insulin activated the PI3K/Akt/mTOR signaling pathway in human monocytes. 
This is in line with activation of the same signaling pathway in murine T cells after 
exposure to insulin [2]. Another similarity between both cell types and studies is 
that insulin did not induce a shift to glycolysis, but rather activated both ECAR 
and OCR, indicating activation of both glycolytic and oxidative metabolism. In 
contrast to stimulating effects after acute exposure to insulin, longer exposure 
to insulin rather inhibited cellular metabolism. Insulin decreased extracellular 
lactate concentrations of monocytes cultured for 24 h and of macrophages 
cultured for six days. Decreased extracellular lactate concentrations indicate a 
reduction in anaerobic glycolysis, which was not accompanied by differential 
gene expression of key glycolytic enzymes, and therefore indicates post-
transcriptional regulation of metabolism by insulin. Lactate accumulates in 
the medium and therefore we cannot pinpoint after which specific time period 
effects of insulin switch from stimulating to inhibiting glycolysis. Long-term 
treatment with insulin during macrophage differentiation decreased SRC, 
indicating that insulin also affected mitochondrial function.
In general, effects of insulin on immune cells seem to be stronger in activated 
compared with quiescent immune cells. Insulin modulated metabolism and 
function of activated, but not of quiescent murine T cells [2]. Similarly, insulin 
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induced stronger activation of signaling pathways in pro-inflammatory M1 
(stimulated with LPS and IFNγ) than in more quiescent M0 or M2 (stimulated 
with IL-13 and IL-4) murine macrophages [8]. In agreement with this finding, we 
observed reduced lactate production in macrophages exposed to insulin when 
differentiated with GM-CSF compared with M-CSF. Macrophages differentiated 
with GM-CSF are in general more pro-inflammatory and have a higher glycolytic 
rate illustrated by increased lactate production. Different dependencies on 
metabolic pathways, and in particular glycolysis, may explain differential 
susceptibility of macrophage subtypes towards insulin. Alternatively, the activity 
or presence of the insulin receptor and downstream signaling cascade might 
be related to specific macrophage phenotypes. This may also be very relevant 
in vivo, where insulin may act together with other metabolic factors, such as 
glucose and fatty acids, to induce a specific polarization of macrophages [18]. 
Our results revealed that insulin increased MCP-1 directed migration of human 
monocytes. In vivo, we observed an association between plasma insulin levels and 
macrophage numbers in adipose tissue of obese individuals, suggesting insulin-
induced migration of myeloid cells into the adipose tissue. On the contrary, 
macrophage accumulation may also have occurred independently of insulin. 
Macrophage accumulation in adipose tissue is contributing to insulin resistance 
and subsequently to elevated plasma insulin levels. A direct influence of plasma 
insulin levels on migration of myeloid cells to the adipose tissue is, however, 
supported by murine studies reporting increased adipose tissue inflammation 
after insulin infusion [17] and decreased adipose tissue inflammation in mice with 
myeloid cell-specific deficiency of the insulin receptor [3], as well as by human 
studies reporting increased macrophage accumulation in adipose tissue of patients 
with type 2 diabetes after start of insulin therapy [13]. Potential mechanisms of 
action may involve insulin-induced activation of the matrix metalloproteinase 
MMP9, which is known to alter migration of immune cells [3, 19, 20]. 
Matrix remodeling capacity, however, should not influence migration capacity in 
our experimental set-up. Alternative mechanisms of insulin-induced migration 
may involve metabolic changes induced by insulin. Active glycolytic metabolism 
for instance has been shown to fuel migration of macrophages via the HIF1α-
PDK1-axis [21]. Furthermore, migration of regulatory T cells is supported via 
PI3K-mTORC2-mediated activation of glucokinase [22]. Whether insulin induces 
monocyte migration via similar metabolic pathways remains to be determined.
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Whereas exposure to insulin slightly increased cytokine production of 
monocytes, long-term exposure during macrophage differentiation decreased 
inflammatory responses. This discrepancy is not surprising given the differences 
in cell types and time of exposure. Nevertheless, both models may be relevant 
for patients in vivo. Patients with diabetes are on the one hand characterized by 
chronic inflammation [23, 24], but are, on the other hand, also more susceptible 
to infections [25], indicating an altered inflammatory response. Similarly, 
obesity – a state of insulin resistance and chronic hyperinsulinemia with normal 
glucose – is also associated with an increased susceptibility to infections [26, 27]. 
Accordingly, studies reporting increased [28], as well as decreased [29] cytokine 
production of immune cells from patients with diabetes exist. Differential 
effects of insulin on cytokine production of monocytes versus macrophages 
may partially be due to time-dependent effects of insulin on metabolism. 
Whereas insulin acutely increased ECAR of monocytes, it diminished lactate 
production after 24h and decreased spare respiratory capacity, when present 
during differentiation. Hence, metabolic effects of insulin may determine 
the modulation of immunological responses. Effects of insulin may also be 
dependent on the cellular location. Whereas cells in the circulation are usually 
exposed to fluctuating concentrations of insulin, macrophages in tissues may 
be exposed to more constant levels of insulin, which may shape differential 
responses towards insulin. 
Particularly in patients with diabetes or insulin resistance, effects of insulin 
probably also depend on the insulin sensitivity of myeloid cells. We did not detect 
impaired insulin sensitivity, as measured by phosphorylation of Akt in response to 
insulin, of monocytes from patients with type 1 diabetes compared with healthy 
individuals. This is in agreement with studies reporting intact insulin signaling 
in monocytes from individuals with impaired glucose metabolism [30], but 
contrasts with studies reporting defective insulin signaling in monocytes from 
individuals with increased diabetes risk [31]. Additionally, studies in patients 
undergoing cardiopulmonary bypass surgery, a condition associated with an 
acute phase of insulin resistance, suggest a relation between insulin signaling 
intermediates in leukocytes and the level of systemic insulin resistance [9]. 
Clearly, further studies are needed to determine whether differences in insulin 
sensitivity of monocytes between insulin resistant and healthy individuals exist 
and how these correlate with cellular function.
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Our study has limitations. We used relatively high concentrations of insulin 
(10-100nM) in our experiments to treat the myeloid cells, although this is in 
the range of insulin concentrations used in other studies [7, 8]. In addition, in 
vivo, even in individuals with hyperinsulinemia, insulin levels will likely fluctuate 
during the course of the day. Fluctuating insulin levels, however, are difficult 
to mimic using in vitro settings, because lowering insulin concentrations by 
removing insulin would also imply the removal of metabolites present in the 
medium, which could directly affect cellular metabolism. Moreover, we mainly 
measured effects of insulin after 24h, and cannot exclude that shorter or 
longer exposure times would better reflect the in vivo situation in patients with 
chronically elevated insulin levels. Nonetheless, our results provide important 
insights into the effects of insulin on myeloid cells. The strength of this study is 
the use of primary human immune cells from healthy individuals and patients 
with diabetes. Additionally, we confirmed part of our results generated in vitro 
with observations from hyperinsulinemic clamps and histological data from 
patients.
In conclusion, our data suggest that insulin acutely activates cellular metabolism 
of human monocytes via the PI3K/Akt/mTOR pathway. Functionally, insulin 
had only mild effects on cytokine production of human monocytes, but 
increased migration capacity. In contrast, long-term exposure to insulin during 
differentiation decreased spare respiratory capacity and IL-β production of 
macrophages. Effects of insulin on monocytes and macrophages may contribute 
to the disturbed innate immune cell function observed in patients with diabetes.
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SUPPLEMENTARY MATERIAL
Suppl. Table 1 Primer sequences
gene forward primer reverse primer
B2M ATGAGTATGCCTGCCGTGTG CCAAATGCGGCATCTTCAAAC
HK2 TTGACCAGGAGATTGACATGGG CAACCGCATCAGGACCTCA
LDHA ATGGCAACTCTAAAGGATCAGC CCAACCCCAACAACTGTAATCT
PDK4 GGAGCATTTCTCGCGCTACA ACAGGCAATTCTTGTCGCAAA
PEPCK (PCK2) CCATCATGCCGTAGCATCCAG GGGCACTGTGCTCTACAAAAT
SREBF2 AACGGTCATTCACCCAGGTC GGCTGAAGAATAGGAGTTGCC
INSIG1 GCCTACTGTACCCCTGTATCG TGGTTAATGCCAACAAAAACTGC
HMGCR TGATTGACCTTTCCAGAGCAAG CTAAAATTGCCATTCCACGAGC
FASN AAGGACCTGTCTAGGTTTGATGC TGGCTTCATAGGTGACTTCCA
189
7

8Transcriptional enrichment of lipid 
metabolism and complement pathways in 
myeloid cells residing in human adipose 
tissue 
Jacqueline M. Ratter, Guido J. Hooiveld, Otmar Buyne, Anneke G. M. 
Hijmans, Mihai G. Netea, Cees J. Tack, Rinke Stienstra
In preparation
8
192
Transcriptional enrichment of lipid metabolism and complement pathways in myeloid cells residing in 
human adipose tissue 
ABSTRACT
Adipose tissue macrophages are assigned with specific tasks including 
efferocytosis - the clearance of dead adipocytes - and regulation of adipose 
tissue lipolysis. As adipose tissue macrophages mostly originate from circulating 
monocytes, their specific phenotype and function is shaped by the adipose 
tissue microenvironment. In order to better characterize human myeloid cells 
from adipose tissue in the context of their microenvironment, we characterized 
the transcriptome of CD14+ myeloid cells from paired samples of human 
subcutaneous (SAT) and visceral (VAT) adipose tissue as well as circulating 
monocytes. Surprisingly, we only detected subtle differences between myeloid 
cells from SAT versus VAT. The most differentially regulated gene between 
myeloid cells from SAT and VAT was intelectin-1 (omentin-1), an adipokine 
produced by stromal vascular cells from VAT and involved in insulin resistance. 
Compared to CD14+ cells isolated from the circulation, CD14+ cells from adipose 
tissue had higher expression of genes involved in lipid metabolism, in particular 
lipid breakdown, accompanied by lower expression of hexokinase, a key regulator 
of glycolysis. Strikingly, CD14+ cells from adipose tissue compared with blood 
also displayed an enrichment in complement pathway genes including C1QB 
and VSIG4. In line with previous studies, the expression of the complement 
genes C1QB and VSIG4 in CD14+ cells isolated from adipose tissue was highly 
correlated with expression of the efferocytosis marker GAS6. To determine a 
potential role of complement in shaping the phenotype of myeloid cells in the 
adipose tissue, we exposed monocytes to purified C1q and observed increased 
expression of mitochondrial biogenesis markers. This may represent a link 
between complement and adaptations of intracellular macrophage metabolism 
geared towards (fatty acid) oxidation to cope with the lipid-rich environment in 
the adipose tissue. Altogether we identified unique transcriptional signatures of 
myeloid cells residing in adipose tissue that may help to understand the specific 
requirements of adipose tissue macrophages and to decipher potential local 
signals shaping their phenotypes. 
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INTRODUCTION
Macrophages play a key role in regulating adipose tissue function in health 
and disease. For example, adipose tissue macrophages are involved in the 
removal of dead adipocytes in a process termed efferocytosis, a key process to 
maintain tissue homeostasis [1, 2]. Cellular turnover in the adipose tissue and 
the subsequent clearance by macrophages is usually a silent, anti-inflammatory 
process, as in many other tissues. In obesity, however, efficient removal of 
adipocytes seems to be disturbed, leading to the accumulation of macrophages 
around dead adipocytes in so-called crown-like structures (CLS) [3]. Also 
during lipolysis, lipid-laden macrophages accumulate in the adipose tissue [4]. 
By taking up and storing excessive amounts of lipids released during fasting, 
macrophages buffer lipolysis and contribute to a gradual release of lipids from 
the adipose tissue.
In recent years, it has become apparent that macrophages adopt tissue-
specific phenotypes, reflected in tissue-specific transcriptional signatures [5, 6]. 
Macrophages isolated from murine and human adipose tissue, for instance, 
were found not to display classical markers of M1 or M2 macrophage activation, 
but rather specific upregulation of proteins involved in metabolism, for example 
ABCA1 and PLIN2 [7]. Interestingly, macrophages treated with glucose, insulin 
and palmitate, factors increasingly present in patients with diabetes or metabolic 
disease, upregulated metabolic markers similar to those highly expressed on 
macrophages isolated from adipose tissue [7]. Consequently, the phenotype of 
adipose tissue macrophages may be determined by metabolic factors present in 
the tissue microenvironment. 
When circulating monocytes migrate into the adipose tissue and differentiate 
into macrophages, they need to adapt to a specific microenvironment dominated 
by lipids. During obesity, macrophages have been shown to induce lysosomal 
biogenesis and lipid catabolism in an attempt to deal with increasing amounts 
of lipid [8]. Comparing circulating monocytes with adipose tissue macrophages 
may provide important information on how myeloid cells adapt to the lipid-rich 
microenvironment in the adipose tissue.
The adipose tissue microenvironment may also differ between various adipose 
tissue locations. It is well-known that the amount of visceral adipose tissue 
(VAT) rather than subcutaneous adipose tissue (SAT) is associated with insulin 
resistance [9]. This may be partially due to increased inflammatory properties of 
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VAT in contrast to SAT [10, 11]. Although a more pro-inflammatory profile in VAT 
compared with SAT likely contributes to the development of insulin resistance, 
underlying mechanisms remain elusive. To characterize human adipose tissue 
macrophages in the context of their micro-environment, we collected matched 
samples of human CD14+ myeloid cells isolated from blood, subcutaneous and 
visceral adipose tissue and analyzed their transcriptional profiles.
MATERIAL AND METHODS
Human subjects
Blood and adipose tissue biopsies were collected from volunteers (6 males/8 
females, age: 56 ± 13 years, BMI: 28.6 ± 4.7 kg/m2) undergoing elective abdominal 
surgery (cholecystectomy, repair of incisional hernia, hernia epigastrica or 
umbilical hernia, rectopexy, stoma correction or adhesiolysis). For in vitro 
experiments, buffy coats from healthy donors were obtained (Sanquin Blood 
Bank, Nijmegen, the Netherlands). Additionally, CD14+ cells were isolated from 
fresh blood donated by healthy volunteers. For all procedures, ethical approval 
was obtained by the institutional review board of the Radboud university medical 
center and all participants gave written informed consent before participation.
Isolation of monocytes from buffycoats
Isolation of PBMCs was performed by differential centrifugation over Ficoll-
Paque PLUS (GE Healthcare Biosciences). Monocytes were separated from the 
PBMCs by hyperosmotic density gradient centrifugation over Percoll (Sigma-
Aldrich) (Fig. 2D, E, Fig. 4D, F, G).
Isolation of CD14+ cells from blood
Isolation of PBMCs was performed by differential centrifugation over Ficoll-
Paque PLUS (GE Healthcare Biosciences). CD14+ monocytes were purified from 
freshly isolated PBMCs using MACS microbeads for positive selection, according 
to the manufacturer’s instructions (Miltenyi Biotec).
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Isolation of CD14+ cells from adipose tissue
Part of the freshly collected SAT and VAT samples was disaggregated using 
collagenase digestion (Collagenase from Clostridium histolyticum, Type II 
(Sigma)) to seperate adipocytes from the stromal vascular fraction (SVF). 
CD14+ monocytes were purified from SVF using MACS microbeads for positive 
selection, according to the manufacturer’s instructions (Miltenyi Biotec).
Microarray analysis
RNA was purified from human CD14+ monocytes using TRIzol reagent 
(Invitrogen), followed by an additional round of purification with RNeasy Minikit 
columns (Qiagen). RNA quality was assessed using RNA 6000 nanochips on an 
Agilent 2100 Bioanalyzer (Agilent). Purified RNA (100 ng) was labelled with aWT 
PLUS Reagent kit (Affymetrix) and hybridized to a Human Gene 1.1 ST array 
plate (Affymetrix). Hybridization, washing and scanning were carried out on a 
GeneTitan platform (Affymetrix) according to the manufacturer’s instructions. 
Arrays were normalized using the robust multiarray average method [12, 13]. 
Probe sets were defined according to the method of Dai et al. [14]. In this 
method, probes are assigned to Entrez IDs as a unique gene identifier, which lead 
to profiling of 29526 unique genes (custom CDF23). The P values were calculated 
using an intensity-based moderated t-statistic [15]. Microarray analysis was 
performed for paired samples from 5 individuals. Adipose tissue samples from 
one donor did not cluster with the corresponding depot samples from the other 
donors (Suppl. Fig. 1A). Further analysis by RT-PCR revealed, that this donor also 
showed different expression patterns compared to all other donors for some of 
the most differentially expressed genes in SAT versus VAT (Suppl. Fig. 1B-E). 
We cannot exclude a sample swap during collection of the tissue biopsies 
and therefore decided to exclude this donor from our analysis. For analysis of 
GSE5099 arrays were normalized and analyzed as described above. The Illumina 
BeadChip array GSE56682 was reanalyzed by background correction followed 
by quantile normalization (neqc) [16]and removal of unspecific probes [17]. The 
principle component analysis was performed using the library mixOmics [18].
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RNA isolation and RT-PCR
For mRNA expression analysis, cells were lysed in TRIzol reagent (Invitrogen) 
and RNA isolation was performed according to the manufacturer’s instructions. 
RNA was transcribed into complementary DNA by reverse transcription using the 
iScript cDNA synthesis kit (Bio-Rad). Power SYBR Green PCR Master Mix (Applied 
Biosystems) was used for semiquantitative RT-PCR in a StepOnePlus™ Real-
Time PCR System (Applied Biosystems). Expression data were normalized to the 
housekeeping gene RPL37A or B2M. Primer sequences can be found in Suppl. Table 1. 
 
 
In vitro experiments
Complement component C1q from human serum, BSA, oleate, palmitate were 
all from Sigma. To generate conditioned medium SGBS adipocytes, cultured in 
0F medium, containing 10% FCS, were exposed to UV light (50 mJ) to induce 
apoptosis. In the experiment monocytes were exposed to 50% conditioned 
medium and 50% RPMI 1640 (supplemented with 50μg/mL gentamycin, 1mM 
pyruvate, 2mM glutamax), containing 10% human pool serum. 
Statistics
Differences between two variables were compared with the paired Wilcoxon’s 
signed rank test and differences for 3 or more variables were compared 
with Friedman’s test with post-hoc Bonferroni test. For correlation analysis 
Spearman’s rank test was used. A p-value <0.05 was considered statistically 
significant. Statistical analyses were performed with GraphPad Prism or IBM 
SPSS Statistics 25. Heatmaps were generated in R studio using the corrplot 
package, volcanoplots were generated with ggplot2.
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RESULTS
To obtain a comprehensive overview of transcriptional profiles of human myeloid 
cells in the context of their microenvironment, we collected paired RNA samples 
of CD14+ cells isolated from SAT, VAT and blood. Additionally, we collected RNA 
samples from total adipose tissue (SAT and VAT) and from CD14- cells isolated from 
the stromal vascular fraction and from blood. To gain insight into transcriptional 
profiles of CD14+ cells from blood compared to SAT and VAT, we performed 
a microarray with paired samples from 4 individuals. Using multidimensional 
scaling, we found a tight clustering of CD14+ cells from blood of different 
donors, while cells isolated from adipose tissue were clearly separated (Fig. 1A). 
Cells isolated from adipose tissue were more heterogeneous between donors 
compared with cells from blood, however, there was still a clear separation of cells 
from SAT versus VAT. Cell type deconvolution [19] revealed that CD14+ cells from 
adipose tissue were mainly macrophages and that the composition of CD14+ cells 
isolated from adipose tissue was very similar between SAT and VAT (Suppl. Fig. 2). 
Morphologically, SAT and VAT were overall very similar, with increased numbers 
of macrophages and crown-like structures in VAT compared with SAT in some 
individuals (Fig. 1B). Slightly elevated CD68 expression in total VAT versus SAT 
confirmed increased abundance of macrophages in VAT of most individuals 
(Fig. 1C). Although macrophage numbers differed between VAT and SAT, we did 
not observe clear differences in expression of classical M1 or M2 macrophage 
polarization markers in CD14+ cells isolated from VAT versus SAT (Fig. 1D).
Further zooming in on the transcriptional differences between myeloid 
cells originating from SAT versus VAT, we found that in total, 73 genes were 
differentially expressed (BH-adj. p-value<0.05) between CD14+ cells from SAT 
compared with VAT (Fig. 1E). The majority of differentially regulated genes was 
expressed higher in CD14+ cells from VAT compared with SAT. Strikingly, the 
most differentially expressed gene with higher expression in CD14+ cells from 
VAT compared with SAT was ITLN1 (intelectin-1/omentin-1) (Fig. 1F). Omentin-1 
is an adipokine, produced by the stromal vascular fraction of VAT [20]. We 
confirmed higher expression of ITLN1 in VAT versus SAT by RT-PCR in paired 
samples from 12 individuals (Fig. 1G). Although plasma levels of omentin-1 and 
gene expression in VAT were shown to inversely correlate with BMI and insulin 
resistance [21], we did not find a correlation of ITLN1 expression in CD14+ cells 
from adipose tissue with BMI (Suppl. Fig. 3A). The second most differentially 
regulated gene with higher expression in CD14+ cells from VAT compared with 
SAT was CLDN1 (claudin-1) (Fig. 1F, H). Claudin-1 is a tight junction protein 
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and may be involved in macrophage polarization, evidenced by a strong IL-4-
mediated induction in murine macrophages [22]. Gene expression of CLDN1 was 
not correlated with BMI (Suppl. Fig. 3A, B), but expression of CLDN1 in CD14+ 
cells from SAT correlated with age (Suppl. Fig. 3A, C). 
Zooming in on genes higher expressed in CD14+ cells from SAT compared to VAT, 
we identified the chemokine CXCL14 as one of the most differentially regulated 
genes (Fig. 1I-J). The expression of CXCL14 in CD14+ cells from adipose tissue 
was not correlated with BMI (Suppl. Fig. 3D). Although HSD17B13, an enzyme 
involved in steroid synthesis, and a lipid droplet-associated protein, which is 
involved in liver inflammation and the development of NAFLD [23], was also 
identified as one of the most differentially expressed genes in CD14+ cells from 
SAT versus VAT in the microarray (Fig. 1I), this could not be confirmed by follow-
up analysis using RT-PCR (Fig. 1K). Interestingly, not the general expression, but 
the expression ratio of HSD17B13 in SAT versus VAT tended to be lower with 
increased BMI (r=-0.51, p=0.0899) (Suppl. Fig. 3D, E).
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In addition to the observed differences between CD14+ cells from SAT compared 
with VAT, we were also interested in the differences between CD14+ cells from 
adipose tissue compared with circulating CD14+ cells from blood. The adipose 
tissue is a lipid-rich microenvironment requiring specific functional traits of 
the residing immune cells. It has been well established that certain functional 
requirements of innate immune cells are mediated by specific intracellular 
metabolic reprogramming. Pro-inflammatory responses of innate immune 
cells, for instance, are accompanied by an increase in glycolytic rate. Compared 
to circulating CD14+ cells, CD14+ cells from adipose tissue showed a lower 
expression of all hexokinase isoforms (HK1, HK2 and HK3), the enzyme catalyzing 
the first reaction in the glycolytic route (Fig. 2A). Furthermore, expression of 
6-phosphofructo-2-kinase/fructose-2,6-biphosphatase (PFKFB) 3 was higher, 
and expression of PFKFB4 was lower in CD14+ cells from adipose tissue compared 
with cells from blood (Fig. 2A), indicating increased glucose utilization through 
glycolysis and decreased glucose entry into the pentose-phosphate pathway [24]. 
In accordance with the lipid-rich environment, genes involved in lipid metabolism 
were expressed at higher levels in CD14+ cells from adipose tissue compared with 
those from the circulation (Fig. 2B). Whereas expression of genes involved in fatty 
acid biosynthesis and triglyceride metabolism was very similar between cells from 
different compartments, expression of lipases and lipid droplet associated proteins 
was substantially higher in CD14+ cells from adipose tissue compared with blood. 
High expression of genes mediating lipid breakdown may be important for the lipid 
buffering function of adipose tissue macrophages [4]. The observed differences in 
metabolic gene expression between circulating cells and cells from adipose tissue 
may partially be due to differences in the differentiation status of the isolated 
cells. According to their function, differentiated macrophages have different 
metabolic requirements in contrast to monocytes, resulting in differential gene 
expression. Differential regulation of genes involved in cholesterol metabolism, for 
example, has been detected in murine monocytes compared with macrophages 
[25]. We therefore compared metabolic gene expression signatures of human 
monocytes and monocyte-differentiated macrophages [26]. High expression 
of genes in lipid breakdown seemed to be specific for the cellular location in 
the adipose tissue, because it was not reflected in the transcriptional changes 
following differentiation of monocytes to macrophages in vitro (Suppl. Fig. 4A, B). 
Low expression of hexokinase and high expression of genes involved in lipid 
metabolism in CD14+ cells from adipose tissue was confirmed by RT-PCR (Fig. 2C). 
Interestingly, expression of LPL and PLIN2 was also higher in murine adipose 
tissue versus peritoneal macrophages [27], again confirming tissue-specificity of 
highly active lipid metabolism in macrophages. 
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Figure 2. Gene expression signatures 
indicate use of lipid metabolism instead 
of glycolysis in myeloid cells in adipose 
tissue. A Microarray analysis of CD14+ 
cells isolated from SAT, VAT and blood. 
Expression data are presented as 
log2FC in a heatmap of selected genes 
involved in glycolysis. B As described in 
A, genes involved in lipid metabolism. 
C Gene expression assessed by RT-
PCR in CD14+ cells isolated from SAT, 
VAT and blood. D Gene expression 
assessed by RT-PCR in monocytes 
treated for 24h with BSA or a mixture 
of oleic/palmitic acid (OA/PA, 100μM). 
E Gene expression assessed by RT-PCR 
in macrophages differentiated with 
GM-CSF and polarized with glucose, 
insulin and palmitate to metabolically 
activated macrophages (Mme) or 
with LPS+IFNγ to M1 macrophages. 
Relative gene expression is displayed 
as 2-∆Ct*10000 and was normalized to 
expression of RPL37A. * p<0.05, ** 
p<0.01, *** p<0.01. 
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The lipid-rich microenvironment in the adipose tissue may induce genes involved 
in lipid metabolism that allow myeloid cells to deal with this metabolic challenge. 
To identify potential external signals that regulate metabolic gene signatures in 
myeloid cells in the adipose tissue, we tested whether monocytes exposed to 
fatty acids develop a similar expression profile of metabolic genes compared 
with macrophages isolated from adipose tissue. Although exposure to fatty 
acids had no consistent effects on expression of HK2 and LPL, the expression of 
PLIN2 and FABP4 indeed was increased (Fig. 2D). In addition to fatty acids, also 
other factors, like glucose and insulin may impact on myeloid cells in the adipose 
tissue. Although macrophages treated with insulin, glucose and palmitate 
were shown to phenotypically resemble adipose tissue macrophages [7], 
we did not find significant differences in the expression of selected metabolic 
genes between untreated macrophages and macrophages treated with 
insulin, glucose and palmitate (Fig. 2E). Nevertheless, gene expression of the 
selected metabolic genes was lower in classically activated M1 compared with 
metabolically activated macrophages. Consequently, neither fatty acids alone, 
nor a combination of insulin, glucose and palmitate were able to induce the 
specific metabolic gene signatures observed in adipose tissue macrophages.
To complement our targeted transcriptional analysis focused on metabolism, 
we also performed unbiased pathway-enrichment analysis to identify pathways 
important for tissue-specific function of macrophages in the adipose tissue. 
Pathway enrichment analysis of the top 200 genes higher expressed in CD14+ 
cells from adipose tissue compared with blood, revealed extracellular matrix 
organization as the top differentially regulated pathway (Fig. 3A). Strikingly, 
complement pathways were also enriched in CD14+ cells isolated from the adipose 
tissue compared with blood (Fig. 3A). High expression of complement factors in 
CD14+ cells from adipose tissue comprised early initiators of the complement 
pathway (C1QA, C1QB, C1QC), effectors (C3), and receptors (C1R) (Fig. 3B). 
Some of the differentially regulated genes are also regulated during in vitro 
differentiation of monocytes to macrophages (Fig. 3C), and may therefore 
just reflect a difference in differentiation status, not necessarily specific to 
the adipose tissue. Nevertheless, differences were more profound in CD14+ 
cells from adipose tissue compared with blood. To determine the specificity 
of the regulation of complement pathways in adipose tissue macrophages, 
we performed a principal component analysis (PCA) using publicly available 
gene expression profiles of macrophages isolated from the peritoneal cavity, 
liver, spleen, lung, intestine and adipose tissue [5]. Transcriptional profiles of 
complement genes seem to be distinct for macrophages located in different 
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tissues (Fig. 3D). Furthermore, expression of various complement genes was 
higher in CD14+ cells from VAT of obese diabetic versus obese individuals 
(Fig. 3E) [28], suggesting an important role for complement in adipose tissue 
macrophages in the development of insulin resistance. For C1QB and VSIG4, 
higher expression in cells from adipose tissue in contrast to circulating cells was 
specific to CD14+ cells, whereas for C3, expression was also higher in CD14- cells 
isolated from adipose tissue in contrast to circulating cells (Fig. 3F). 
C1QA, C1QB and C1QC were amongst the most differentially regulated 
complement components. The complement factor C1q has been implicated in 
mediating efferocytosis of apoptotic cells [29], which is very relevant for adipose 
tissue macrophages, because macrophages play an important role in removing 
dead adipocytes from the adipose tissue [1]. Interestingly, gene expression of 
the complement components C1QB, C1QC and VSIG4 in CD14+ from VAT highly 
correlated with gene expression of GAS6, a receptor important for efferocytosis 
(Fig. 4A). Interestingly, expression of the apoptosis marker BCL2 in total adipose 
tissue also correlated with expression of C1QB in total adipose tissue. However, 
expression of CD68 also correlated with C1QB and BCL2 expression, suggesting 
a link between cell death and increased numbers of macrophages in the adipose 
tissue, accompanied by increased expression of C1QB. 
Expression of C1q in macrophages is regulated by the transcription factors 
LXRα and MAFB [30] and in line with this, we found strong correlations of 
C1QB gene expression in CD14+ cells from adipose tissue with LXRα (NR1H3) 
(Fig. 4B) and MAFB expression (Fig. 4C). To identify adipose-tissue relevant 
factors controlling C1QB expression, monocytes were exposed to fatty acids. 
However, only limited effects of fatty acids on C1Q expression were observed. 
(Fig. 4D). In contrast, exposure of monocytes to conditioned medium from 
apoptotic adipocytes versus live adipocytes strongly increased expression of 
C1QB (Fig. 4E). Recently, C1q has been shown to locate to mitochondria in T 
cells and furthermore to be involved in regulation of mitochondrial biogenesis in 
these cells [31]. Exposure of monocytes to C1q increased expression of Tfam and 
PGC-1β, transcription factors involved in mitochondrial biogenesis (Fig. 4F-G). 
Consequently, C1q may interfere with intracellular metabolism of immune cells 
in the adipose tissue and may enable adipose tissue macrophages to cope with 
the lipid-rich microenvironment by increasing oxidative capacity.
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Figure 4. Complement may facilitate efferocytosis of adipose tissue macrophages. A Correlation 
heatmap of gene expression measured in whole adipose tissue or CD14+ cells isolated from 
adipose tissue with BMI and age. Color scale indicates Spearman’s correlation coefficient. 
A-B Correlation of C1QB in CD14+ cells with NR1H3 (A) and MAFB (B). C Gene expression 
assessed by RT-PCR in monocytes stimulated for 24h with BSA as a control or a mixture of 
oleic acid/palmitic acid (OA/PA, 100 μM). D Gene expression assessed by RT-PCR in monocytes 
stimulated for 24h with medium (MC) or conditioned medium of live (live) or apoptotic (apop.) 
SGBS adipocytes. F-G Gene expression assessed by RT-PCR in monocytes treated for 24h with 
medium or purified C1q (8μg/mL). Relative gene expression is displayed as 2-∆Ct*10000 and was 
normalized to expression of RPL37A (A-C) or B2M (D-G). * p<0.05, ** p<0.01, *** p<0.001.
DISCUSSION
Adipose tissue macrophages are important in maintaining tissue homeostasis, but 
function may vary amongst different adipose tissue compartments. Here we show 
that transcriptional profiles of human myeloid cells isolated from adipose tissue are 
very similar between subcutaneous and visceral fat, but quite distinct from expression 
signatures of circulating monocytes. In particular, CD14+ cells from adipose tissue 
are characterized by high expression of genes involved in lipid breakdown and, 
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strikingly, complement pathways. These findings highlight adaptations of myeloid 
cells to the adipose tissue microenvironment and suggest an as yet unidentified role 
for intracellular complement in adipose tissue macrophages.
Our findings extend earlier described differences in the inflammatory profiles 
of different adipose tissue depots [11]. In our cohort, we found increased CD68 
expression in total VAT in contrast to SAT, indicating increased macrophage 
accumulation in VAT. Transcriptional profiles of CD14+ cells from SAT versus 
VAT, however, showed only a limited number of genes that were differentially 
regulated. First, this may indicate, that overall, the number of immune cells 
rather than the immune cell phenotype may contribute to distinct inflammatory 
profiles of SAT versus VAT. Second, phenotypical differences may rather occur 
on protein than on gene expression level. In the case of metabolism, differences 
may not become apparent at the gene expression level of enzymes involved in 
metabolism, but rather after measuring levels of intracellular metabolites.
Comparing tissue CD14+ cells with circulating CD14+ cells can reveal relevant 
tissue-specific adaptations. Several studies have already indicated that 
macrophages in the adipose tissue are characterized by increased expression 
of genes involved in lipid metabolism [7]. In particular lysosomal-dependent 
lipid metabolism [8] and lipid-droplet biogenesis [32] seem to be important 
for functional adipose tissue macrophages. In line with this, we found higher 
expression of lipid droplet-associated genes (PLIN2, LIPA) in CD14+ cells isolated 
from adipose tissue compared with blood. Functional lipid droplets play an 
important role in regulation of adipose tissue lipolysis [8] and future studies 
investigating lipid droplet-associated genes in adipose tissue macrophages 
during obesity seem warranted. Our findings are in agreement with the 
increased expression of PLIN2 and LIPA in adipose tissue macrophages isolated 
from obese versus lean mice [27], and the observation that several metabolic 
pathways, for example ‘lysosome’, were enriched in CD14+ cells isolated from 
VAT of obese diabetic compared with obese individuals [27].
Using an unbiased analysis approach, we detected an enrichment of complement 
pathways in transcriptional profiles of CD14+ cells from adipose tissue versus 
blood. Although classically, the complement system is important for the 
defense against bacterial pathogens, the complement system is also involved 
in regulation of metabolic processes, such as lipid metabolism, in health and 
disease [33]. Upregulation of early and downregulation of terminal complement 
pathway genes, for example, was found in SAT of obese versus lean siblings of 
8209
BMI-discordant monozygotic twins [34]. Furthermore, mice deficient for C1q, the 
initiator of the classical complement pathway, are protected from high fat diet-
induced insulin resistance and impaired glucose homeostasis [35]. Although the 
role of intracellular complement has been increasingly investigated recently [36], 
the role of complement factors in adipose tissue immune cells has not been 
elucidated yet. 
We found that C1q, among other complement components, was highly 
expressed in myeloid cells from adipose tissue compared with circulating cells. 
A strong correlation between gene expression of C1QB as well as VSIG4 and the 
efferocytosis marker GAS6 (Fig. 4A) indicates a role for complement components 
in the clearance of apoptotic adipocytes, an essential process for maintaining 
adipose tissue homeostasis. Although it was already shown that C1q enhances 
phagocytic engulfment of apoptotic cells via upregulation of genes like Mer and 
Gas6 [29], it remains to be determined whether macrophages with increased 
C1q expression are indeed able to clear apoptotic adipocytes more efficiently. 
Similarly, the exact role of Vsig4, which was shown to play an important role in 
phagocytosis of circulating pathogens [37], in the clearance of dead adipocytes 
needs to be investigated further. 
In addition to regulating efferocytosis, C1q may also be involved in adipose 
tissue lipid metabolism. Intracellularly, C1q may regulate macrophage lipid 
handling, and, after secretion, extracellular C1q may interfere with adipose 
tissue lipid metabolism. Recently, it was found that C1q increases markers of 
mitochondrial biogenesis and influences spare respiratory capacity of T cells [31]. 
In line with these findings, we observed increased expression of mitochondrial 
biogenesis markers, after exposure of monocytes to purified C1q, which may 
allow macrophages to cope with an increased lipid load. Whether changes in C1q 
expression can likewise influence mitochondrial metabolism in myeloid cells, 
needs to be determined. In addition to C1q, also other complement components 
may affect adipose tissue macrophage function by reprogramming intracellular 
metabolism. Vsig4, for instance, inhibits pro-inflammatory macrophage 
polarization by reprogramming pyruvate metabolism [38].
C1q was shown to directly bind to unesterified fatty acids [39] and, consequently, 
increased C1q expression in macrophages may influence lipid handling, which 
is important for adipose tissue homeostasis [4]. Several studies have already 
indicated that C1q can modulate lipid handling of macrophages. C1q promotes 
an anti-inflammatory macrophage response during the ingestion of atherogenic 
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lipoproteins, such as oxLDL [40, 41], but seems also crucial for cholesterol 
crystal-induced inflammasome activation and pro-inflammatory cytokine 
production in monocytes [42]. It needs to be determined whether increased C1q 
expression in adipose tissue macrophages supports pro- or anti-inflammatory 
responses and whether it is beneficial or not in the context of obesity-induced 
insulin resistance. The finding of elevated C1q expression in CD14+ cells of 
obese diabetic versus obese individuals (Fig. 3E) suggests an important role for 
macrophage-specific complement expression in the development of obesity-
induced insulin resistance.  
We isolated cells from blood and adipose tissue based on the marker CD14, 
which enabled us to directly compare similarities and differences in expression 
signatures of myeloid cells between different locations within one individual. 
We cannot clearly distinguish whether differences between cells from blood 
and cells from adipose tissue are mainly determined by the cellular location 
or by differences in cellular differentiation status or cell subsets. This would 
require flow cytometry-based cell sorting. Recent advances in single cell-
sequencing technologies will allow for a detailed characterization of different 
macrophage subsets, along with other immune cells from adipose tissue [43, 44]. 
Several recent studies revealed, that macrophages in the adipose tissue are 
not characterized by expression of classical M1 and M2 markers, but rather 
show signs of metabolic activation [7, 27]. This may complicate the selection of 
appropriate markers for sorting of macrophages. 
Our study has limitations, including the limited sample size and the fact that our 
conclusions are mainly based on gene expression data. In order to draw clear 
conclusions, our findings need to be confirmed on protein level. Additionally, 
analysis of metabolites in myeloid cells may help to understand the role of 
metabolic reprogramming in adipose tissue macrophage functioning. Due to the 
limited availability of material, we were not able to include these measurements. 
Nonetheless, our results shed light on specific transcriptional signatures of 
human adipose tissue macrophages that increase our understanding of adipose 
tissue macrophage function in health and disease.
In conclusion, we identified several differentially regulated genes between CD14+ 
cells from VAT and SAT, which may be interesting targets for future studies on 
the functional differences of adipose tissue depots. Moreover, we revealed 
that CD14+ cells from adipose tissue are characterized by high expression of 
genes involved in lipid breakdown and, intriguingly, complement pathways. 
8211
This transcriptional profile may be important for adipose tissue macrophage 
functions, such as efferocytosis and lipid buffering. 
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[10] Harman-Boehm I, Blüher M, Redel H, et al. (2007) Macrophage Infiltration into Omental 
Versus Subcutaneous Fat across Different Populations: Effect of Regional Adiposity and the 
Comorbidities of Obesity. The Journal of Clinical Endocrinology & Metabolism 92: 2240-2247
[11] Koenen TB, Stienstra R, van Tits LJ, et al. (2011) The inflammasome and caspase-1 activation: a 
new mechanism underlying increased inflammatory activity in human visceral adipose tissue. 
Endocrinology 152: 3769-3778
[12] Bolstad BM, Irizarry RA, Astrand M, Speed TP (2003) A comparison of normalization methods for 
high density oligonucleotide array data based on variance and bias. Bioinformatics 19: 185-193
[13] Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, Speed TP (2003) Summaries of Affymetrix 
GeneChip probe level data. Nucleic Acids Res 31: e15
[14] Dai M, Wang P, Boyd AD, et al. (2005) Evolving gene/transcript definitions significantly alter the 
interpretation of GeneChip data. Nucleic Acids Res 33: e175
[15] Sartor MA, Tomlinson CR, Wesselkamper SC, Sivaganesan S, Leikauf GD, Medvedovic M (2006) 
Intensity-based hierarchical Bayes method improves testing for differentially expressed genes in 
microarray experiments. BMC Bioinformatics 7: 538
8213
[16] Shi W, Oshlack A, Smyth GK (2010) Optimizing the noise versus bias trade-off for Illumina whole 
genome expression BeadChips. Nucleic Acids Res 38: e204
[17] Barbosa-Morais NL, Dunning MJ, Samarajiwa SA, et al. (2010) A re-annotation pipeline for 
Illumina BeadArrays: improving the interpretation of gene expression data. Nucleic Acids Res 38: 
e17
[18] Le Cao KA, Gonzalez I, Dejean S (2009) integrOmics: an R package to unravel relationships 
between two omics datasets. Bioinformatics 25: 2855-2856
[19] Newman AM, Liu CL, Green MR, et al. (2015) Robust enumeration of cell subsets from tissue 
expression profiles. Nat Methods 12: 453-457
[20] Yang RZ, Lee MJ, Hu H, et al. (2006) Identification of omentin as a novel depot-specific adipokine 
in human adipose tissue: possible role in modulating insulin action. Am J Physiol Endocrinol 
Metab 290: E1253-1261
[21] de Souza Batista CM, Yang RZ, Lee MJ, et al. (2007) Omentin plasma levels and gene expression 
are decreased in obesity. Diabetes 56: 1655-1661
[22] Van den Bossche J, Laoui D, Morias Y, et al. (2012) Claudin-1, claudin-2 and claudin-11 genes 
differentially associate with distinct types of anti-inflammatory macrophages in vitro and with 
parasite- and tumour-elicited macrophages in vivo. Scand J Immunol 75: 588-598
[23] Su W, Wang Y, Jia X, et al. (2014) Comparative proteomic study reveals 17beta-HSD13 as a 
pathogenic protein in nonalcoholic fatty liver disease. Proc Natl Acad Sci U S A 111: 11437-11442
[24] Yi M, Ban Y, Tan Y, Xiong W, Li G, Xiang B (2018) 6-Phosphofructo-2-kinase/fructose-2,6-
biphosphatase 3 and 4: A pair of valves for fine-tuning of glucose metabolism in human cancer. 
Mol Metab
[25] Fernandez-Ruiz I, Puchalska P, Narasimhulu CA, Sengupta B, Parthasarathy S (2016) Differential 
lipid metabolism in monocytes and macrophages: influence of cholesterol loading. J Lipid Res 57: 
574-586
[26] Martinez FO, Gordon S, Locati M, Mantovani A (2006) Transcriptional profiling of the human 
monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene 
expression. J Immunol 177: 7303-7311
[27] Boutens L, Hooiveld GJ, Dhingra S, Cramer RA, Netea MG, Stienstra R (2018) Unique metabolic 
activation of adipose tissue macrophages in obesity promotes inflammatory responses. 
Diabetologia 61: 942-953
[28] Dalmas E, Venteclef N, Caer C, et al. (2014) T cell-derived IL-22 amplifies IL-1beta-driven 
inflammation in human adipose tissue: relevance to obesity and type 2 diabetes. Diabetes 63: 
1966-1977
[29] Galvan MD, Foreman DB, Zeng E, Tan JC, Bohlson SS (2012) Complement component C1q 
regulates macrophage expression of Mer tyrosine kinase to promote clearance of apoptotic 
cells. J Immunol 188: 3716-3723
[30] Tran MTN, Hamada M, Jeon H, et al. (2017) MafB is a critical regulator of complement component 
C1q. Nat Commun 8: 1700
214
Transcriptional enrichment of lipid metabolism and complement pathways in myeloid cells residing in 
human adipose tissue 
[31] Ling GS, Crawford G, Buang N, et al. (2018) C1q restrains autoimmunity and viral infection by 
regulating CD8(+) T cell metabolism. Science 360: 558-563
[32] Bechor S, Nachmias D, Elia N, et al. (2017) Adipose tissue conditioned media support macrophage 
lipid-droplet biogenesis by interfering with autophagic flux. Biochim Biophys Acta Mol Cell Biol 
Lipids 1862: 1001-1012
[33] Kolev M, Kemper C (2017) Keeping It All Going-Complement Meets Metabolism. Front Immunol 
8: 1
[34] Kaye S, Lokki AI, Hanttu A, et al. (2017) Upregulation of Early and Downregulation of Terminal 
Pathway Complement Genes in Subcutaneous Adipose Tissue and Adipocytes in Acquired 
Obesity. Front Immunol 8: 545
[35] Hillian AD, McMullen MR, Sebastian BM, et al. (2013) Mice lacking C1q are protected from high 
fat diet-induced hepatic insulin resistance and impaired glucose homeostasis. J Biol Chem 288: 
22565-22575
[36] Arbore G, Kemper C, Kolev M (2017) Intracellular complement - the complosome - in immune cell 
regulation. Mol Immunol 89: 2-9
[37] Helmy KY, Katschke KJ, Jr., Gorgani NN, et al. (2006) CRIg: a macrophage complement receptor 
required for phagocytosis of circulating pathogens. Cell 124: 915-927
[38] Li J, Diao B, Guo S, et al. (2017) VSIG4 inhibits proinflammatory macrophage activation by 
reprogramming mitochondrial pyruvate metabolism. Nat Commun 8: 1322
[39] Biro A, Ling WL, Arlaud GJ (2010) Complement protein C1q recognizes enzymatically modified 
low-density lipoprotein through unesterified fatty acids generated by cholesterol esterase. 
Biochemistry 49: 2167-2176
[40] Ho MM, Manughian-Peter A, Spivia WR, Taylor A, Fraser DA (2016) Macrophage molecular 
signaling and inflammatory responses during ingestion of atherogenic lipoproteins are 
modulated by complement protein C1q. Atherosclerosis 253: 38-46
[41] Spivia W, Magno PS, Le P, Fraser DA (2014) Complement protein C1q promotes macrophage anti-
inflammatory M2-like polarization during the clearance of atherogenic lipoproteins. Inflamm Res 
63: 885-893
[42] Samstad EO, Niyonzima N, Nymo S, et al. (2014) Cholesterol crystals induce complement-
dependent inflammasome activation and cytokine release. J Immunol 192: 2837-2845
[43] Acosta JR, Joost S, Karlsson K, et al. (2017) Single cell transcriptomics suggest that human 
adipocyte progenitor cells constitute a homogeneous cell population. Stem Cell Res Ther 8: 250
[44] Ehrlund A, Acosta JR, Bjork C, et al. (2017) The cell-type specific transcriptome in human adipose 
tissue and influence of obesity on adipocyte progenitors. Sci Data 4: 170164
8215
SUPPLEMENTARY MATERIAL
Suppl. Figure 1. 
Genes differentially expressed between CD14+ cells isolated from SAT and VAT. A MDS plot 
of CD14+ cells from SAT, VAT and blood, seperated based on their transcriptome. B-E Gene 
expression levels assessed by RT-PCR in CD14+ cells from adipose tissue. Relative gene 
expression is displayed as 2-∆Ct*10000 and was normalized to expression of RPL37A. * p<0.05, 
** p<0.01.
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Suppl. Figure 4. 
Metabolic gene expression signatures during in vitro macrophage differentiation. A-B 
Microarray analysis of human monocytes (mon) differentiated into macrophages. Data are 
derived from GSE5099. Expression data are presented as log
2
FC in a heatmap of selected genes 
involved in glycolysis (A) or lipid metabolism (B). Macrophages were differentiated with GM-
CSF (Md3=day3, Md6=day6) and polarized to M1 (LPS + IFNγ) or M2 (IL-4) macrophages. 
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Suppl. Table 1
gene forward primer reverse primer
B2M ATGAGTATGCCTGCCGTGTG CCAAATGCGGCATCTTCAAAC
RPL37A ATTGAAATCAGCCAGCACG AGGAACCACAGTGCCAGAT
C1QB CTTCCCAGGAGGCGTCTGA GGAGCAGGAGCAACATCAGT
CD163 TGAAGACTCTGGATCTGCTGA GAACTGGTGACAAAACAGGCA
MRC1 (CD206) CTACAAGGGATCGGGTTTATGGA TTGGCATTGCCTAGTAGCGTA
C3 CGGATCTTCACCGTCAACCA GATGCCTTCCGGGTTCTCAA
CFB CTCTTGTCTGGAGGTGTGACC CCGCCTTTGATCTCTACCCC
CLDN1 CAGTCAATGCCAGGTACGAA ACACGTAGTCTTTCCCGCTG
CXCL14 GGGTCCAAATGCAAGTGCTC CACGCTCTTGGTGGTGATGATAA
FABP4 AGCACCATAACCTTAGATGGGG CGTGGAAGTGACGCCTTTCA
HK2 TTGACCAGGAGATTGACATGGG CAACCGCATCAGGACCTCA
HSD17B13 GAAAACTAGGCGTCACTGCG ACCCACTTCTTTCTTCACCTGAT
ITLN1 TAACACTGAGCACCACTGCAT GGGTTCCCTCCCACAAAACT
LPL TCATTCCCGGAGTAGCAGAGT GGCCACAAGTTTTGGCACC
MAFB CGAGGCATAGTCCCGAGAAG GGCTTAACGCGCAAAGTTCA
NR1H3 CATGGCACCAGATCCCCATAG GGGTAGCTGTTTAGCAAAGTCAA
PLIN2 TAACAACACGCCCCTCAACT GCACCTTGGTCCTGAGCATT
PPARGC1B GATGCCAGCGACTTTGACTC ACCCACGTCATCTTCAGGGA
TFAM GGGTTCCAGTTGTGATTGCT CAGATGAAAACCACCTCGGTA
VSIG4 AGCAGGCAAAGTACCAGGG TGGCTCCGGTCATCCATCT
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Summary
Diabetes, a state of chronically elevated blood glucose levels, is associated 
with various long-term complications. Immune cells and inflammation play 
an important role in the pathogenesis of both the disease itself, as well as the 
diabetes-associated complications. Patients with diabetes have impaired acute 
immune responses, resulting in an increased susceptibility for infections, but 
are also characterized by a chronic pro-inflammatory state, contributing to 
vascular complications of diabetes. Although altered function of myeloid cells 
has been suggested to play a role in the pathophysiology of various diabetes-
associated complications, underlying mechanisms remain insufficiently 
understood. Myeloid cells in patients with diabetes reside in a specific metabolic 
environment, characterized by altered concentrations of, for example, 
glucose, lipids and insulin. Since intracellular immune cell metabolism can be 
reprogrammed by external factors, we aimed to investigate how diabetes-
associated (metabolic) factors may influence metabolism of monocytes and 
macrophages, subsequently resulting in altered immune cell function. 
In Chapter 2 we first reviewed the current literature on immune cell metabolism 
in the context of diabetes. Several studies have demonstrated differential 
activation of metabolic pathways in patients with diabetes compared with 
healthy individuals. Additionally, there is evidence that glucose, insulin and 
lipids influence both cellular metabolism and function of monocytes and 
macrophages. Data from human studies and direct evidence from patients, 
however, is limited.
To understand the altered phenotype of immune cells in patients with diabetes, 
we first need to understand the metabolic phenotype of human myeloid cells 
from healthy individuals. In Chapter 3 we show that various TLR ligands and 
lysates of bacteria induce glycolysis in human monocytes. Whereas increased 
glycolysis is accompanied by decreased OXPHOS in cells stimulated with the 
TLR4 ligand LPS, various other pathogenic stimuli, such as the TLR2 ligand 
Pam3Cys, can also increase OXPHOS and consequently promote a more general 
activation of cellular metabolism. Specific metabolic reprogramming induced by 
various pathogenic stimuli may be important to fuel specific cellular functions, 
such as cytokine production and phagocytosis.
Increased glycolysis in pro-inflammatory immune cells is reflected by elevated 
lactate production. Although some studies have indicated immunomodulating 
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effects of lactate via metabolic routes, results from human studies are scarce. 
We therefore investigated the influence of lactate on human immune cells. As 
described in Chapter 4, we found limited effects of a short-term lactate infusion 
on ex vivo metabolism and cytokine production, suggesting a rapid adaptation 
of immune cells to their metabolic environment. Long-term treatment with 
lactate in vitro however directly shifted metabolism from glycolysis to oxidative 
phosphorylation and resulted mainly in anti-inflammatory effects. Altogether, 
immunomodulating effects of lactate are concentration-, time- and stimulus-
dependent, and are therefore highly influenced by (metabolic) factors in the 
environment. 
Activated immune cells are highly dependent on glycolysis and therefore 
fluctuations in blood glucose levels in patients with diabetes may impact on 
immune cell metabolism and function. In Chapter 5 we report the effects of 
hypoglycemia on ex vivo immune cell function in healthy individuals and patients 
with type 1 diabetes. Hypoglycemia clearly increased leukocyte numbers and 
stimulated inflammatory responses of PBMCs and monocytes. Interestingly, 
increased leukocyte numbers after hypoglycemia were strongly correlated 
with increased plasma adrenaline levels after hypoglycemia, suggesting an 
important role for counterregulatory hormone responses in the recruitment of 
pro-inflammatory immune cells. This was confirmed by blunted recruitment of 
immune cells and attenuated pro-inflammatory responses in patients with type 1 
diabetes and impaired awareness of hypoglycemia, who lack counterregulatory 
hormone responses. We did not observe differences in ex vivo intracellular 
glucose metabolism between samples isolated before and after hypoglycemia. 
To investigate which immune cell subsets are specifically recruited upon 
hypoglycemia and may thus contribute to hypoglycemia-induced inflammation, 
we characterized circulating immune cells in patients with type 1 diabetes 
before and after hypoglycemia (Chapter 6). After hypoglycemia, numbers 
of NK cells as well as CD8+, but not CD4+ T cells were increased. Additionally, 
frequencies of non-classical monocytes were increased, whereas frequencies of 
classical monocytes decreased. Non-classical monocytes play a key role in the 
development of atherosclerosis and consequently these findings may identify 
an important link between hypoglycemia and cardiovascular disease. 
Insulin has been shown to promote glycolysis and subsequently pro-inflammatory 
cytokine production in murine macrophages. We therefore investigated whether 
insulin can also effect cellular metabolism and function in human monocytes 
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and macrophages. The results are described in Chapter 7. We found that insulin 
acutely activates metabolic signaling pathways and changes metabolic rates of 
monocytes. These changes in metabolism may contribute to increased cytokine 
production and migration of human monocytes after stimulation with insulin. 
Long-term exposure to insulin during differentiation of macrophages, on the 
contrary, reduced spare respiratory capacity and decreased cytokine production 
of pro-inflammatory macrophages. Consequently, elevated insulin levels in 
patients with diabetes may contribute to chronic inflammation as well as 
impaired function of myeloid cells, possibly relevant in the context of infections.
Whereas fluctuating glucose concentrations may impact the number and 
function of circulating immune cells in the blood, the lipid-rich environment 
may determine the phenotype of macrophages in the adipose tissue. In Chapter 
8 we depict the comparison of myeloid cells from blood, subcutaneous adipose 
tissue and visceral adipose tissue. Although differences between subcutaneous 
and visceral adipose tissue macrophages were limited, we found strong 
differences between gene expression profiles of circulating cells and cells 
residing in the adipose tissue. Metabolically, myeloid cells from the adipose 
tissue are characterized by high expression of genes involved in lipid breakdown. 
Moreover, we observed that the expression of genes of the complement 
pathway is higher in myeloid cells from adipose tissue compared with myeloid 
cells from the circulation. High expression of complement factors like C1q may 
regulate metabolism and efferocytotic capacity of adipose tissue macrophages. 
Altogether, complement factors seem to play an important role for myeloid cells 
in adipose tissue and may thus be interesting targets to interfere with adipose 
tissue inflammation and insulin resistance.
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Discussion
Patients with diabetes are characterized by several metabolic disturbances, 
especially chronically elevated glucose concentrations. Patients treated with 
insulin also frequently experience hypoglycemic events during treatment. 
Moreover, in the development of obesity-induced insulin resistance, increased 
lipolysis in the adipose tissue promotes increased free fatty acid flux and, to 
compensate for the development of insulin resistance, pancreatic beta cells 
initially increase their production of insulin, resulting in hyperinsulinemia. In 
addition to various metabolic disturbances, the function of monocytes and 
macrophages is altered and known to be involved in the pathogenesis of diabetes 
and its (vascular) complications. In this thesis, we investigated whether various 
metabolic factors known to be altered during diabetes influence metabolism 
of monocytes and macrophages and thereby contribute to altered immune cell 
function and subsequent complications in diabetes. 
The studies in this thesis show that extracellular lactate, glucose and insulin 
affect the metabolism and function of human myeloid cells. In this chapter, 
we discuss the relevance and implications of our findings for patients with 
diabetes. Firstly, we will describe the impact of specific metabolic changes on 
diabetic complications, in particular atherosclerosis and infections, and how 
this could be mediated by direct effects of metabolic changes on myeloid cells. 
Secondly, we will discuss whether the metabolic changes are mainly influencing 
myeloid cell function via reprogramming of intracellular metabolism or via 
other mechanisms, e.g. receptor-mediated signaling pathways. Finally, we 
will provide suggestions for future studies to further unravel the influence 
of metabolic factors on myeloid cells in diabetes-associated complications. 
Altogether, this chapter will put our research into context and highlight how 
our studies contribute to better understand the pathophysiology of diabetes-
associated complications.
The role of lactate in patients with diabetes
Mechanisms linking lactate to diabetic complications
Lactate is the end product of anaerobic glycolysis and continuously produced by 
most tissues in the human body, in particular by the skeletal muscle and adipose 
tissue [1, 2]. In resting conditions, human plasma lactate concentrations range 
from 0.5-2 mM. After intense exercise, however, lactate production in the 
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skeletal muscle increases, leading to increased plasma lactate concentrations 
of up to 10-25 mM [3]. In the adipose tissue, lactate production can be increased 
by glucose and insulin [4]. Although plasma levels of lactate are generally not 
elevated in patients with diabetes compared with healthy individuals, they are 
associated with diabetes risk and insulin resistance [5, 6]. Conversely, treatment 
with the lactate dehydrogenase-inhibitor oxamate decreased lactate levels 
and improved insulin sensitivity in db/db mice [7]. How increased lactate levels 
promote insulin resistance, however, remains unknown.  
In addition to circulating lactate concentrations, lactate concentrations in 
tissues may be altered in patients with diabetes. Lactate levels in obese adipose 
tissue are, for example, higher compared with levels in lean adipose tissue [4]. 
This may partially be due to hyperglycemia, because adipocytes cultured in 
medium with increased glucose concentrations produced increased amounts of 
lactate [8]. Moreover, larger adipocytes convert increased quantities of glucose 
to lactate [4]. How elevated lactate levels in obese adipose tissue contribute to 
diabetic complications is not yet fully elucidated. Increased lactate production by 
adipocytes in obese adipose tissue may influence the inflammatory phenotype 
of adipose tissue macrophages. In the tumor microenvironment, tumor-derived 
lactate has been shown to polarize macrophages to more anti-inflammatory M2-
like macrophages [9]. Similarly, we found anti-inflammatory effects of lactate in 
human immune cells using ex vivo approaches (Chapter 4). Whether adipocyte-
derived lactate also induces an anti-inflammatory phenotype in adipose tissue 
macrophages is unknown. 
As the end product of glycolysis, lactate is also secreted by activated immune 
cells [10], and therefore its concentrations are also elevated at local sites of 
inflammation. Although altered activation of immune cells from patients 
with diabetes [11] may influence lactate production, no difference in lactate 
concentration secreted by PBMCs from T1D patients compared with healthy 
individuals have been detected (Chapter 5) [12]. Whether immunomodulating 
effects of lactate are relevant at local sites of infection in patients with diabetes 
still needs to be investigated.
Lactate-induced changes in intracellular metabolism: lactate as a 
metabolic substrate vs. lactate as a signaling molecule
Lactate may impact on cellular function via two different pathways. First, 
lactate can be transported into immune cells via the monocarboxylate 
transporters MCT1 [13] and MCT4 [14]. After conversion into pyruvate by lactate 
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dehydrogenase, lactate may subsequently fuel oxidative metabolism via the 
TCA cycle [15]. Second, lactate can act as a signaling molecule by binding to 
the G-protein-coupled receptors GPR81 [16] and GPR132 [17]. In immune cells, 
binding of lactate to GPR81 induced downregulation of cytokine production via 
arrestin β-2 and NFκB [16]. In adipocytes, binding of lactate to GPR81 has been 
shown to decrease lipolysis via downregulation of cAMP [18]. Whether lactate 
also modulates intracellular cAMP concentrations and metabolism in immune 
cells via GPR81-mediated signaling is unknown. GPR81-independent effects of 
lactate on intracellular metabolism of macrophages [19], however, argue for a 
function of lactate as a metabolic substrate. Accordingly, we found that acute 
effects of lactate on monocyte metabolism were abolished by inhibition of 
lactate dehydrogenase (Chapter 4).
Whether lactate functions as a signaling molecule acting via G-protein-coupled 
receptors, or as a metabolic substrate directly influencing metabolism, may 
also depend on the expression level of lactate receptors and transporters. 
Expression of lactate transporters changes upon inflammatory stimulation of 
monocytes, as demonstrated in Chapter 4. Likewise, expression of GPR81 seems 
to be dependent on inflammatory stimuli, as evidenced by decreased GPR81 
expression in adipose tissue induced by LPS [20]. Interestingly, expression of 
GPR81 in adipose tissue was also decreased in diabetic mice [20] and in mice 
on a high fat diet [21], demonstrating an influence of the metabolic state on 
the expression of lactate receptors. Whether diabetic conditions or obesity also 
influence GPR81 expression in immune cells, in particular in humans, is currently 
unknown.
Future research
To dissect whether lactate is mainly exerting its effects on immune cells via 
GPR81-mediated signaling or via metabolic reprogramming after entering the 
cell, knock down experiments of MCT1, MCT4 and GPR81 in immune cells would 
be warranted. Information on the functional response of human immune cells 
to lactate can be combined with genetic data. Single nucleotide polymorphisms 
(SNPs) in GPR81 [22] and MCTs [23, 24] exist and have been associated, for 
example, with clinical outcome in cancer patients. Effects of SNPs in lactate 
receptors or transporters on responses of immune cells to lactate will provide 
important information on the relative contribution of different mechanisms of 
action.
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In addition to lactate, MCTs can transport various other monocarboxylates, 
such as pyruvate, and the ketone bodies acetoacetate and β-hydroxybutyrate. 
Consequently, the influence of lactate on immune cells via MCTs may not only 
depend on the concentration of lactate, but also the concentration of other 
monocarboxylates in the cellular environment that may compete for transport 
via MCTs. In the context of diabetic ketoacidosis, it might be interesting 
to investigate the influence of acetoacetate and β-hydroxybutyrate on 
immunomodulating effects of lactate. 
To better understand the immunomodulating effects of lactate, more information 
on the metabolic fate of lactate in myeloid cells is needed. Systemically, 
circulating lactate has been suggested to fuel the TCA cycle [15]. Whether this 
is also happening in immune cells is unknown. Studies using 13C-labeled lactate 
would help to determine which metabolic routes extracellular lactate is fueling 
after entering myeloid cells. Identifying the most important pathways fueled by 
lactate, will clarify how lactate influences cytokine production and how we may 
ultimately interfere with these pathways to alter immune responses.
We only found limited effects of an in vivo lactate infusion in T1D patients on 
immune cell function (Chapter 4). This might be indicative for the high degree 
of metabolic flexibility in immune cells. In vivo, immune cells may adapt their 
metabolism to high lactate concentrations, but ex vivo, after extraction from the 
lactate-rich environment, the cells may quickly return back to their basal state. 
In addition, effects of lactate may depend on the inflammatory state of the 
immune cells. Whereas increased inflammasome activation and IL-1β production 
of PBMCs have been described in insulin-resistant patients with T2D [11] and 
in newly diagnosed T1D [25], we only detected increased IL-1β production at 
baseline in a subset of our patient group (Chapter 4). In order to further investigate 
immunomodulating effects of lactate in vivo, lactate infusions in patients with 
diabetes suffering from elevated levels of inflammation are valuable. 
The role of hypoglycemia in cardiovascular disease in patients 
with diabetes
Mechanisms linking hypoglycemia to cardiovascular disease
Hyperglycemia has been postulated to be one of the major risk factors for the 
development of cardiovascular disease in patients with diabetes. Importantly, 
even a transient period of hyperglycemia can increase the risk for cardiovascular 
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disease even after return to normal HbA1c levels [26]. In addition to effects of 
hyperglycemia on endothelial cells and vascular smooth muscle cells, activation 
of myeloid cells plays a major role in this process [27]. Hyperglycemia, for 
example, increases the number of circulating monocytes in diabetic mice, 
promoting atherosclerosis [28]. 
In addition to hyperglycemia, also hypoglycemic events have been associated 
with an increased risk for cardiovascular disease. Mechanistically, endothelial 
dysfunction, increased inflammation and activation of the coagulation system 
have all been shown to contribute to the association between hypoglycemia 
and the development of atherosclerosis and cardiovascular disease in patients 
with diabetes. Markers for endothelial dysfunction, such as VCAM-1, ICAM-1, 
E-selectin and P-selectin, as well as oxidative stress markers are increased after 
hypoglycemia [29, 30]. Endothelial dysfunction may promote the adhesion of 
pro-inflammatory monocytes to the vascular wall, a first step in the development 
of fatty streaks, plaques and overt atherosclerosis. In addition to endothelial 
dysfunction, prothrombotic changes, evidenced by increased levels of vWF and 
TAT, has been observed after hypoglycemia [31]. In line with prothrombotic 
changes, increased platelet aggregation and more platelet-monocyte complexes 
have been detected after hypoglycemia [32]. Hypoglycemia also increased 
inflammation, another important driver of cardiovascular disease, as evidenced by 
increased circulating levels of the pro-inflammatory cytokines IL-6 and TNFα [33]. 
Our results have further demonstrated that the number of circulating immune 
cells is increased after hypoglycemia and that circulating immune cells are 
activated after hypoglycemia illustrated by increased production of the pro-
inflammatory cytokines IL-1β, IL-6 and TNFα, ex vivo (Chapter 5). In conclusion, 
the interplay of several mechanisms contributes to the increased risk for 
cardiovascular disease in patients with diabetes and hypoglycemia. 
Importantly, the impact of hypoglycemia on cardiovascular disease may also 
depend on the frequency of hypoglycemic events. T1D patients experiencing 
repeated hypoglycemia had increased signs of preclinical atherosclerosis 
compared with diabetic controls [34]. Likewise, healthy individuals had increased 
proatherothrombotic responses after antecedent hypoglycemia [29]. Accordingly, 
one might expect that the association of hypoglycemia with cardiovascular disease 
would be stronger in patients with T1D compared with T2D, given the fact that 
patients with T1D experience more hypoglycemic events, probably due to longer 
duration of insulin treatment [35]. However, the association between hypoglycemia 
and increased mortality from cardiovascular disease is best documented in patients 
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with T2D [36-40], whereas studies on T1D patients are less consistent [39, 41-44]. 
One explanation may be habituation processes involving counterregulatory 
hormone responses. About one third of T1D patients suffers from impaired 
awareness of hypoglycemia, meaning that due to defective adrenaline responses 
hypoglycemia cannot be perceived accurately and timely anymore. We found 
attenuated inflammatory responses in response to hypoglycemia in patients with 
T1D and impaired awareness of hypoglycemia compared with patients having 
normal awareness (Chapter 5). This is in line with studies reporting that impaired 
awareness of hypoglycemia is not affecting all-cause or cardiovascular mortality 
in patients with T1D [44]. Patients with impaired awareness experience more 
hypoglycemic events, but also some level of habituation can occur, which could 
include the immune cell response to hypoglycemia. 
Hypoglycemia-induced changes in intracellular metabolism: 
experimental vs. physiologic conditions
Glucose is one of the main substrates for immune cell metabolism and fueling 
various functions, such as cytokine production [45] and migration [46]. We 
therefore hypothesized that hypoglycemia may alter immune cell function by 
limiting metabolic substrate availability and subsequently changing metabolism. 
Unexpectedly, we did not find any effects of hypoglycemia on glucose 
consumption or lactate production of PBMCs ex vivo (Chapter 5). Metabolic 
parameters were only measured after 24h of culture and consequently, we cannot 
exclude changes in metabolic fluxes occurring in vivo, which were later masked 
by cellular adaptations to the metabolic conditions in culture. Furthermore, 
metabolic changes were assessed in PBMCs, a mixture of different immune 
cells relying on different metabolic pathways. In vitro experiments, in which 
monocytes were deprived of glucose for a longer period of time, revealed that in 
the absence of glucose, metabolism is shifted towards oxidative phosphorylation 
and is fueled by lipid metabolism [47]. Switching to lipid metabolism, monocytes 
sustained functional cytokine production, migration and phagocytosis, but had 
decreased ROS production. Importantly, these results demonstrate the metabolic 
flexibility of monocytes. It is currently unknown whether immune cells maintain 
their metabolic flexibility and can readapt their metabolism if glucose is available 
again, or if metabolic adaptations become irreversible after some time. Moreover, 
whether metabolic adaptations to glucose deprivation may be different in patients 
with diabetes compared with healthy individuals needs to be established. Due to 
chronic hyperglycemia, monocytes are likely adapted to increased concentrations 
of glucose. Deprivation of glucose may therefore have a larger effect in monocytes 
from patients with diabetes and require more adaptations.
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Glucose is an important energy source for immune cells and consequently, 
hyperglycemia may directly alter myeloid cell function by metabolic routes. 
Increased availability of glucose during hyperglycemia mimicked in vitro by 
overexpression of the glucose transporter GLUT1, increased glycolytic metabolism 
of macrophages, but whether this translates to altered cellular function in vivo, is 
still debated [48, 49]. Likewise, high glucose concentrations in culture medium only 
marginally affected cytokine production of PBMCs in response to various stimuli [50]. 
Nevertheless, it may be possible that increased glucose concentrations prime 
myeloid cell metabolism and induce epigenetic changes, which subsequently 
promote a stronger inflammatory response upon activation [51]. If monocytes 
adapt to chronic hyperglycemia by upregulating intracellular glucose metabolism, 
they are likely also highly dependent on glucose. Consequently, if a hypoglycemic 
event occurs, cells are deprived of their main metabolic substrate. To maintain 
cellular function, rapid adaptations of metabolic pathways are necessary. Vice versa, 
cells quickly have to readapt their metabolism when hypoglycemia is resolved and 
followed by hyperglycemia. Consequently, a combination of hyperglycemic and 
hypoglycemic episodes may challenge the metabolic flexibility of immune cells and 
ultimately increase the risk for cardiovascular disease in patients with diabetes. This 
is in agreement with recent findings identifying glycemic variability as a risk factor 
for vascular complications [52].
Future research
Our studies revealed recruitment of pro-inflammatory immune cell subsets after 
hypoglycemia in vivo (Chapter 5 & 6). Consequently, effects of hypoglycemia can 
hardly be mimicked in vitro and further in vivo studies with hypoglycemic clamps 
are warranted. Hypoglycemia induces recruitment of specific pro-inflammatory 
immune cell subsets, and therefore future studies should focus on the analysis 
of specific cell types, for example on the function of classical versus non-classical 
monocytes, instead of PBMCs. In addition to cytokine production, also adhesion 
and migration capacity as well as ROS production are relevant functional read-
outs. To reveal possible persistent pro-inflammatory effects of hypoglycemia, 
measurements at different time points after hypoglycemia should be included. Since 
antecedent hypoglycemia had aggravating effects on endothelial damage [29] and 
prothrombotic changes [53], it would be interesting to study effects of antecedent 
hypoglycemia on inflammatory function of immune cells. Regarding the persistency 
of pro-inflammatory effects of hypoglycemia, the influence of diabetes duration and 
impaired awareness of hypoglycemia needs to be taken into consideration. Analysis 
of epigenetic marks would be a valuable tool to better understand mechanisms 
underlying persistent pro-inflammatory effects of hypoglycemia. 
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In addition to effects of hypoglycemia-induced inflammation on cardiovascular 
disease, it may be interesting to consider the immunomodulating effects of 
hypoglycemia in the context of infections. We observed that hypoglycemia 
promoted the recruitment of CD8+ T cells and NK cells (Chapter 6). Both cell 
types are important for the defense against pathogens and consequently it 
would be relevant to determine effects of hypoglycemia on cellular functions of 
CD8+ T cells and NK cells, for example killing capacity. Recent studies indicate 
that hypoglycemia not only increased numbers of intermediate and non-
classical monocytes, but also led to more leukocyte recruitment in response to 
a subsequent low-dose endotoxin challenge [32]. Again, this indicates a role for 
hypoglycemia in infections, but further studies are needed to unravel detailed 
mechanisms. Studies to decipher the link between infections and the frequency 
of hypoglycemic events in patients with diabetes would therefore be valuable. 
The role of insulin in chronic inflammation in patients with diabetes
Mechanisms linking insulin to diabetic complications
Patients with diabetes have chronically elevated circulating insulin levels due 
to exogenous systemic administration or due to endogenous compensatory 
hyperinsulinemia as a result of insulin resistance. Interestingly, most cell types 
involved in atherosclerosis – endothelial cells, vascular smooth muscle cells 
and macrophages – all express the insulin receptor and other components of 
the insulin-signaling cascade. Several studies have been performed to decipher 
the contribution of the insulin signaling cascade to the development of 
atherosclerosis. For example, deficient insulin signaling in vascular endothelial 
cells has been shown to accelerate atherosclerosis in mice [54] and likewise, insulin 
receptor deficiency in macrophages increased atherosclerotic lesion size [55]. 
In contrast, myeloid-specific deficiency of the insulin receptor protected mice 
from atherosclerosis [56]. Insulin may disturb lipid handling of myeloid cells, for 
example by increasing macrophage expression of CD36, which may then promote 
foam cell and plaque formation [57]. Macrophages isolated from diabetic mice 
had defective insulin signaling, but increased expression of CD36 [58]. Whether 
insulin can directly influence lipid uptake and foam cell formation in human 
macrophages and thereby increase the risk for atherosclerosis in patients with 
diabetes, still needs to be determined. Insulin-induced changes in intracellular 
metabolism, such as lipid metabolism or glycolytic flux, may contribute to 
altered macrophage polarization. Although hyperinsulinemia impairs M2 
macrophage differentiation in mice [59], direct evidence for the involvement 
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of insulin-receptor mediated signaling in macrophage polarization in humans is 
still lacking. Isolating macrophages upon hyperinsulinemia may help to unravel 
the link between insulin, macrophage metabolism and macrophage function. 
The effect of insulin on myeloid cells may also be important for other diabetes-
associated complications. Deficiency of the insulin receptor in myeloid 
cells ameliorated inflammatory skin diseases [60], suggesting that direct 
effects of insulin on macrophages are also involved in diabetes-associated 
skin complications, such as cutaneous infections and impaired wound 
healing. Moreover, insulin regulated inflammatory function of macrophages 
postprandially by enhancing intracellular glucose metabolism and stimulating 
IL-1β production [61]. The physiologic consequences of postprandial IL-1β 
release in health and disease, however, need to be determined. 
In patients with diabetes, the actual link between insulin, myeloid cells and 
complications, such as atherosclerosis or infections, is probably strongly 
determined by the insulin sensitivity of myeloid cells. Evidence exists for both 
intact (Chapter 7), [62, 63] and defective [64] insulin signaling in immune 
cells of insulin resistant patients. This may, on the one hand, be due to actual 
interindividual variations in insulin sensitivity of myeloid cells, but may, on 
the other hand, also be due to differences in assessment of insulin sensitivity. 
Some studies directly measured the response of immune cells to insulin ex vivo, 
for example by assessing phosphorylation of Akt [62]. Although this provides 
direct measurements of insulin sensitivity, insulin concentrations and exposure 
times may strongly affect results. Other studies overcome this limitation by 
analyzing signaling intermediates of the insulin pathway, for example levels of 
IRS2 or phosphorylated Akt, directly after isolation [64]. These results may be 
influenced by the acute concentration of insulin in the circulation and by other 
insulin-independent factors that influence the assessed signaling pathways. 
Insulin-induced changes in intracellular metabolism vs. intracellular 
signaling 
Previous studies on the effects of insulin on monocytes and macrophages 
have mainly focused on signaling routes activated by insulin in immune cells. 
In several studies, functional effects of insulin were shown to be mediated by 
PI3K-signaling and downstream signaling via MAPK signaling [65, 66], or ERK 
activation [67]. Importantly, activation of specific signaling pathways may also 
interfere with intracellular metabolism. We detected insulin-induced activation 
of the PI3K-Akt-mTOR-pathway in human monocytes (Chapter 7), indicating 
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an effect of insulin on central regulators of metabolism. Moreover, insulin-
induced activation of glycogen synthase kinase (GSK)-3β in monocytes [65] 
may influence cellular function not only by regulating downstream activation 
of RhoA and Rac-1 [68], important kinases for cell migration, but also by 
modulating glycogen metabolism. Intracellular glycogen stores are important 
for dendritic cell activation [69] and likewise an influence of insulin on glycogen 
metabolism may affect monocyte activation. In addition to carbohydrate 
metabolism, insulin may also impact on lipid metabolism. Insulin activated 
hormone sensitive lipase (HSL) in a macrophage cell line, which may result in 
accumulation of esterified cholesterols and foam cell formation [70]. Whether 
this is also relevant in humans needs to be determined. Although insulin 
regulates lipid metabolism via transcriptional mechanisms involving SREBP2 
activation in other cell types, we did not detect significant changes in gene 
expression related to lipid metabolism in human monocytes (Chapter 7). 
This may also indicate that effects of insulin on immune cell metabolism are 
rather mediated via posttranscriptional mechanisms and changes in metabolic 
fluxes as compared to transcriptional reprogramming. This would allow for 
rapid adaptations of monocyte metabolism and function in response to swift 
postprandial changes in insulin concentrations. 
Future research
To reveal the functional role of the insulin receptor in human myeloid cells, in 
vitro experiments with cells exposed to insulin should be combined with ex vivo 
experiments with cells isolated from individuals undergoing hyperinsulinemic 
clamps. Comparing cells from healthy individuals with those from patients with 
diabetes will provide further insight into mechanisms of potential insulin resistance 
in immune cells and add information on acute vs. long-term effects of insulin 
on myeloid cells. Studies of myeloid cells from patients with mutations in the 
INSR gene that cause severe insulin resistance syndromes (Rabson-Mendenhall 
syndrome, Type A insulin resistance syndrome, Donohue syndrome) could shed 
more light on the importance of insulin signaling in human myeloid cells.
In this thesis we demonstrate acute effects of insulin on metabolic rates of 
human monocytes (Chapter 7). To better understand mechanisms of metabolic 
reprogramming induced by insulin, extracellular flux analysis using inhibitors of 
different metabolic pathways would be valuable. Moreover, flux experiments 
with variable metabolic substrates, such as glucose, glutamine and fatty acids, 
would help to understand which metabolites may act synergistically with 
insulin. In healthy individuals, insulin concentrations increase postprandially and 
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therefore insulin likely acts on immune cells in the presence of elevated levels 
of glucose and fatty acids. In order to fully understand effects of insulin-induced 
signaling on intracellular metabolism, studies combining phosphoproteomics 
with metabolomics measurements are warranted. Dynamic metabolomics 
using 13C-labeled glucose combined with phosphoproteomics revealed that in 
adipocytes phosphorylation of metabolic enzymes by insulin primes the cell 
for changes in glucose metabolism [71]. Similar studies in monocytes could 
help to determine specific metabolic pathways activated by insulin and would 
furthermore lead to the identification of possible therapeutic targets to interfere 
with aberrant insulin-induced changes in monocytes of patients with diabetes.
Concluding remarks and general future perspectives
Disturbed function of monocytes and macrophages is a hallmark of diabetes 
and –associated complications. Our studies identify important direct effects of 
diabetes-associated factors on human myeloid cell metabolism and function 
and therefore help to enhance our understanding of the pathophysiology of 
diabetes-associated complications. In order to better understand the complex 
interplay of metabolic changes in the microenvironment and functional changes 
in immune cells, integrative studies using samples from healthy individuals 
and patients with diabetes are warranted. Combining clinical parameters with 
measurements of metabolites in the circulation as well as in immune cells 
with functional data, such as cytokine production, migration or phagocytosis, 
will help us to pinpoint metabolic changes and pathways involved in the 
development of diabetes-associated complications. Such an approach requires 
a joined effort of biomedical and clinical scientists and could ultimately result 
in better understanding of the role of myeloid cells in diabetes and develop 
targeted interventions. Interventions may, on the one hand, target the 
availability of metabolic substrates, but may, on the other hand, directly aim 
to modify specific metabolic pathways in monocytes and macrophages in order 
to change their inflammatory properties and interfere with the development 
of diabetic complications. Clearly, more work is needed to unravel the complex 
interaction between metabolism and immune cells both in normal physiology 
and in metabolic disorders. 
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Nederlandse Samenvatting
Diabetes mellitus, ook wel suikerziekte genoemd, is een steeds vaker 
voorkomende ziekte waarbij patiënten te hoge suikerspiegels in het bloed 
hebben. Er zijn verschillende vormen van diabetes, waarvan de meest 
voorkomende type 1 en type 2 diabetes zijn. Type 1 diabetes komt bij ongeveer 
10% van de mensen met diabetes voor. Het is een auto-immuunziekte waarbij de 
cellen in de alvleesklier, die insuline aanmaken, door het eigen afweersysteem 
worden afgebroken. Insuline is een belangrijk hormoon dat zorgt voor opname 
van suiker uit het bloed voor gebruik in de weefsels, bijvoorbeeld spieren en 
vet. Door het gebrek aan insuline is de opname van suiker in de weefsels van 
patiënten met type 1 diabetes gestoord, waardoor de bloedsuikerspiegel stijgt. 
Insuline is onmisbaar, daarom moeten patiënten met type 1 diabetes zichzelf 
dagelijks meerdere malen insuline met een spuit of pomp toedienen. Diabetes 
type 2 komt vaker voor, bij ongeveer 85-95% van de mensen met diabetes, en 
is vaak een gevolg van overgewicht. Overgewicht leidt tot verstoringen in het 
vetweefsel met insuline resistentie als gevolg. Dit betekent dat cellen minder 
gevoelig zijn voor insuline en dat mensen met type 2 diabetes relatief te weinig 
insuline hebben. Ook dit kan leiden tot een verhoogde bloedsuikerspiegel.
Een chronische verhoging van de bloedsuikerspiegel kan bij patiënten 
met diabetes leiden tot ernstige complicaties, zoals hart- en vaatziekten, 
blindheid, zenuw- en nierschade. Daarnaast hebben mensen met diabetes ook 
een grotere kans op infecties, zoals de griep. Bij deze infecties zijn zij vaker 
ernstig ziek en is vaker een opname in het ziekenhuis nodig. Het is bekend 
dat cellen van het afweersysteem, de witte bloedcellen, een belangrijke rol 
spelen bij het ontwikkelen van complicaties. Immuuncellen van patiënten 
met diabetes hebben vaak een hoge activiteit. Dit kan voordelig zijn voor de 
afweer van ziekteverwekkers, maar is in sommige gevallen ook schadelijk. 
Actieve immuuncellen plakken bijvoorbeeld vaker aan de vaatwand vast en 
dragen zo bij aan het ontstaan van aderverkalking en hart- en vaatziekten. 
Hoewel de immuuncellen van patiënten met diabetes vaak te actief lijken, zijn 
er tegelijkertijd ook aanwijzingen voor een verminderde functie. Immuuncellen 
van patiënten met diabetes lijken bijvoorbeeld minder goed in staat bacteriën 
op te ruimen.
Recente studies hebben laten zien dat de stofwisseling (het metabolisme) 
van immuuncellen het functioneren van deze cellen kan beïnvloeden. Actieve 
immuun cellen hebben erg veel energie nodig om hun functies uit te voeren. 
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Zo verbruiken immuuncellen die bloot zijn gesteld aan een ziekteverwekker 
vaak grote hoeveelheden glucose (suiker). Wat voor type brandstof de cel nodig 
heeft, is ook afhankelijk van de taken van de immuuncel. Immuuncellen die bezig 
zijn om een ziekteverwekker op te ruimen, hebben bijvoorbeeld meer vetzuren 
nodig. Daarnaast kan de beschikbaarheid van brandstoffen in de omgeving van 
de immuuncel de activiteit van de cel beïnvloeden. In een omgeving met veel 
glucose nemen immuuncellen gewoonlijk meer glucose op en hierdoor zijn ze 
verhoogd actief. 
Bij patiënten met diabetes is de beschikbaarheid van brandstoffen veelal anders 
dan bij gezonde mensen. Zo zijn de spiegels van glucose en vetzuren in het 
bloed veel hoger dan bij gezonde mensen. Wij hadden daarom de hypothese 
dat de metabole omgeving bij patiënten met diabetes de stofwisseling van 
immuuncellen beïnvloedt, wat leidt tot een verandering in de activiteit van 
immuuncellen en uiteindelijk kan bijdragen aan het ontstaan van complicaties. 
Om deze hypothese te onderzoeken hebben we een aantal studies opgezet 
waarin we immuuncellen uit het bloed van gezonde mensen of patiënten met 
diabetes hebben gefilterd. Deze immuuncellen hebben we blootgesteld aan een 
aantal factoren die de stofwisseling kunnen beïnvloeden. Vervolgens hebben we 
onderzocht hoe de stofwisseling en activiteit van de immuuncellen veranderde.
Allereerst hebben we onderzocht wat er al bekend is over dit onderwerp en deze 
informatie samengevat in hoofdstuk 2. Er zijn aanwijzingen voor veranderingen 
in de stofwisseling van immuuncellen bij patiënten met diabetes en er zijn 
studies die een effect van glucose, vetzuren en insuline op het functioneren 
van immuuncellen laten zien. Niettemin zijn er weinig studies die deze twee 
bevindingen met elkaar verbinden. Ook is maar een klein deel van de studies 
uitgevoerd met menselijke cellen, zodat nog niet duidelijk is wat er daadwerkelijk 
bij patiënten met diabetes gebeurt.
Om goed te kunnen begrijpen hoe de stofwisseling in immuuncellen van 
patiënten met diabetes werkt, hadden we eerst meer kennis nodig over hoe dit 
verloopt in immuuncellen van gezonde mensen. Van bepaalde ziekteverwekkers 
is al bekend hoe ze de stofwisseling van immuuncellen veranderen. Zo weten 
we dat immuuncellen de opname en snelle afbraak van glucose (glycolyse) 
verhogen wanneer ze een onderdeel van de bacterie E. coli, een bacterie die 
vaak blaasontstekingen of darminfecties geeft, herkennen. Tegelijkertijd wordt 
er minder gebruik gemaakt van een andere manier van brandstofverwerking 
– de oxidatieve fosforylering. De oxidatieve fosforylering, ook wel 
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elektronentransportketen genoemd, is een reactiereeks, waarbij zuurstof wordt 
gebruikt om energie aan te maken. Door het verhogen van de glycolyse kan de 
immuuncel snel energie aanmaken, wat nodig is voor een effectieve afweer tegen 
de bacterie. Het was nog niet bekend, of immuuncellen op dezelfde manier op 
andere ziekteverwekkers reageren. Om dit te onderzoeken hebben we monocyten, 
een bepaald type immuuncel, uit het bloed van gezonde mensen gehaald. 
Monocyten zijn witte bloedcellen, die de lichaam tegen ziekteverwekkers kunnen 
beschermen, onder andere door het opnemen van lichaamsvreemde stoffen. We 
hebben monocyten in een kweekschaal bloot gesteld aan verschillende bacteriën 
of delen van een bacterie (hoofdstuk 3). Vervolgens hebben we het metabolisme 
van de monocyten onderzocht. In reactie op nagenoeg alle bacteriën zagen we 
een toename van de glycolyse. Daarnaast ontdekten we dat vrijwel alle bacteriën 
ook zorgden voor een toename in de oxidatieve fosforylering. Dit was niet het 
geval bij de reactie op een onderdeel van de eerder genoemde E. coli bacterie. 
De manier waarop een immuuncel energie vrij maakt, is dus afhankelijk van de 
bacterie waaraan de immuuncel blootgesteld is.
Wanneer immuuncellen geactiveerd zijn en glucose verbruiken, wordt hierbij 
lactaat (melkzuur) aangemaakt. Lactaat is dus eigenlijk een afvalproduct. 
Niettemin hebben eerdere studies aangetoond dat immuuncellen lactaat ook 
op kunnen nemen en dat er minder ontsteking optreedt in muizen wanneer 
ze lactaat toegediend krijgen. Lactaat zou op deze manier een therapeutische 
optie kunnen zijn voor mensen bij wie er teveel ontstekingsstoffen worden 
aangemaakt. Wij waren daarom benieuwd naar de effecten van lactaat op 
menselijke immuuncellen. Hiervoor hebben we patiënten met type 1 diabetes 
dertig minuten lactaat gegeven met behulp van een infuus (hoofstuk 4). Zowel 
voorafgaand als na de infusie hebben we immuuncellen uit het bloed gehaald en 
eventuele verschillen onderzocht. Hoewel we ontdekten dat de immuuncellen 
na het lactaatinfuus meer glucose verbruikten, zagen we verder geen 
verschillen in het metabolisme en de activiteit van de immuuncellen. Er was 
veel variatie in de reactie op lactaat tussen de verschillende studiedeelnemers: 
de ontstekingsremmende effecten van lactaat leken groter bij mensen die 
voorafgaand meer ontsteking in het bloed hadden. Omdat de infusie van 
lactaat maar kort was, hebben we ook onderzocht wat er gebeurt wanneer we 
immuuncellen in een kweekschal voor langere tijd aan lactaat blootstellen. 
In dit geval maakten de immuun cellen minder gebruik van de glycolyse en 
meer van oxidatieve fosforylering. Verder maakten de immuuncellen minder 
afweerstoffen (cytokines) aan nadat ze gedurende een dag aan lactaat 
blootgesteld waren. Concluderend denken we dat de effecten van lactaat 
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op menselijke immuuncellen niet zo groot zijn na kortdurende expositie aan 
lactaat, maar wel wanneer cellen langer worden blootgesteld aan lactaat.   
Mensen met diabetes hebben een hogere risico om aan hart- en vaatziekten te 
overlijden. Het is bekend dat hoge bloedsuikerspiegels immuuncellen activeren 
in patiënten met diabetes en zo bijdragen aan het ontstaan van aderverkalking. 
Verder is ook bekend dat er een relatie is tussen lage bloedsuikers, ook 
hypoglykemie genoemd, en hart- en vaatziekten. Wij hebben daarom 
onderzocht of een hypoglykemie ook kan leiden tot activatie van immuuncellen 
en door verhoging van ontstekingsstoffen kan bijdragen aan het ontstaan aan 
hart- en vaatziekten (hoofdstuk 5). Hiervoor hebben we gezonde mensen 
en mensen met type 1 diabetes onderzocht, omdat deze laatst genoemde 
patiënten ongeveer één tot twee keer per week een hypoglykemie hebben. 
Voor ons onderzoek hebben we met de hulp van een insuline en glucoseinfuus 
de bloedsuikerspiegel op een lage waarde gehouden en zo voor een uur een 
hypoglykemie laten ontstaan. Voorafgaand aan de hypoglykemie en na de 
hypoglykemie hebben we bloed van de deelnemers verzameld. Opvallend was 
de sterke toename in immuuncellen in het bloed. Na de hypoglykemie vonden 
we sommige deelnemers bijna dubbel zoveel immuuncellen. We zagen een 
sterke correlatie tussen de stijging in het aantal immuuncellen en de stijging 
in het stresshormoon adrenaline. Adrenaline komt tijdens een hypoglykemie 
vrij als waarschuwing voor het lichaam, om aan te geven dat er een energie 
tekort is. Adrenaline leidt onder andere tot verschillende symptomen zoals 
honger en trillen. Daarnaast kan adrenaline ook inactieve immuuncellen die 
aan de bloedvatwand vastplakken, losmaken, zodat ze actief rond stromen in 
het bloed. Tenslotte hebben we naast een verhoogd aantal immuuncellen na 
de hypglykemie ook een hogere activiteit van immuuncellen en een verhoogde 
productie van ontstekingsbevorderende stoffen gemeten.
Omdat we zagen dat een hypoglykemie de samenstelling van immuuncellen 
in het bloed kan veranderen, hebben we in een vervolgstudie onderzocht 
welke immuuncellen precies veranderen na een hypoglykemie (hoofdstuk 6). 
In patiënten met type 1 diabetes zagen we na een hypoglykemie meer pro-
inflammatoire cellen, dat wil zeggen cellen die een ontsteking bevorderen. 
We zagen meer NK-cellen en cytotoxische T cellen, cellen die belangrijk zijn 
om bacteriën op te ruimen. Verder hebben we na een hypoglykemie meer pro-
inflammatoire monocyten gezien. Omdat deze cellen een belangrijke rol spelen 
in het ontstaan van hart- en vaatziekten, denken we dat immuun cellen een 
belangrijke verbinding vormen tussen hypoglykemieën en hart- en vaatziekten. 
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Insuline is een hormoon dat de bloedsuikerspiegels regelt en ervoor zorgt dat 
glucose in spier- en vetcellen wordt opgenomen. Studies in muizen hebben 
aangetoond dat ook immuuncellen gevoelig zijn voor insuline en dat insuline 
mogelijk de functie van immuuncellen kan beïnvloeden. We wilden daarom 
weten of insuline ook in mensen de functie van immuuncellen kan beïnvloeden. 
Om deze vraag te beantwoorden hebben we immuuncellen van gezonde mensen 
en mensen met diabetes kort- en langdurend aan insuline blootgesteld en naar 
de stofwisseling en functie van de immuuncellen gekeken (hoofdstuk 7). Op 
de korte termijn activeert insuline de stofwisseling van immuuncellen. Kort na 
de toevoeging van insuline zagen we niet alleen een stijging in de glycolyse, 
maar ook in de oxidatieve fosforylering. Dit betekent dat insuline niet alleen de 
suikerstofwisseling in immuuncellen beïnvloedt, maar een algemene activatie 
van de algehele stofwisseling bevorderd. Insuline heeft vrijwel geen invloed op 
de productie van afweerstoffen maar bevordert wel de migratie van monocyten. 
Monocyten migreren bijvoorbeeld naar het vetweefsel en ontwikkelen zich hier 
verder naar macrofagen. Macrofagen zijn immuuncellen, die in de weefsels zitten 
en beschadigde lichaamseigen cellen en lichaamsvreemde cellen opnemen en 
afbreken. Zo vonden we ook meer macrofagen in het vetweefsel van mensen die 
hogere insulinespiegels in het bloed hadden. Nadat we monocyten chronisch 
aan insuline blootstelden tijdens de ontwikkeling naar macrofagen, zagen we 
dat de macrofagen die eerder blootgesteld waren aan insuline, minder actief 
waren. Insuline zou dus een rol kunnen spelen in het ontstaan van de verstoorde 
functie van immuuncellen in patiënten met diabetes.
De invloed van metabole factoren op immuuncellen is niet alleen van belang in 
het bloed, maar ook in de weefsels. In het vetweefsel spelen macrofagen een 
essentiële rol in het opruimen van dode vetcellen, maar ook in de stofwisseling 
van het vet. Vooral bij mensen is nog niet goed onderzocht hoe de lokale 
omgeving de functie van de immuuncellen beïnvloedt. We hebben daarom 
mensen die een buikoperatie moesten ondergaan, gevraagd of we een stukje 
van hun onderhuids vetweefsel, buikvet en een aantal buisjes bloed mochten 
afnemen (hoofstuk 8). We isoleerden immuuncellen uit alle drie de locaties en 
vergeleken deze cellen onderling. De verschillen tussen immuuncellen uit het 
onderhuids vet en buikvet waren niet groot, maar er waren duidelijke verschillen 
tussen cellen uit het bloed en cellen uit het vetweefsel. Immuuncellen uit het 
vetweefsel zijn voorzien van mechanismen die helpen om vetzuren af te 
breken. Verder zagen we een hoge activatie van het complement systeem in 
de beide vetweefsels. Complement is belangrijk om bacteriën te verwijderen, 
maar speelt ook een belangrijke rol bij de stofwisseling. We hebben gevonden 
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dat de complement factor C1q waarschijnlijk een belangrijke rol speelt bij het 
opruimen van dode vetcellen en bovendien een invloed zou kunnen hebben op 
de stofwisseling in vetweefselmacrofagen. Deze bevindingen helpen ons de 
functie van macrofagen in het vetweefsel te begrijpen.
Conclusie
De functie van immuuncellen is vaak verstoord bij patiënten met diabetes 
en draagt bij aan complicaties zoals hart- en vaatziekten en een hoger risico 
op infecties. In dit proefschrift heb ik laten zien dat metabole factoren, zoals 
insuline en vetzuren, de stofwisseling van immuuncellen kunnen beïnvloeden. 
Dit kan leiden tot een veranderde functie van immuuncellen en ontsteking 
bevorderen. Als we de veranderingen in de stofwisseling in immuuncellen 
van patiënten met diabetes beter verstaan, zouden we in de toekomst deze 
processen mogelijk kunnen beïnvloeden en daarmee de ontstekingsreacties bij 
de patiënten verbeteren. Bovendien kunnen onze studies helpen om biologische 
markers te ontwikkelen om complicaties vroeg te herkennen. 
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Deutsche Zusammenfassung
Diabetes mellitus, auch Zuckerkrankheit genannt, ist eine metabolische 
Erkrankung, die durch einen chronisch erhöhten Blutzuckerspiegel 
gekennzeichnet ist und deren Prävalenz sowie Inzidenzrate seit mehreren 
Jahrzehnten insbesondere in Industrie- und Schwellenländern stetig zunimmt. 
Allein in Deutschland leben etwa 6 Millionen Menschen mit Diabetes; weltweit 
sind es etwa 422 Millionen Betroffene.
Es werden verschiedene Arten von Diabetes unterschieden, wobei die 
häufigsten Formen Typ 1 (T1D) und Typ 2 (T2D) Diabetes sind. Typ 1 Diabetes 
betrifft etwa 10% aller Diabetiker und ist eine Autoimmunerkrankung, bei der 
die insulinproduzierenden Zellen der Bauchspeicheldrüse (β-Zellen) von den 
körpereigenen Abwehrzellen zerstört werden. Insulin ist ein Hormon, das die 
Aufnahme von Zucker aus dem Blut in die Gewebe, zum Beispiel Muskeln oder 
Fett, stimuliert. In Typ 1 Diabetikern wird Zucker daher nicht mehr effizient in 
die Gewebe aufgenommen, wodurch der Blutzuckerspiegel steigt. Da Zucker 
ein essentieller Energielieferant für die Zellen im Gewebe ist, müssen sich 
Typ 1 Diabetiker im Zuge von Mahlzeiten ihr Leben lang Insulin mit einer Spritze 
oder Pumpe zuführen, um das Fehlen ihrer β-Zellen zu kompensieren und das 
energetische Gleichgewicht ihres Körpers aufrecht zu erhalten. Typ 2 Diabetes 
ist mit 85-95% die am häufigsten vorkommende Form von Diabetes. Typ 2 
Diabetes ist hingegen keine Autoimmunkrankheit, sondern entsteht oft als 
Folge von körperlicher Inaktivität, Fehlernährung und dem daraus resultierenden 
Übergewicht. Dieses führt auf komplexen und bisher nur teilweise verstandenen 
Wegen zu einer verminderten Insulinsensitivität der Gewebe. Folglich ist relativ 
zu wenig Insulin vorhanden, was auch zu einem erhöhten Blutzuckerspiegel 
führt.
Chronisch erhöhte Blutzuckerspiegel von Diabetikern können zu 
schwerwiegenden Komplikationen führen, zum Beispiel Herz- und 
Gefäßerkrankungen, Blindheit, Nerven- und Nierenschäden. Außerdem haben 
Menschen mit Diabetes ein erhöhtes Risiko für Infektionserkrankungen, wie zum 
Beispiel Grippe. Patienten mit Diabetes erkranken nicht nur öfter an Infektionen, 
sondern werden auch schwerwiegender krank und müssen deshalb häufiger 
stationär behandelt werden. Es ist bekannt, dass das Immunsystem, eine wichtige 
Rolle bei der Entstehung von Diabetes-assoziierten Komplikationen spielt. Es 
wurde zum Beispiel gezeigt, dass Immunzellen von Patienten mit Diabetes oft 
ein pathologisches Aktivitätsprofil aufweisen. Obwohl vieles auf eine erhöhte 
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Aktivität von Immunzellen bei Patienten mit Diabetes hindeutet, scheint 
es, dass die Immunzellen von Patienten mit Diabetes trotzdem nicht immer 
voll funktionsfähig sind. So können zum Beispiel Immunzellen von Patienten 
mit Diabetes Bakterien nicht mehr gut beseitigen und so zur Verbesserung 
einer Infektion beitragen. Außerdem kann eine erhöhte Immunzellaktivität in 
Abwesenheit von Pathogenen hat sie jedoch häufig negative Konsequenzen. So 
adhärieren Immunzellen mit erhöhter Aktivität leichter an Gefäßwänden tragen 
so zur Entstehung von Arteriosklerose bei. 
In den letzten Jahren haben viele Studien gezeigt, dass der Stoffwechsel 
(Metabolismus) von Immunzellen ihre Funktion erheblich beeinflusst. Aktive 
Immunzellen brauchen viel Energie, um ihre verschiedenen Aufgaben ausführen 
zu können. Es wurde beispielsweise gezeigt, dass Immunzellen, die in Kontakt 
mit einem Krankheitserreger kommen, oft viel Zucker (Glukose) verbrauchen. 
Welchen Energieträger eine Zelle benötigt, um Energie zu gewinnen, ist aber 
auch abhängig von den Aufgaben der Zelle. Immunzellen, die Krankheitserreger 
in sich aufnehmen, um sie dann zu beseitigen, brauchen zum Beispiel viele 
Fettsäuren. Die Verfügbarkeit von Energieträgern in der Umgebung der 
Immunzelle ist also auch sehr wichtig für ihre Aktivität. So wurde zum Beispiel 
gezeigt, dass Immunzellen in einer Umgebung mit hoher Glukosekonzentration 
mehr Glukose aufnehmen und aktiver werden.     
Bei Patienten mit Diabetes ist die Verfügbarkeit von Energieträgern anders als 
in gesunden Menschen. Oft sind zum Beispiel die Glukose- und Fettsäurespiegel 
im Blut erhöht. Außerdem sind andere Faktoren, die den Metabolismus 
beeinflussen können, wie zum Beispiel Insulin, verändert. Wir haben deshalb 
die Hypothese aufgestellt, dass eine veränderte metabolische Umgebung bei 
Patienten mit Diabetes den Metabolismus und damit auch die Funktion von 
Immunzellen verändern kann. Das kann schlussendlich auch zur Entstehung 
von Komplikationen beitragen. Um diese Hypothese zu untersuchen, haben 
wir mehrere Studien durchgeführt, bei denen wir Immunzellen aus dem 
Blut von gesunden Menschen oder Patienten mit Diabetes isoliert haben. 
Diese Immunzellen haben wir dann verschiedenen Faktoren ausgesetzt, und 
anschließend den Stoffwechsel und die Funktion der Immunzellen untersucht.
Zuerst haben wir in Kapitel 2 zusammengefasst, was bereits über dieses Thema 
bekannt ist. Es gibt Hinweise dafür, dass der Stoffwechsel von Immunzellen von 
Patienten mit Diabetes verändert ist und auch Studien, die einen Einfluss von 
Glukose, Fettsäuren oder Insulin auf Immunzellen zeigen. Dennoch gibt es kaum 
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Studien, die diese zwei Ergebnisse miteinander verbinden. Außerdem gibt es nur 
wenige Studien, die mit frisch isolierten menschlichen Immunzellen arbeiten, 
weshalb noch weitestgehend unklar ist, was hinsichtlich unserer Fragestellung 
tatsächlich in Patienten mit Diabetes geschieht.  
Um zu verstehen, wie der Metabolismus von Immunzellen in Patienten mit 
Diabetes verändert ist, benötigten wir erst mehr Informationen über die 
Funktionsweise des Metabolismus von Immunzellen gesunder Menschen. Für 
LPS, ein Bestandteil der Zellwand des Bakteriums E. coli, ist schon sehr gut 
beschrieben, wie es den Energiestoffwechsel von Immunzellen beeinflusst. 
Erkennt eine Immunzelle LPS, bewirkt dies eine erhöhte Aufnahme von 
Glukose in die Immunzelle und aktiviert außerdem den Abbau von Glukose, 
auch Glykolyse genannt. Gleichzeitig wird die Gewinnung von Energie durch 
die Atmungskette, auch oxidative Phosphorylierung oder OXPHOS genannt, 
vermindert. Die oxidative Phosphorylierung ist eine Reaktionskette, bei der 
Sauerstoff verbraucht wird, um Energie zu gewinnen. Durch die erhöhte 
Nutzung der Glykolyse kann die Immunzelle sehr schnell Energie produzieren, 
was wichtig ist, um schnell eine effektive Immunantwort auszulösen und das 
Bakterium E. coli abzuwehren. Es war noch nicht bekannt, ob Immunzellen 
auch auf andere Krankheitserreger mit ähnlichen Veränderungen des 
Energiestoffwechsels reagieren. Um das zu untersuchen, haben wir Monozyten, 
eine bestimmte Untergruppe von Immunzellen, die den Körper unter anderem 
durch die Aufnahme und Beseitigung von Bakterien schützen, aus dem Blut 
von gesunden Menschen isoliert und in einer Kulturschale verschiedenen 
Bakterien oder bestimmten Bestandteilen von Bakterien ausgesetzt (Kapitel 3). 
Anschließend haben wir den Metabolismus der Monozyten gemessen. Alle 
Bakterien, die wir untersucht haben, aktivierten die Glykolyse. Unerwartet 
verminderte gleichzeitig nur LPS die oxidative Phosphorylierung. Alle anderen 
untersuchten Bakterien aktivierten die oxidative Phosphorylierung. Wie eine 
Immunzelle Energie gewinnt ist also abhängig von den Bakterien, denen die 
Zelle ausgesetzt ist.
Wenn Immunzellen aktiviert werden und Glukose verbrauchen, stellen sie Laktat 
(Milchsäure) her und scheiden es aus. Laktat ist also eigentlich ein Abfallprodukt, 
das sich in der Umgebung der Zelle ansammelt. Einige Studien haben gezeigt, 
dass Immunzellen Laktat aber auch aufnehmen können, was die Funktion 
der Zellen eventuell beeinflusst. Studien an Mäusen belegen, dass Laktat die 
Entzündung bei Hepatitis oder Kolitis vermindern kann. Laktat könnte also auch 
eine therapeutische Option für Menschen sein, die an entzündlichen Erkrankungen 
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leiden. Wir wollten deshalb aufzeigen, welche Effekte Laktat auf menschliche 
Immunzellen hat. Hierfür haben wir Patienten mit Typ 1 Diabetes für 30 Minuten 
eine Infusion mit Laktat gegeben (Kapitel 4). Sowohl vor, als auch nach der Infusion 
haben wir Immunzellen aus dem Blut isoliert und die Unterschiede zwischen 
den beiden Zeitpunkten analysiert. Obwohl die Immunzellen nach der Laktat-
Infusion mehr Glukose verbrauchten, haben wir keine weiteren Unterschiede 
im Metabolismus oder der Aktivität der Immunzellen gefunden. Der Effekt von 
Laktat variierte stark zwischen den Studienteilnehmern und es schien, als ob 
entzündungshemmende Effekte von Laktat vor allem bei Menschen auftreten, 
die aktivere Immunzellen haben. Weil die relativ geringen Effekte von Laktat 
eventuell durch die recht kurze Infusionszeit zu erklären sein könnten, haben wir 
zusätzlich untersucht, was passiert, wenn Immunzellen in einer Kulturschale für 
längere Zeit Laktat ausgesetzt sind. Schon kurz nach dem Zufügen von Laktat 
benutzten die Zellen weniger Glykolyse und mehr oxidative Phosphorylierung. 
Außerdem stellten die Zellen weniger Abwehrstoffe (Zytokine) her, wenn sie 
einen Tag lang Laktat ausgesetzt waren. Obwohl die kurzfristigen Effekte von 
Laktat auf menschliche Immunzellen begrenzt sind, kann Laktat auf längere Zeit 
entzündungshemmend wirken.
Menschen mit Diabetes haben ein erhöhtes Risiko, an Herz- und 
Kreislauferkrankungen zu erkranken und daran zu sterben. Es wird vermutet, 
dass hohe Blutzuckerspiegel bei Patienten mit Diabetes Immunzellen aktivieren 
und so dazu beitragen, dass Arteriosklerose entsteht. Des Weiteren ist 
bekannt, dass auch eine Korrelation zwischen niedrigen Blutzuckerspiegeln, 
Hypoglykämie genannt, und Herz- und Kreislauferkrankungen besteht. Wir 
haben deshalb untersucht, ob auch eine Hypoglykämie die Funktion von 
Immunzellen verändern kann (Kapitel 5). Hierfür haben wir gesunde Menschen 
und Menschen mit Typ 1 Diabetes untersucht. Diabetiker haben ungefähr 
ein Mal pro Woche eine leichte Hypoglykämie. Für unsere Studie haben wir 
jedoch künstlich eine Hypoglykämie herbeigeführt, indem wir mit Hilfe von 
Insulin- und Glukoseinfusionen den Blutzuckerspiegel niedrig gehalten haben. 
Kurz vor und nach einer Stunde Hypoglykämie haben wir Blutproben von 
den Studienteilnehmern genommen. Besonders auffallend war eine starke 
Zunahme von Immunzellen im Blut nach einer Hypoglykämie. Hierbei hatten 
einige Studienteilnehmer fast doppelt so viele Immunzellen im Blut. Es gab 
eine starke Korrelation zwischen dem Anstieg in der Anzahl der Immunzellen 
und dem Anstieg des Stresshormons Adrenalin. Adrenalin wird bei einer 
Hypoglykämie als Warnsignal freigesetzt, um dem Körper zu signalisieren, 
dass er schnell Energie braucht. Das führt zu verschiedenen Symptomen, wie 
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zum Beispiel Hunger oder Konzentrationsschwierigkeiten. Adrenalin kann aber 
auch Immunzellen in die Zirkulation bringen, die an der Gefäßwand festkleben. 
Nach einer Hypoglykämie beobachteten wir nicht nur eine erhöhte Anzahl 
von Immunzellen im Blut, sondern auch eine erhöhte Aktivität und Produktion 
entzündungsfördernder Stoffe. 
Da wir eine Veränderung in der Zusammensetzung der Immunzellen im Blut 
nach einer Hypoglykämie beobachtet haben, haben wir in einer Folgestudie 
detaillierter untersucht, welche Immunzell-Untergruppen nach einer 
Hypoglykämie verändert sind (Kapitel 6). In Patienten mit Typ 1 Diabetes haben 
wir nach einer Hypoglykämie mehr pro-inflammatorische Zellen, also Zellen, 
die eine Entzündung fördern, gefunden. Die Anzahl von natürlichen Killerzellen 
und zytotoxischen T-Zellen, Zelltypen die für die Abwehr von Bakterien wichtig 
sind, waren nach einer Hypoglykämie ebenfalls erhöht. Außerdem stieg die 
Anzahl der pro-inflammatorischen Monozyten, welche eine entscheidende 
Rolle bei der Entstehung von Herz- und Kreislauferkrankungen spielen. Folglich 
könnte die Rekrutierung von entzündungsfördernden Immunzellen eine 
wichtige Verbindung zwischen Hypoglykämie und der Entstehung von Herz- und 
Kreislauferkrankungen sein.
Insulin ist ein Hormon, das die Höhe des Blutzuckerspiegels reguliert und dafür 
sorgt, dass Glukose zum Beispiel in Muskel- und Fettzellen aufgenommen wird. 
Experimente mit Mäusen haben gezeigt, dass auch Immunzellen auf Insulin 
reagieren und, dass Insulin die Funktion von Immunzellen beeinflussen kann. Wir 
wollten deshalb wissen, ob auch die Funktion von menschlichen Immunzellen 
von Insulin beeinflusst werden kann. Um diese Frage zu beantworten, haben 
wir Immunzellen von gesunden Menschen und Menschen mit Diabetes für 
kurze und lange Zeit Insulin ausgesetzt und den Energiestoffwechsel der 
Immunzellen untersucht (Kapitel 7). Kurz nach dem Zufügen von Insulin zeigten 
Monozyten nicht nur eine erhöhte Aktivität der Glykolyse, sondern auch der 
oxidativen Phosphorylierung. Das bedeutet, dass Insulin zu einer allgemeinen 
Aktivierung des Energiestoffwechsels führt. Funktionell beeinflusste Insulin 
die Produktion von Abwehrstoffen kaum, aber förderte die Wanderung von 
Monozyten. Monozyten wandern zum Beispiel aus dem Blut ins Fettgewebe und 
entwickeln sich hier zu sogenannten Makrophagen, weiter. Makrophagen, auch 
Fresszellen genannt, sind Immunzellen, die sich in verschiedenen Geweben 
befinden und körperfremde, sowie beschädigte körpereigene Zellen aufnehmen 
und beseitigen können. Wir fanden eine erhöhte Anzahl an Makrophagen im 
Fettgewebe von Menschen mit erhöhtem Insulinspiegel im Blut. Setzten wir 
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Monozyten während der Entwicklung zu Makrophagen dauerhaft Insulin aus, 
waren die Makrophagen weniger aktiv und produzierten weniger Zytokine. 
Somit könnte Insulin bei der gestörten Funktion von Immunzellen in Patienten 
mit Diabetes eine Rolle spielen. 
Der Einfluss von metabolischen Faktoren aus der Umgebung auf Immunzellen 
kann nicht nur im Blut Auswirkungen haben, sondern auch im Gewebe. Im 
Fettgewebe spielen Makrophagen eine wichtige Rolle bei der Aufrechterhaltung 
des Gewebes, zum Beispiel durch die Beseitigung toter Fettzellen. Wie die 
lokale Umgebung die Funktion der Immunzellen im Fettgewebe beeinflusst ist 
aber noch nicht gut erforscht. Wir haben deshalb Fettgewebe von Menschen 
untersucht, die sich einer Bauchoperation unterziehen mussten (Kapitel 8). 
Dabei haben wir sowohl ein kleines Stück Unterhautfett, als auch ein Stück 
Bauchfett und etwas Blut erhalten. Aus allen drei Proben haben wir Immunzellen 
isoliert und verglichen. Die Unterschiede zwischen dem Unterhautfett und dem 
Bauchfett waren nicht sehr groß, dafür unterschieden sich die Zellen aus dem 
Blut und dem Fettgewebe jedoch stark. Immunzellen aus dem Fettgewebe 
waren besonders gut mit Mechanismen ausgestattet, die es ihnen erlauben, 
Fette abzubauen. Außerdem fanden wir eine hohe Aktivität des Komplement-
Systems in den Immunzellen aus dem Unterhaut- und dem Bauchfettgewebe. 
Komplement ist wichtig, um Bakterien zu bekämpfen, spielt aber auch eine Rolle 
bei Prozessen des Energiestoffwechsels. Wir haben herausgefunden, dass der 
so genannte Komplement-Faktor C1q wahrscheinlich eine Rolle beim Beseitigen 
toter Fettzellen spielt und möglicherweise auch den Energiestoffwechsel der 
Makrophagen im Fettgewebe reguliert. Diese Erkenntnisse helfen uns, die 
Funktion von Makrophagen im Fettgewebe besser zu verstehen.
Schlussfolgerung
Die Funktion von Immunzellen ist bei Patienten mit Diabetes oft gestört 
und trägt zur Entstehung von Komplikationen, wie zum Beispiel Herz- und 
Kreislauferkrankungen, sowie einem erhöhten Risiko für Infektionen, bei. In 
dieser Arbeit haben wir gezeigt, dass metabolische Faktoren, zum Beispiel 
Insulin, den Energiestoffwechsel von Immunzellen beeinflussen können, was zu 
einer veränderten Immunzellfunktion führen und Entzündungsprozesse fördern 
kann. Diese Erkenntnisse könnten in der Zukunft zur Entwicklung von Markern 
beitragen, um Komplikationen früh zu erkennen, oder um Therapien gegen die 
bei Diabetes auftretenden Komplikationen zu verbessern.
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Research data management
The data obtained in this thesis are archived according to the Findable, Accessible, 
Interoperable and Reusable (FAIR) principles [1]. Raw and processed data were 
stored digitally on a local server of the department of Internal Medicine, which 
is backed up daily on the Radboudumc server, and on paper in the form of lab 
journals. All human studies described in this thesis were conducted according to 
the principles of the declaration of Helsinki and were approved by the Medical 
Ethics Committee of the Radboudumc. All participants gave written informed 
consent before participation. Data generated in this thesis are part of published 
articles and files are available upon reasonable request. The microarray data 
presented in Chapter 3 is publically available at the gene expression omnibus 
(GEO) data repository. The microarray data presented in Chapter 8 will be 
accessible at GEO after publication. 
[1] Wilkinson MD, Dumontier M, Aalbersberg IJ, et al. (2016) The FAIR Guiding Principles for scientific 
data management and stewardship. Sci Data 3: 160018
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